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Muscle Dysfunction Associated With ACL Injury and Reconstruction 
By 
Abbey C. Thomas 
 
Chair: Riann M. Smith 
 
Anterior cruciate ligament (ACL) injuries occur in over 200,000 individuals per year in 
the United States. Quadriceps central activation failure (CAF) is a common consequence 
of these knee injuries, though why it presents remains elusive. Neuromuscular 
impairments resulting from ACL injury may not be limited to the muscles crossing the 
knee joint, however, though limited data are available to confirm this. The overall goal of 
this dissertation is to examine the muscle dysfunction associated with ACL injury and 
reconstruction, possible mechanisms leading to the lingering quadriceps muscle weakness 
after ACL reconstruction (ACLr), and to determine the immediate impacts of this 
weakness on the affected individual. In the first study, I sought to establish the presence 
of muscle dysfunction throughout the lower extremity following ACL injury and ACLr. I 
found that significant quadriceps and hamstrings strength deficits were present in the 
injured/reconstructed limb compared to the contralateral side both pre- and post-
operatively, with pre-operative injured limb strength deficits also present compared to 
healthy individuals. There was no hip or ankle weakness, however, compared to healthy 
individuals. Given the presence of quadriceps weakness following ACLr, identifying the 
contributing factors to this muscle weakness seemed critical. Therefore, in study two I 
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examined the contributions of quadriceps atrophy and CAF to persistent quadriceps 
strength impairments. Individuals who were six-months post-operatively following ACLr 
underwent quadriceps CAF and magnetic resonance imaging assessment. Results 
demonstrated that neither quadriceps CAF nor atrophy significantly contributed to the 
persistent quadriceps weakness in these individuals. Finally, I examined the effects of 
neuromuscular fatigue on quadriceps strength, CAF, and lower extremity biomechanics 
after ACLr. Individuals 7-10 months after ACLr demonstrated lower extremity 
biomechanics consistent with non-contact ACL injury risk prior to fatigue. Both ACLr 
and healthy individuals demonstrated greater quadriceps weakness and CAF following 
fatigue. Healthy individuals concurrently altered their biomechanics, potentially 
increasing their non-contact ACL injury risk. Surprisingly, ACLr subjects demonstrated 
similar, potentially injurious sagittal plane biomechanics pre- and post-fatigue, 
suggesting that reconstruction and/or rehabilitation are not sufficiently reducing the 




CHAPTER 1  
INTRODUCTION  
OVERVIEW 
Over 200,000 anterior cruciate ligament (ACL) injuries occur per year in the United 
States.
1
 As of 1999, Gotlob and colleagues
2
 had estimated the annual cost of all primary 
surgical reconstructions of the ACL to be $2 billion. 
ACL injuries not only lead to pain and disability for the injured individual, but have also 
been implicated in the development of post-traumatic osteoarthritis (OA). In fact, over 
50% of individuals suffering an ACL tear have been demonstrated to develop  OA within 
5-12 years following injury, regardless of treatment strategy (i.e., surgical vs. 
conservative management).
3-5
 In individuals opting for surgical reconstruction, 





Quadriceps muscle weakness presents frequently after ACL injury and reconstruction, 
though how it ensues and why it persists despite otherwise successful rehabilitation 
remain elusive. The quadriceps are important during dynamic control of the lower 
extremity and, as such, quadriceps weakness may lend to altered lower limb 
neuromechanical control strategies. These strategies may be hazardous not only when an 
individual returns to activity following ACL reconstruction, but the long term effects of 
these altered mechanics may potentiate joint degeneration. 
Previous studies examining post-operative strength deficits are limited in that they only 
examine quadriceps, and even hamstrings, strength. Recent evidence is emerging, though, 
to suggest that muscle weakness may arise elsewhere in the lower extremity following 
knee injury.
6
 Confirming the presence of weakness within these proximal and distal 




Several studies have been undertaken examining the origin of quadriceps weakness 
following ACL injury
7, 8
, suggesting that quadriceps atrophy and central activation failure 
may be key contributors to lingering weakness within this muscle group. These studies, 
however, examined only an ACL-injured population and did not consider individuals 
following ACL reconstruction. As the majority of individuals undergo surgical 
reconstruction of the torn ACL
9
, understanding the contributors to lingering quadriceps 
weakness following ACL reconstruction is imperative and a critical step to countering it. 
 Finally, the lingering quadriceps weakness may be especially hazardous when 
individuals return to activity. Neuromuscular fatigue is prevalent in athletic activity and 
has been shown to decrease central drive to the musculature
10
, with this effect being 
magnified in the presence of muscle weakness.
11
 Understanding the response of this 
neurologically impaired muscle to the demands of physical activity following ACL injury 
and reconstruction is imperative to improving rehabilitation strategies to reduce 
fatigability within the musculature. Additionally, elucidating how neuromuscular fatigue 
influences lower extremity biomechanics following ACL reconstruction may allow for 
the development of strategies to counter these potentially hazardous neuromechanical 
consequences prior to individuals returning to activity post-operatively.  
OBJECTIVE 
The objective of this research was to further elucidate the effects of ACL injury and 
reconstruction on muscle dysfunction throughout the lower extremity. Specifically, we 
examined isokinetic hip, knee, and ankle muscle strength. We utilized a combination of 
neuromuscular and imaging assessment techniques to examine the origin of quadriceps 
dysfunction. And, we employed neuromuscular and biomechanical assessment techniques 
to explore the effects of quadriceps dysfunction under realistic movement conditions.  
SIGNIFICANCE 
This research may have important implications for rehabilitation following ACL 
reconstruction. By determining where muscle weakness exists, strategies to improve 
neuromuscular function with the hope of preventing re-injury and possibly OA can be 
implemented. Similarly, elucidating the underlying contributors to persistent quadriceps 
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dysfunction known to afflict ACL reconstruction patients will lend to the development of 
treatment strategies designed to better counter it during rehabilitation.. Lastly, by 
determining the need for, and incorporating fatigue-resistance training within, current 
rehabilitation strategies, we may be able to better protect an individual from re-injury 
when he/she returns to activity following ACL reconstruction.  
ORGANIZATION OF THE DISSERTATION 
This dissertation contains 7 chapters. Chapters 2-4 present the individual studies as full-
length manuscripts prepared for publication. Chapter 2 examines strength in the 
musculature crossing the hip, knee, and ankle joints in the injured versus uninjured limbs 
of individuals pre- and post-ACL reconstruction as well as compared to healthy persons. 
Chapter 3 investigates the origin of persistent quadriceps dysfunction after ACL 
reconstruction by examining muscle atrophy (as assessed via muscle cross sectional area 
recorded from magnetic resonance images) and quadriceps central activation ratio 
determined utilizing the burst superimposition technique. Chapter 4 examines the effects 
of neuromuscular fatigue on quadriceps strength and central activation failure as well as 
the effects of fatigue on lower extremity biomechanics during dynamic landing in 
individuals 7-10 months after ACL reconstruction compared to healthy people. Chapter 5 
provides an overall discussion of chapters 2-4. Chapter 6 contains a conclusion; Chapter 
7 recommendations for future work. Chapter 8 provides a review of pertinent literature.  
SPECIFIC AIM 1 
To determine the presence of weakness in the lower extremity musculature following 
ACL injury and subsequent reconstruction.  
Specifically, this study aimed to examine strength of the hip, knee, and ankle flexor and 
extensor musculature as well as the hip abductors/adductors to elucidate the presence of 
weakness within each of these muscle groups. Bilateral isokinetic muscle strength was 
assessed pre-operatively and 6-months post-operatively in individuals undergoing ACLr 




Subjects would demonstrate weakness of the hip, knee, and ankle musculature. They 
would demonstrate this weakness in the injured compared to the uninjured limb as well as 
when compared to healthy persons. 
Subhypothesis 1: Subjects would demonstrate hip flexor, extensor, and abductor 
weakness. 
Subhypothesis 2: Subjects would demonstrate weakness of the quadriceps and 
hamstrings muscle groups. 
 Subhypothesis 3: Subjects would demonstrate weakness of the ankle plantar flexor and 
dorsiflexor musculature.  
SPECIFIC AIM 2 
To determine the contributors to lingering quadriceps weakness following ACLr.   
Specifically, this study sought to examine muscle cross sectional area (CSA) as well as 
the central activation ratio (CAR) to elucidate whether quadriceps weakness manifests 
through peripheral or central mechanisms, respectively. Bilateral quadriceps CAR 
assessment and magnetic resonance imaging were performed in individuals 6-months 
after ACLr.  
Hypotheses: 
Persistent quadriceps weakness would result from a combination of CAF and muscle 
atrophy. 
Subhypothesis 1: CAF would more strongly predict quadriceps weakness than atrophy.  
Subhypothesis 2: CAF as well as quadriceps CSA would be decreased in the injured 
versus uninjured limbs. 
SPECIFIC AIM 3 
To determine whether the magnitude of quadriceps weakness and CAF was greater in 
patients following ACLr compared to healthy individuals. Additionally, this study sought 
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to determine if the magnitude of knee biomechanical changes differed between 
individuals after ACLr compared to healthy persons prior to and following 
neuromuscular fatigue.  
Quadriceps isometric strength and CAF as well as sagittal and frontal plane knee joint 
angles and moments were measured prior to and immediately following lower extremity 
neuromuscular fatigue in patients who underwent ACLr and healthy persons.  
Hypotheses: 
Subjects would demonstrate altered kinetics and kinematics as well as greater CAF 
following fatigue. 
Subhypothesis 1: All subjects would demonstrate greater knee extension and abduction 
angles/moments post-fatigue.  
Subhypothesis 2: ACLr subjects would demonstrate greater CAF prior to fatigue 
compared to controls and will demonstrate greater biomechanical changes (increased 
greater knee extension and abduction angles/moments) post-fatigue compared to their 
healthy counterparts.  
Subhypothesis 3: ACLr subjects would reach maximal fatigue faster (i.e., in less 
repetitions of the fatiguing exercise) than healthy individuals.   
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CHAPTER 2  
LOWER EXTREMITY MUSCLE STRENGTH FOLLOWING ACL INJURY 
AND RECONSTRUCTION 
ABSTRACT 
Quadriceps and hamstrings muscle weakness have been demonstrated frequently 
following anterior cruciate ligament (ACL) injury and reconstruction. Though studied 
less often, evidence suggests that knee injury may precipitate weakness in the hip and 
ankle musculature; however, few data support this contention after ACL injury and 
reconstruction. Given the importance of these muscles in controlling lower extremity 
neuromechanics, it seems imperative to ascertain where strength deficits present so that 
rehabilitation strategies to combat these potential impairments can be developed and 
implemented. Therefore, the purpose of this study was to determine if hip flexor, 
extensor, abductor, and adductor, quadriceps and hamstrings, and ankle plantar and 
dorsiflexor weakness presented following ACL injury and reconstruction. Fourteen ACL-
injured individuals underwent bilateral strength assessment pre-operatively and 6-months 
post-operatively. Fifteen healthy participants performed strength testing in a matched 
limb at a single testing session. Strength was assessed at 60°/s. Statistical analyses 
consisted of 2x2 (limb x time) repeated measures as well as 1x2 (limb x group) 
ANOVAs. Paired t-tests were used for post hoc analyses. The injured limb quadriceps 
and hamstrings were weaker compared to the uninjured limb both pre- and post-
operatively (P<0.001). Limb by time interactions were revealed for the hamstrings 
(P=0.016) and ankle plantar flexors (P=0.008), with post hoc tests demonstrating plantar 
flexor weakness pre- versus post-operatively (P=0.021). There were no significant pre- or 
post-operative differences in strength between groups for any muscle tested (P>0.05). 
Weakness did not present within the hip or ankle dorsiflexor musculature, suggesting 
rehabilitation need not target these muscle groups. ACL rupture induced injured limb 
ankle plantar flexor weakness that appeared to be countered during post-operative 
rehabilitation. Further, our results confirmed previous reports suggesting insufficient 
restoration of quadriceps and hamstrings strength compared to the contralateral limb 
post-operatively. The quadriceps and hamstrings are important stabilizers during dynamic 
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activity, and weakness in these muscles could impair knee joint stability upon return to 
activity. As such, improving rehabilitation strategies to better target these lingering 
strength deficits seems imperative.  
INTRODUCTION 
Traumatic anterior cruciate ligament (ACL) injury occurs frequently during athletic 
activity, precipitating numerous immediate and long-term consequences, such as pain, 
disability, and, ultimately, joint degeneration.
4
  Lower extremity muscle weakness, 
particularly in the quadriceps and hamstrings, is also commonly reported following ACL 




strength deficits in the injured versus uninjured limb reportedly range from 5-
30%
12-17
, with hamstrings strength deficits of 9-13%
14, 17, 18
 having been described. The 
muscle weakness following ACL reconstruction, however, seems to be more problematic 
in the quadriceps than the hamstrings with reports of quadriceps strength deficits 
persisting upwards of seven years post-operatively, while hamstring weakness frequently 
resolves within the first post-operative year.
12
 Of additional concern is the bilateral 
presence of quadriceps and hamstrings muscle weakness.
14
  
Less often considered is strength of the triceps surae and hip musculature. Clinical 
observation and emerging evidence
6
 suggest, however, that strength within these muscle 
groups may be negatively influenced by the injury and reconstruction processes. 
Jaramillo and colleagues
19
 reported hip flexor/extensor and abductor/adductor weakness 
following knee surgery, though their results were not limited to an ACL-reconstructed 
population. The presence of both hip flexor
6
  and adductor
20
  weakness have been 
confirmed following ACL reconstruction. Hip adductor weakness, specifically, was 
demonstrated following semitendinosus/gracilis (STG) autograft reconstruction, with the 
authors suggesting that donor site morbidity and neurological alterations may have 
contributed to the resultant weakness.
20
  
Few studies have examined strength of the ankle joint musculature following ACL injury 
or reconstruction. Karanikas et al.
6
 reported no differences bilaterally in isokinetic ankle 
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plantar flexor strength between 3-6 months or 6-12 months post-operatively; however, 
decreased gastrocnemius electromyographic activity has been demonstrated during gait in 
ACL deficient individuals as well as during landing following ACL reconstruction, 
findings which could be the result of muscle weakness.
21
  
Considering the importance of muscle strength for controlling dynamic stability of the 
lower limb and that long term sequelae, such as OA, have been proposed to result from 
lingering muscle weakness, confirming and quantifying the presence of lower extremity 
muscle weakness seems imperative so that strategies to counter it can be better 
implemented within rehabilitation protocols. The purpose of this study, therefore, was to 
determine the magnitude of weakness present in the lower extremity musculature 
following ACL injury and subsequent reconstruction. Specifically, we sought to examine 
strength of the hip, knee, and ankle flexor and extensor musculature as well as the hip 
abductors/adductors before and after ACL reconstruction. We hypothesized that subjects 
would demonstrate weakness pre- and post-operatively within the 1) hip flexor, extensor, 
and abductor muscle groups, 2) quadriceps and hamstrings, and 3) ankle plantar flexor 
and dorsiflexor musculature.  
METHODS 
Subjects 
Fourteen ACL-injured individuals (8 male, 6 female; age: 19.43±5.21years; height: 
1.73±0.09m; mass: 74.03±13.61kg) and 15 control subjects (7 male, 8 female; age: 
24.73±3.37years; height: 1.75±0.09m; mass: 73.25±13.48kg) were included in this study. 
A power analysis based on pilot data collected on ACL reconstructed individuals in our 
laboratory revealed that to achieve injured versus uninjured quadriceps and hamstrings 
isokinetic strength differences with 80% statistical power and an -level of 0.05, thirteen 
subjects would be needed per group.  
Potential subjects had to have sustained a complete ACL rupture during athletic activity. 
Individuals were excluded if they: 1) had a history of previous surgery to either knee, 2) 
had a previous partial ACL tear, 3) had other ligamentous damage concurrent with ACL 
injury, and 4) were not scheduled for ipsilateral bone patellar tendon bone (BPTB) or 
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STG autograft ACL reconstruction. Pregnant females were also excluded. Individuals in 
the healthy group were further excluded if they had a history of any lower extremity 
surgery or suffered a lower extremity injury in the previous six months. The rehabilitation 
completed by all ACL-injured subjects in this study was performed at a single outpatient 
clinic and was a standard rehabilitation protocol (Appendix B) initiated during the first 
post-operative week and concluded during the twelfth through sixteenth post-operative 
week, depending on the individual‘s progression. The Medical School Institutional 
Review Board at University of Michigan approved this study. All subjects provided 
informed consent prior to participation.  
Strength Testing Procedures 
ACL-injured subjects reported for testing on two occasions, pre-operatively and six 
months post-operatively, whereas control subjects reported for testing on a single 
occasion only. Strength assessments were performed bilaterally for each muscle group on 
an isokinetic dynamometer (Biodex System 3, Biodex Medical Systems, Shirley, New 
York, USA) at 60º/s and recorded using a custom-written Labview program (Labview 
8.5, National Instruments, Austin, TX, USA). Three maximal voluntary concentric 
contractions (MVCC) were performed for each muscle group tested. The peak value over 
those three repetitions was normalized to subject body mass (kg) and used to quantify 
strength (Nm/kg). Verbal encouragement was provided throughout testing in an attempt 
to help elicit each subject‘s maximal effort. Testing order (limb and muscle group) was 




For all hip strength measurements, the 
mechanical axis of the dynamometer was aligned 
with the greater trochanter of the limb being 
tested, and the distal femur was strapped to the 
dynamometer arm. Specifically, for hip 
flexion/extension strength assessment,  
subjects stood facing away from the back of the 
dynamometer chair as shown in figure 2.1.
22
 For 
hip abduction/adduction assessment, subjects 
were positioned side-lying on the dynamometer 
chair with the hip in a neutral position (Figure 
2.2). Subjects were instructed to keep the 
trunk as still as possible and only to 
abduct/adduct the hip, not to rotate, flex, 
or extend it. The full, available range of 
motion was utilized for strength 
assessment for both muscle groups during 
testing. Subject positioning was monitored 
throughout testing by the investigator.  
Knee Strength 
Figure 2.1. Hip flexion/extension strength 
testing position. 




For knee flexion/extension, subjects 
were seated on the dynamometer chair 
with the hip flexed to 85°.
12
 The 
mechanical axis of the dynamometer 
was aligned with the lateral aspect of 
the knee joint center of the test limb 
and the distal shank was strapped to the 
dynamometer arm (Figure 2.3). A 
stabilization strap was placed over the 
pelvis. Subjects were instructed to 
move the knee from 0-100° of flexion 
during testing.
12
 If subjects were lacking full 
extension, they were instructed to move 
through the full, available range of motion 
during testing.  
Ankle Strength 
Ankle plantar flexion and dorsiflexion 
strength were assessed with subjects 
positioned supine on the dynamometer chair 
with the knee flexed to approximately 15° 
(Figure 2.4). This position was chosen to avoid subject discomfort at full knee extension 
but still target the gastrocnemius muscle as much as possible. The mechanical axis of the 
dynamometer was aligned with the lateral malleolus of the test leg and the foot was 
strapped to the dynamometer‘s foot plate attachment. The full, available range of motion 
was utilized for strength assessment. 
Statistical Analyses 
The dependent variables used for analysis were strength (Nm/kg) of each muscle group 
(hip flexors and extensors, abductors and adductors; knee flexors and extensors; ankle 
plantar flexors and dorsiflexors) and the independent variables were limb (injured and 
Figure 2.2.  Knee extension/flexion strength testing 
position. 
Figure 2.3. Ankle plantar flexion/dorsiflexion 
strength testing position. 
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uninjured for the ACL-injured group or a randomly determined test limb in control 
subjects), group (ACL reconstructed and control), and time (pre- and post-operatively). 
Two x two repeated measures ANOVAs were utilized to examine the dependent variables 
in the ACL-injured group between limbs and over time. Additional 1x2 ANOVAs were 
performed to compare the dependent variables between the ACL-injured group at the pre- 
and post-operative time points to the control group (injured limb vs. test limb only).  The 
a priori alpha level was P≤0.05. Sidak multiple comparisons procedures and paired t-
tests were used for all post hoc analyses. Effect sizes and their associated confidence 
intervals were calculated in Microsoft Excel 2007 (Microsoft Corporation, Redmond, 
Washington) using Cohen‘s d.
23
 Effect sizes were calculated as 
either 
 C -injured mean-control mean
pooled standard deviation
 or 
post-operative mean-p  -operative mean
pooled standard deviation
 . Effect sizes were 
interpreted as having small (0.2-0.5), moderate (0.51-0.8), or large (>0.81) impacts in 
accordance with Cohen‘s guidelines.
23
 The Statistical Package for the Social Sciences 
(SPSS Inc., Chicago, IL) version 17.0 was utilized for all other analyses. 
RESULTS 
Hip Strength 
Statistical analyses failed to reveal a main effect for time for hip muscle strength, 
demonstrating that no differences were present between the pre- and post-operative time 
points in the ACL-injured group (flexors P=0.09; extensors P=0.053; abductors P=0.67; 
adductors P=0.76 [Figure 2.5]) (Table 2.1). Similarly, no main effects for limb were 
detected suggesting hip muscle strength was not different between limbs (flexors P=0.94; 
extensors P=0.08; abductors P=0.31; adductors P=0.15). Hip strength was not 
significantly different in the ACL-injured group compared to the control group either pre-
operatively (flexors P=0.16; extensors P=0.79; abductors P=0.59; adductors P=0.28) or 




There was no time main effect for quadriceps (P=0.66) or hamstrings (P=0.85) strength 
(Table 2.1) (Figure 2.5) in the ACL-injured group. The ACL-injured subjects did 
 
Figure 2.4. Mean ± standard deviation hip, knee, and ankle muscle strength. *Indicates significant 
difference between ACL-injured (pre-operative time point) and control groups. †Indicates significant 




demonstrate a significant effect of limb, with greater healthy limb quadriceps (P<0.001) 
and hamstrings (P<0.001) strength. Additionally, there was a significant time by limb 
interaction for the hamstrings (P=0.016); however, post hoc testing revealed the pre-
operative strength was not different from that recorded post-operatively in either the 
injured (P=0.13) or uninjured limbs (P=0.47) There were differences in pre-operative 
(quadriceps P=0.032; hamstrings P=0.047) but not post-operative (quadriceps P=0.066; 
hamstrings P=0.62) strength in the ACL-injured group versus the control group.  
Table 2.1. Hip, knee, and ankle strength data (Nm/kg) for ACL-injured and control subjects. Data are 
mean±standard deviation. 
 ACL-Injured Control 
 Pre-Operative Post-Operative  
 Injured Uninjured Injured Uninjured  
Hip Flexion 1.15±0.29 1.13±0.33 1.34±0.59 1.41±0.58 1.40±0.59 
Hip Extension 1.39±0.50 1.16±0.46 1.57±0.60 1.54±0.65 1.24±0.49 
Hip Abduction 0.77±0.38 0.73±0.33 0.82±0.29 0.77±0.29 0.83±0.28 
Hip Adduction 0.73±0.24 0.83±0.23 0.80±0.30 0.82±0.26 0.65±0.24 
Knee Extension 1.33±0.56 1.95±.059 1.38±0.59 2.06±0.86 1.73±0.42 
Knee Flexion 0.80±0.23 1.13±0.29 0.93±0.36 1.05±0.39 0.98±0.23 
Ankle Plantar Flexion 0.51±017 0.60±0.25 0.77±0.29 0.67±0.21 0.69±0.36 
Ankle Dorsiflexion 0.26±0.08 0.28±0.07 0.25±0.10 0.24±0.11 0.27±0.08 
 
Ankle Strength 
The ACL-injured group failed to demonstrate a time main effect for either the ankle 
plantar flexors (P=0.11) or dorsiflexors (P=0.33) (Table 2.1) (Figure 2.5). Further, there 
were no significant limb main effects for either muscle group (plantar flexors P=0.95; 
dorsiflexors P=0.72). Subjects in the ACL-injured group demonstrated a significant time 
x limb interaction for the ankle plantar flexors (P=0.008), with post hoc analyses 
revealing the injured limb plantar flexors were weaker pre- versus post-operatively 
(P=0.02), though no differences were noted for the uninjured limb between the pre- and 
post-operative time points (P=0.52). There were no differences in strength between the 
ACL-injured group compared to the control group pre-operatively (plantar flexors 





Quadriceps and hamstrings weakness are prevalent following ACL injury and subsequent 
reconstruction. Though clinical speculation suggests weakness also arises in the 
musculature crossing the hip and ankle joints, few data are available to confirm this 
contention. As weakness in the lower extremity musculature may dynamic lower 
extremity control, determining which muscles are weak is imperative so that strategies to 
better counter this weakness may be developed and implemented. This study sought to 
confirm and quantify the presence of lower extremity muscle weakness following ACL 
injury and reconstruction. 
Hip Strength 
We hypothesized that following ACL injury and reconstruction weakness would present 
in the hip flexors and extensors. Given that the quadriceps and the hamstrings are weak 
following both injury and reconstruction and that rectus femoris and hamstrings cross the 
hip joint, it seems likely that weakness at one joint may translate to strength deficits at the 
other. The absence of hip flexor weakness in the injured versus the uninjured limb in the 
ACL-injured group disagreed with a recent study by Karanikas et al.,
6
 suggesting hip 
flexor strength deficits present upwards of one year after ACL reconstruction. 
Differences in strength assessment technique may contribute to discrepancies in our 
findings and those reported previously. The previous study
6
 utilized a supine position, 
while we tested our subjects in standing, though both positions allowed for a similar anti-
gravity position of the hip flexors and stabilization of the trunk. Additionally, the 
previously reported hip flexor strength values were not normalized to subject body mass
6
; 
doing so may eliminate side-to-side statistical differences in hip flexor strength. Future 
research seems necessary, however, to clarify the role of ACL reconstruction on hip 
flexor strength.  
It should be noted that the ACLr group demonstrated hip flexor weakness pre-operatively 
versus post-operatively regardless of limb, though this relationship did not achieve 
statistical significance. Additionally, the effect size for this relationship was moderate, 
0.60 (Table 2.2), indicating a relationship that may be clinically significant and should be 
investigated in future studies. As mentioned above, hip flexor weakness may be a direct 
result of the injury process, itself, due to the bi-articular nature of the rectus femoris and 
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the prevalence of quadriceps weakness following ACL injury. Hip flexor strength values 
were restored to levels comparable to those demonstrated in the control group post-
operatively, suggesting that current rehabilitation strategies are successfully able to 
counter pre-operative hip flexion weakness.   
Table 2.2.  Effect sizes and confidence intervals for strength data. 
Time Main Effects Effect Size Confidence Interval 
  Lower Bound Upper Bound 
Hip Flexion 0.60 0.32 0.89 
Hip Extension 0.56 0.30 0.82 
Hip Abduction 0.14 -0.05 0.32 
Hip Adduction 0.12 -0.05 0.29 
Knee Extension 0.14 -0.21 0.49 
Knee Flexion 0.06 -0.12 0.24 
Ankle Plantar Flexion 0.72 0.52 0.91 
Ankle Dorsiflexion -0.28 -0.32 -0.23 
Limb Main Effects    
    
Hip Flexion 0.01 -0.07 0.08 
Hip Extension 0.28 0.15 0.42 
Hip Abduction 0.02 -0.07 0.10 
Hip Adduction -0.35 -0.43 -0.26 
Knee Extension -1.23 -1.48 -0.98 
Knee Flexion -0.86 -0.93 -0.79 
Ankle Plantar Flexion 0.01 -0.05 0.07 
Ankle Dorsiflexion -0.07 -0.09 -0.04 
ACL-injured vs. Control Pre-op    
    
Hip Flexion -0.54 -0.96 -0.12 
Hip Extension 0.31 -0.07 0.69 
Hip Abduction -0.19 -0.38 0.00 
Hip Adduction 0.33 0.14 0.53 
Knee Extension -0.84 -1.25 -0.43 
Knee Flexion -0.78 -0.99 -0.56 
Ankle Plantar Flexion -0.65 -0.89 -0.42 
Ankle Dorsiflexion -0.12 -0.18 -0.05 
ACL-injured vs. Control Post-op    
    
Hip Flexion -0.01 -0.27 0.24 
Hip Extension 0.60 0.25 0.95 
Hip Abduction -0.04 -0.27 0.19 
Hip Adduction 0.54 0.37 0.72 
Knee Extension -0.71 -1.11 -0.31 
Knee Flexion -0.19 -0.36 -0.02 
Ankle Plantar Flexion 0.24 0.04 0.44 
Ankle Dorsiflexion -0.18 -0.24 -0.12 
 
Though not achieving statistical significance, the ACLr subjects demonstrated a trend 
toward a significant time main effect of the hip extensors being weaker pre-operatively 
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versus post-operatively regardless of the limb being tested. This result was supported by a 
moderate effect size of 0.56 (Table 2.2). As the hamstrings are hip extensors and 
hamstrings weakness is a likely consequence of the ACL injury process
24
, it seems 
logical that hip extensor weakness could result from ACL injury. Disuse of the hip 
extensors during the pre-operative period may also contribute to weakness. Subjects were 
tested, on average, 76 days post-injury, which was sufficient time for disuse atrophy and 
associated muscle weakness to set in.
25
 It should be noted that our hip strength testing 
position may have made it difficult to detect hip extensor weakness caused by the 
hamstrings, as subjects were instructed to maintain knee flexion while extending their 
hips. This is typically believed to target the gluteus maximus over the hamstrings. Future 
studies isolating the hamstrings during hip extensor strength testing may further elucidate 
the relations between ACL injury and reconstruction and hip extension strength. That hip 
extensor strength improved post-operatively in our subjects, however, may suggest that 
standard ACL rehabilitation is successfully targeting and combating hip extensor 
weakness.  
The ACLr group also demonstrated greater hip extensor strength in the injured compared 
to the uninjured limb. This relationship did not reach statistical significance and the 
calculated effect size was small at 0.28 (Table 2.2) suggesting the relationship may not be 
clinically meaningful. It is possible that the testing position employed may account for 
these results. That our subjects were tested in standing necessitated that while testing the 
uninjured limb‘s hip extensor strength, the subject be standing on his/her injured limb. 
Despite sufficient stabilization provided by the researchers, it is possible the subjects felt 
instability in the injured knee and, thus did not put forth maximal effort. Future studies 
may consider utilizing different testing positions or stabilization methods.  
Our subjects did not demonstrate hip abductor weakness, which was unexpected. 
Previous research in animal models indicates that the rectus femoris sends heteronymous 
neural projections to its hip synergists (i.e., sartorius)
26
, suggesting that strength 
impairments within the rectus femoris could yield similar impairments within the hip 
abductors. A previous study
19
 examining hip abductor strength following knee surgery 
did indicate weakness within this muscle group, though strength was tested in the 
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immediate post-operative period, making direct comparisons between this study and the 
previously conducted one difficult. Nonetheless, our results seem to suggest that neither 
ACL injury nor surgical reconstruction negatively influences strength within the hip 
abductor muscle group. 
While we did not hypothesize that our subjects would demonstrate hip adductor weakness 
it is worth noting that our findings disagree with those of Hiemstra and colleagues
20
 who 
found hip adductor strength deficits following STG autograft ACL reconstruction. Donor 
site morbidity likely explains the hip adductor muscle weakness in the previous study. 
The majority of our subjects (n =12) received BPTB autografts, however, and, as such, 
donor site morbidity would did not likely play a role in their hip adductor strength and 
may explain the differences in findings between our work and that of others.   
Knee Strength 
In accordance with our hypothesis, our subjects demonstrated bilateral differences in 
quadriceps and hamstrings strength. Specifically, our subjects demonstrated injured vs. 
uninjured strength deficits of 32% in the quadriceps and 21% in the hamstrings. These 





 The hamstrings strength deficits in our subjects also appear to differ from 




 than those reported by 
previous investigators. The presence of quadriceps and hamstrings weakness in the 
injured versus uninjured limb in our subjects seems to confirm that current rehabilitation 
strategies do not fully restore strength by the time that individuals return to activity. Why 





, and incomplete rehabilitation
14
 have been 
suggested to contribute. As the quadriceps and hamstrings cross the knee joint, weakness 
within these muscles may directly alter tibiofemoral biomechanics, possibly contributing 
to joint degeneration. In fact, quadriceps weakness is suggested to limit its ability to 
absorb energy on weight bearing, precipitating increased articular cartilage loading, 
which may lead to joint degeneration.
32
 Further, hamstrings strength deficits at the time 
that individuals return to full activity may also be hazardous given that the hamstrings 
restrain anterior tibial translation, a known contributor to ACL injury.
33
 Future studies 
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elucidating the underlying mechanisms behind these persistent quadriceps and hamstrings 
strength deficits seem warranted so that interventions to better counter them during the 
rehabilitation process can be developed and implemented. 
That there were no differences in pre-operative compared to post-operative quadriceps 
and hamstrings strength in the ACL-injured group disagrees with previously reported 
findings
34
 and seems somewhat counterintuitive. However, the surgical process likely 
introduces trauma to the joint beyond that of the injury process itself, which may 
intensify quadriceps and hamstrings weakness. Thus, while based on pre-operative testing 
our subjects had a 32% quadriceps strength deficit to overcome compared to their 
uninjured limb, it is likely that on the first post-operative day this deficit was quite a bit 
larger. Traditional rehabilitation often dictates that individuals are discharged from 
supervised care between 3-4 months post-operatively. This does not appear to be 
sufficient time to restore quadriceps or hamstrings strength. Retaining patients in 
rehabilitation (i.e., beyond 3-4 months post-operatively) may be one effective way to 
ensure more adequate quadriceps and hamstrings strength upon return to activity 
following ACL reconstruction. This may be especially beneficial for individuals in whom 
discharge from supervised rehabilitation and clearance for return to activity do not 
coincide. Additionally, the use of interventions designed to counter the underlying causes 
of quadriceps weakness are needed; however, successfully restoring quadriceps strength 
following ACL reconstruction will likely prove challenging until the underlying causes of 
this impairment are known and targeted treatments established. While the precise cause 





 have been suggested to contribute. Previous research 
into the removal of artificially induced quadriceps muscle inhibition has suggested that 
the use of cryotherapy
37
 and transcutaneous electrical nerve stimulation
37
 may be useful 
adjuncts to traditional rehabilitation. Further, the use of neuromuscular electrical nerve 
stimulation has been explored 
38, 39
, though how long-lasting the strength benefits of this 
treatment are remain unknown. Future research into the benefits of each of these 
treatments within post-operative ACL rehabilitation seems warranted. 
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The ACL-injured subjects had weaker quadriceps and hamstrings pre-operatively 
compared to the control group. There was also a trend toward significant differences in 
post-operative quadriceps strength that was supported by a moderate (-0.71) effect size 
(Table 2.2), indicating quadriceps weakness is not sufficiently countered post-operatively 
when compared to healthy individuals. Previous research comparing strength in healthy 
individuals to those who have undergone ACL reconstruction is conflicting. Konishi and 
colleagues
18
 failed to establish a difference in hamstrings torque per unit volume between 
the injured limb following ACL reconstruction and control subjects 12 months post-
operatively. However, Hiemstra et al.
14
 demonstrated differences in quadriceps and 
hamstrings strength between individuals an average of 40-months following ACL 
reconstruction and control subjects. The reason for the discrepancies in these findings is 
unclear, though the time since surgery could be playing a role. It would seem greater 
strength deficits would be expected closer to surgery when compared to controls. 
Rehabilitation does account for some strength gains, however, and failure to maintain 
these strength gains over time could lead to weakness in the years subsequent to ACL 
reconstruction when compared to healthy individuals. As was suggested by Hiemstra et 
al.
14
 and has been reported previously, the presence of bilateral weakness may make the 
contralateral limb an inappropriate guideline for judging strength following ACL 
reconstruction. These authors have suggested, instead, that healthy people should serve as 
the barometer against which to measure strength gains.
14
 However, the conflicting results 
demonstrated previously suggest the need for future research to clarify the relation 
between strength in ACL-reconstructed individuals and healthy persons. 
Ankle Strength 
Our subjects demonstrated significant pre-operative ankle plantar flexion weakness 
relative to the uninjured limb. Recently, Karanikas and colleagues
6
 demonstrated that 
ankle plantar flexor strength was not influenced at any post-operative time point assessed 
in their study (3-6, 6-9, or 9-12 months post-operatively), suggesting that the restoration 
of plantar flexor strength may occur early during rehabilitation. That ankle plantar flexor 
strength improved post-operatively in our subjects, becoming nearly equivalent between 
the injured and uninjured limb and not differing from control subjects, agrees with these 
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recent findings. With the gastrocnemius crossing the knee joint, the pre-operative plantar 
flexor weakness in our ACL-injured subjects may have been a direct consequence of the 
ACL injury. Additionally, the gastrocnemius is neurally connected to the quadriceps
40, 41
 
and altered strength and neuromuscular activity within the quadriceps following ACL 
injury could potentiate gastrocnemius weakness
40, 41
. Disuse atrophy of the gastrocnemius 
may have further contributed to the pre-operative weakness demonstrated by our subjects. 
Calf girth measurements, recorded with a cloth tape measure, were not significantly 
different between limbs in the ACL-injured individuals in our study (P>0.05). However, 





Injured limb quadriceps and hamstrings weakness are present six-months following ACL 
reconstruction. As these muscles directly contribute to safe and effective lower extremity 
dynamic stability when individuals return to full activity following injury, determining 
the precise cause of and developing more effective strategies to counter this weakness 
appears vital. Additionally, ankle plantar flexor weakness presented in the injured limb 
pre-operatively, though current rehabilitation strategies appear effective in countering this 
weakness following ACL reconstruction. With the exception of the trend toward hip 














CHAPTER 3  
 CONTRIBUTIONS OF CENTRAL ACTIVATION FAILURE AND ATROPHY 
TO QUADRICEPS WEAKNESS ASSOCIATED WITH ACL 
RECONSTRUCTION 
ABSTRACT 
Persistent quadriceps weakness presents after anterior cruciate ligament reconstruction 
(ACLr) in spite of otherwise successful rehabilitation. The precise contributors to 
lingering quadriceps weakness are unknown, though muscle atrophy and activation 
failure have been implicated. This study sought to elucidate the roles of activation failure 
and muscle atrophy in persistent quadriceps weakness after ACLr. Eleven individuals 
undergoing ACLr six months previously participated. Muscle atrophy was determined as 
the peak quadriceps cross sectional area (CSA) from magnetic resonance images. 
Quadriceps activation was assessed using the burst superimposition technique and 
quantified via the central activation ratio (CAR). Quadriceps strength was determined 
from a knee extension maximal voluntary isometric contraction (MVIC). All testing was 
performed bilaterally. Hierarchical linear regression analysis was performed to determine 
the association between quadriceps CAR and CSA and quadriceps MVIC in the injured 
limb. One-way ANOVAs were performed to determine if CAR, CSA, and MVIC differed 
between limbs. Regression analysis failed to demonstrate a significant relation between 
CAR and CSA and the peak MVIC following ACL reconstruction (R
2
= 0.357, P=0.17). 
The CAR accounted for 27.3% (P=0.073) of the variance in quadriceps MVIC; 





; P<0.001) and the quadriceps MVIC 
(ACLr=1.94Nm/kg; uninjured=2.8Nm/kg; P=0.001) but not the CAR (ACLr=0.82; 
uninjured=0.86; P=0.16) differed between limbs. Though both quadriceps atrophy and 
activation failure were present in our subjects, neither quadriceps CSA nor CAR was 
related to MVIC. Future studies seem necessary to determine what additional factors may 
be associated with quadriceps MVIC so necessary modifications to current rehabilitation 
strategies can be made. Until quadriceps weakness is sufficiently countered during 




Quadriceps weakness is nearly ubiquitous following ACL injury and reconstruction. The 
magnitude of the reported strength deficits varies, but may be as high as 30% in the 
reconstructed compared to the contralateral limb 6-months post-operatively
27
, a time 
when individuals often return to full activity. Further, this weakness been shown to 
persist for years after reconstruction, with deficits between limbs upwards of 20% being 
reported seven years post-operatively.
17
  
Quadriceps weakness may have hazardous short- and long-term consequences for the 
injured individual. The quadriceps are important to lower limb control during dynamic 
activity and the presence of weakness could alter movement strategies potentiating re-
injury.
43
 Quadriceps weakness has also been implicated in the onset/progression of 
tibiofemoral osteoarthritis
32
; thus, failing to remove strength deficits may precipitate joint 
degeneration in these individuals. Before quadriceps strength can be effectively 
countered during the rehabilitation process, however, a deeper understanding of why 
quadriceps weakness persists is needed. 
Muscle atrophy following disuse of the quadriceps and knee joint immobilization has 
been suggested to contribute to quadriceps weakness after ACL injury and 
reconstruction.
36
 Quadriceps atrophy has been demonstrated following ACL 
reconstruction, with Konishi and colleagues
29
 reporting an approximately 7% deficit in 
total quadriceps volume in the reconstructed versus contralateral limb in individuals 
between 6-12 months post-operatively. Similar magnitudes of quadriceps atrophy were 
reported by Lorentzon et al.
44
 in people with ACL deficiency, though no relation between 
quadriceps atrophy and strength was identified. The authors thus concluded that muscle 




Central activation failure (CAF) is a common consequence of ACL injury and 
reconstruction, with activation deficits upwards of 15% reported two years post-
operatively.
31
 In individuals with radiographic tibiofemoral osteoarthritis, a population 





was found to account for nearly twice the quadriceps strength deficit that muscle atrophy 
does.
45, 47
 Elucidating the relationship between quadriceps muscle atrophy and CAF with 
lingering weakness seems imperative. Until it is known why quadriceps strength deficits 
persist, they cannot be effectively countered during the rehabilitation process. Thus, the 
purpose of this study was to determine if quadriceps atrophy and CAF contribute to 
persistent knee extension strength deficits in individuals six-months after ACL 
reconstruction. We hypothesized that persistent quadriceps dysfunction would result from 
a combination of CAF and muscle atrophy and that CAF would more strongly predict 
quadriceps dysfunction than would muscle atrophy. A secondary hypothesis was that the 
magnitudes of quadriceps CAF and atrophy would be greater in the injured compared 
with the uninjured limb. 
METHODS 
Subjects  
Thirteen individuals were recruited to participate in this study; one was excluded after 
secondary screening revealed that she did not fulfill all of the study inclusion criteria. 
Another individual reported for magnetic resonance imaging testing but failed to report 
for CAF assessment. He could not be reached for follow-up and was, thus, excluded from 
analysis, leaving 11 individuals (4 males, 7 females; age: 20.64±6.31years; height: 
1.73±0.09m; mass: 74.55±15.33kg) who underwent patellar tendon autograft ACL 
reconstruction six-months prior to enrollment participating in this study. A power 
analysis based on data examining the relation between quadriceps strength and atrophy
48
 
revealed the need for 12 subjects to detect 80% power with an alpha level ≤0.05.  
Subjects reported for testing on two occasions with bilateral quadriceps muscle atrophy, 
in the form of muscle cross sectional area (CSA) measured at one session and strength 
and CAF measured at the other (average 5.73±9.60 days between testing sessions). 
Potential subjects were excluded if they: had a history of lower extremity surgery other 
than their recent ACL reconstruction, had suffered a lower extremity injury since 
undergoing ACL reconstruction, had current pain in either knee, underwent partial or 
complete meniscectomy with their ACL reconstruction, had other ligamentous damage 
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concurrent with their ACL injury, or had a known heart condition. Pregnant females were 
also excluded. This study was approved by the medical school institutional review board 
at the University of Michigan. All subjects provided written consent prior to 
participation. 
Quadriceps Cross Sectional Area Assessment 
Subjects were positioned supine in a magnetic resonance imaging scanner (Philips 
Achieva 3T Quasar Dual, Philips Electronics, Andover, MA, USA) and underwent 
bilateral thigh scans, with both limbs scanned simultaneously. The following parameters 
were utilized for the imaging protocol: repetition time 2000-3000 ms, echo time 35 ms, 
slice thickness 6 mm, gap between slices 6 mm, with a 364x180 matrix, and a 480x281 
mm field of view. 
Peak CSA for each of the four quadriceps muscles as well as total quadriceps peak CSA 
were evaluated. The contours of each muscle were traced in every axial image in which 
the muscle appeared using ImageJ software (version 1.42q, National Institutes of Health, 
USA) and an Intuos4 pen tablet (Wacom Technology Corporation., Vancouver, WA, 
USA). The sum of each muscle‘s CS  yielded the maximal CSA for each slice. The slice 
with the greatest combined CSA was used for statistical analysis.
45
 All CSA 
measurements were performed by a single investigator with high intrarater reliability 
(intraclass correlation coefficient [ICC] of 0.988).  
Quadriceps Strength and Central Activation Failure Assessment 
Quadriceps strength was assessed during the performance of a knee extension maximal 
voluntary isometric contraction (MVIC) while subjects were seated on an isokinetic 
dynamometer (Biodex System 3, Biodex Medical Systems, Shirley, NY, USA) with the 
hip flexed to 85° and the knee flexed to 90°. For the MVICs, subjects were instructed to 
kick out as hard as they could while watching a computer monitor running a custom-
written Labview (Labview 8.5, National Instruments, Austin, TX, USA) program that 
displayed their real-time torque output. After completion of the first MVIC, the program 
displayed a solid line reflecting the subject‘s peak torque value from the initial trial and a 
dashed line that was set 10% above the peak torque recorded during the initial MVIC 
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trial. (Figure 3.1). For all subsequent trials, subjects were encouraged to reach this target 
torque value denoted by the dashed line. If subjects increased their torque during any of 
the ensuing trials, the height of the solid and dashed lines would be adjusted 
appropriately. Knee extension MVICs were performed (minimum of three), with at least 
two minutes of rest in between each repetition, until no improvements in torque were 
observed by an investigator. Once each subject‘s knee extension torque ceased to 
increase any further, the peak torque value from all recorded repetitions was noted and 
used as a threshold value for subsequent CAF assessment.  
For CAF testing, self-adhesive, stimulating electrodes (Dura-Stick II [5 cm x 9 cm] 
Chattanooga 
Group, Hixson, 
TN, USA) were 
applied proximally 
over the rectus 
femoris and distally 
over the vastus 
medialis. At the 
beginning of 
testing, the peak 
torque value 
recorded during the 
MVIC trials was 
inputted into the 
custom-written 
program. The 
program utilized this threshold (peak torque) value to determine whether or not it would 
trigger the electrical stimulator (S88 and SIU8T, GRASS Technologies, West Warwick, 
RI, USA) to deliver a stimulus (100 ms-long train, pulse duration: 600 s, delivery rate: 
100 pulses per second, maximal voltage: 130V). Similar to the MVIC testing, subjects 
were instructed to generate enough torque to reach the dashed target line displayed on the 
















Figure 3.1. Screenshot from strength and central activation failure testing 
(C F). The blue line represents the subject‘s real-time torque output. The solid 
black line corresponds to the subject‘s peak value from the MVIC trials and also 
serves as a threshold for CAF testing. Real-time torque output must cross 
threshold for the electrical stimulus to be delivered. The dotted line represents 
the subject‘s target value, which was set 10% above maximal strength. The 




The custom-written program was set to deliver the stimulus once a subject‘s torque value 
reached threshold and then fell 1 Nm below their peak torque for the current trial. If a 
subject failed to reach the solid threshold line, the program would not deliver the stimuli, 
and the subject would be given two minutes of rest before the trial was repeated. The 
dashed target line was set so as to be unreachable for the subject; however, in the event 
that a subject did reach the target value, the maximal strength value (solid threshold line) 
was reset and CAF testing was reinitiated. Three repetitions of CAF testing were 
performed with two minutes of rest provided between repetitions.  
Maximal strength was determined from these three CAF repetitions. The largest of the 
peak torque values generated immediately prior to delivery of the electrical stimulus was 
divided by the subject‘s body mass (kg) and utilized to quantity maximal strength 
(Nm/kg). From this same trial yielding maximal strength, CAF was quantified via the 
central activation ratio (C R). To determine the C R, the subject‘s peak torque 
generated immediately prior to the delivery of the electrical stimulus was divided by the 
peak torque generated as a result of the electrical stimulus.  
Statistical Analyses 
A hierarchical multiple regression analysis was used to determine the association 
between knee extension MVIC and quadriceps CAR and CSA in the injured limb, with 
the CAR entered into the model first. A series of 1x2 ANOVAs were performed to 
determine if MVIC, CSA, and CAR differed between limbs. The alpha level for all tests 
was set a priori at P≤ 0.05. Effect sizes (Cohen‘s d)
23
 examining the magnitude of the 
between-limb difference for quadriceps strength, CSA, and CAF were calculated as the  
                 –                  
                         
 and were determined in Microsoft Excel 2007 (Microsoft 
Corporation, Redmond, WA, USA). SPSS (SPSS, Chicago, IL, USA), version 17.0, was 
utilized for all other statistical procedures.  
RESULTS 
Regression analysis failed to demonstrate a significant relation between CAR and CSA 
and the peak MVIC following ACL reconstruction (R
2
= 0.357, P=0.171) (Figure 3.2). 
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When CAR was entered into the model first, it accounted for 27.3% (P=0.073) of the 
variance in quadriceps MVIC. The subsequent inclusion of CSA into the regression 
model accounted for the remaining 8.5% (P=0.335). 
 
Figure 3.2. Scatter plot depicting the relation between quadriceps strength (Nm/kg) and predicted strength 
from hierarchical regression. 
Quadriceps strength, CSA, CAR, and effect size values can be found in Table 3.1. Peak 
quadriceps CSA differed between limbs, with the injured limb demonstrating a 
significantly smaller CSA six-months post-operatively than the uninjured limb (P 
<0.001) (Figure 3.3). Knee extension MVIC also differed between limbs, with the injured 
limb being significantly weaker than the uninjured (P=0.001) limb. The CAR did not 
differ between limbs (P=0.16), though the mean values indicated CAF was present 
bilaterally.   
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Table 3.1. Quadriceps maximal voluntary isometric contraction, cross sectional area, and central activation 
ratio data for the injured and uninjured limbs. 
 Mean±SD P-value Effect Size (95% CI) 
Injured Limb Uninjured Limb   
MVIC (Nm/kg) 1.96±0.54 2.81±0.96 0.001 -0.8 (-1.16, -0.44) 
CAR 0.83±0.13 0.79±0.14 0.3 0.24 (0.16, 0.32) 
CSA (cm
2




Quadriceps dysfunction is a common complication following ACL injury and 
reconstruction. 
While the precise 












The present study 
sought to determine 
the contributions of 
atrophy and CAF to lingering quadriceps weakness following ACL reconstruction.  
Neither peak quadriceps CSA nor CAR were associated with knee extension MVIC six-
months following ACL reconstruction, which was in disagreement with our hypothesis. 
While no studies to which our results can be directly compared are available, findings by 
Williams and colleagues
7
 and Mizner et al.
45
 showed that quadriceps muscle CSA and 
CAR contributed to strength loss in ACL deficient (non-copers) and total knee 
arthroplasty patients, respectively. Differences in the population studied may help to 
Figure 3.3.  Representative magnetic resonance image demonstrating quadriceps 




account for discrepancies between our results and those reported previously. 
Additionally, recent evidence suggests the relation between CSA and CAR and volitional 





 examined quadriceps atrophy and CAF in relation to strength following 
total knee arthroplasty. These authors reported that as patients reached and surpassed the 
1-year post-operative time point, quadriceps MVIC became less associated with CAF and 
more associated with muscle atrophy. Thus, it seems possible that while in the early 
stages following ACL injury or surgery CAF is significantly associated with quadriceps 
strength, the same may not be true six-months post-operatively. What is associated with 
quadriceps strength at this time point is unclear based on the present findings and it 
seems that longitudinal studies within the ACL reconstructed population may be 
warranted to elucidate the long-term contributions of both muscle atrophy and CAF to 
quadriceps strength so that appropriate intervention strategies can be employed 
Previous reports have suggested that both muscle morphology and architecture may 
mediate the relation between muscle CSA and strength, which may have contributed to 
our results. If our subjects demonstrated a selective atrophy of their Type II muscle 
fibers, this could have yielded a greater strength deficit than in the presence of more 
selective Type I fiber atrophy. Previous investigations of quadriceps muscle morphology, 
however, are conflicting. Both selective Type I
50
 and Type II 
51
 atrophy have been 
demonstrated. Additionally, previous reports have suggested that no consistent 
morphological changes may occur (i.e., both Types I and II atrophy arise).
44, 52
 Regarding 
muscle architecture, previous research
53, 54
 suggests that fiber pennation angle may 
influence muscle strength and this angle may be altered by training/detraining. In fact, 
strength training sufficient to increase muscle CSA has been shown to increase fiber 
pennation angle such that the force generating capacity of the muscle improves.
53
 As 
detraining has the opposite effect
54
, it would seem that if quadriceps strength gains are 
not being made during rehabilitation to the point that CSA is improving, that muscle 
architecture may not be influencing the relation between quadriceps strength and CSA. 
We did not assess quadriceps muscle morphology or architecture in our study and, thus, 
cannot determine if selective fiber type atrophy or fiber pennation angle played a role in 
influencing the present outcomes.  
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Together, CSA and CAF explained only 16.4% of the variance in knee extension strength 
in our subjects, raising the question of what explains the other 83.6%. The above-
mentioned factors of muscle morphology and architecture may contribute to this 
remaining variance in quadriceps strength, as well as the stiffness of the patellar tendon. 
Recent research
55
, however, suggests that patellar tendon stiffness may not be directly 
related to quadriceps strength. While factors such as knee joint effusion and pain may 
contribute, our subjects did not present with side-to-side differences in knee joint effusion 
as measured 1 cm proximal to the superior pole of the patella with a cloth tape measure 
(P=0.53).
56
 It remains possible that there may have been effusion present within the knee 
that was not detectable on clinical examination but that could have contributed to the 
CAF detected bilaterally. It has been demonstrated previously that only 20-30 mL of fluid 
is necessary to inhibit the vastus medialis
57
; however, whether this amount of effusion 
would be detectable with the measurement technique employed in the present study is 
unknown. Further, our subjects reported pain levels at only 2.36 /10 (as taken from IKDC 
questionnaire). Thus, it seems unlikely that either residual knee joint effusion or pain 
contributed substantially to the present results. Additionally, it is worth noting that the 
use of the burst superimposition technique to assess quadriceps central activation is not 
without limitations.
58, 59
 This technique allows for an estimation of maximal torque 
production and voluntary activation without regard to descending drive to the 
motoneuron pool; however, what is actually contributing to the voluntary activation 
assessed with this measurement technique is unknown.
59
 It is possible that had we 
utilized a different assessment technique, such as the Hoffman reflex or V-wave, our 
results could have been different. Future studies may benefit from the incorporation of 
these measurement techniques so a more complete understanding of central and 
descending drive to the motoneuron pool can be achieved. As this knowledge may lend to 
the development of more successful rehabilitation strategies, this research appears vital.   
In accordance with our hypothesis, the injured limb peak quadriceps CSA was smaller 
than that in the uninjured limb six-months post-operatively. Compared to previous reports 
of healthy individuals, our subjects demonstrated smaller injured limb and similar 
uninjured limb quadriceps CSA
60, 61
, suggesting that muscle atrophy in the ACL 
reconstructed limb is not sufficiently countered through post-operative rehabilitation. 
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Further, when compared to individuals three-months after ACL injury
7
, our subjects 
demonstrate greater quadriceps atrophy. It is likely that the ACL reconstruction results in 
additional atrophy to that generated by the initial injury itself, thus resulting in greater 
magnitudes of quadriceps atrophy in individuals undergoing reconstruction than ACL 
deficient individuals. Greater post-operative atrophy has been demonstrated in the 
hamstrings musculature following ACL injury and subsequent semitendinosus/gracilis 
autograft reconstruction
62
 as well as in the quadriceps following total knee arthroplasty.
45
 
Similar outcomes could be expected in the quadriceps following patellar tendon 
reconstruction, though longitudinal studies are needed to confirm this.  
Possibly contributing to the quadriceps strength deficits noted in our subjects is that all of 
our subjects underwent ACL reconstruction using a patellar tendon autograft procedure. 
It has been demonstrated previously that incomplete healing of the patellar tendon  is 
present six-months post-operatively, as indicated by increased tendon thickness and 
width
63
 and a visually present tendon defect on MRI.
64
 However, whether or not this 
influenced strength is inconclusive. Shelbourne and colleagues demonstrated that pre-
operative patellar tendon width may influence the recovery of post-operative quadriceps 
strength.
65
 However, it has also been demonstrated that by the sixth post-operative 
month, patellar tendon width no longer influences isokinetic quadriceps strength .
66
 
Future studies may benefit from incorporation of patellar tendon CSA to clarify the 
relation between patellar tendon width and quadriceps strength. 
It is worth noting that hamstrings co-contraction during MVIC and, therefore, CAF, 
testing may have additionally contributed to quadriceps weakness in our subjects. 
Hamstrings co-contraction during a knee extension MVIC would counteract the moment 
being generated by the quadriceps, thus giving the appearance of a loss of quadriceps 
strength. This relation had been demonstrated previously, though the results appear 
conflicting. A recent report by Heiden et al.
67
 noted greater hamstrings co-contraction 
during MVIC or CAF testing in persons with knee osteoarthritis compared to healthy 
persons. However, a study by Krishnan and Williams
68
 demonstrated an approximately 
2% increase in hamstrings activity during CAF testing, though these authors did not 
believe this was a clinically meaningful response. As we did not assess hamstrings 
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electromyography during the present study, we cannot determine if hamstrings co-
contraction influenced our results. 
Substantial quadriceps strength deficits were noted in our subjects. The average injured 
limb quadriceps strength was approximately 69% that of the uninjured limb, which is 
consistent with previous reports at six-months post-operatively.
12, 69, 70
 This large of a 
strength deficit, however, may be confounded by the presence of bilateral quadriceps 
CAF, which may lead to an underestimate of weakness in the injured limb.
71
 All of our 
subjects completed standard, outpatient rehabilitation, emphasizing restoration of 
quadriceps strength beginning during the first post-operative week and lasting for 
approximately four months post-operatively. It seems based on these results that 
traditional rehabilitation is insufficient in restoring quadriceps strength by the time 
individuals are released to full activity. Given that quadriceps muscle contraction is 
required for the execution of various dynamic movement strategies, it would seem ideal 
to be returning individuals to activity with as near maximal strength as possible. A study 
examining isolated quadriceps fatigue as a means of generating muscle weakness 
demonstrated reductions in the external knee extension moment, a finding consistently 
implicated in the non-contact ACL injury mechanism.
72
 Similar results have been 
demonstrated following induction of an experimental knee joint effusion
73
, which is 
known to cause quadriceps CAF.
71
 Additionally, considering the importance of the 
quadriceps in energy absorption on weight bearing and the potential implications for joint 
degeneration, more complete restoration of quadriceps strength following ACL 
reconstruction seems imperative.   
 Substantial deficits in CAF were present bilaterally in our subjects (17% in the 
reconstructed and 21% in the contralateral limb). The magnitude of CAF in those with 
ACL injury varies, with some studies reporting greater
74
 and others reporting smaller
7, 75
 
levels of activation failure than those demonstrated presently. Bilateral CAF has also 
been reported following ACL reconstruction, with Urbach and colleagues reporting 15% 
and 16% quadriceps central activation deficits in the reconstructed and contralateral 
limbs, respectively upwards of two years post-operatively.
35
 Together, these results 
34 
 
suggest that central drive to the quadriceps musculature is relatively equally impaired 
bilaterally and that that impairment lingers six-months post-operatively. 
It should be noted that the relation between quadriceps CAF and strength was close to 
achieving statistical significance in the present study. It is possible that this lack of 
significance is a result of insufficient statistical power. Future investigations could benefit 
from the inclusion of additional subjects.   
CONCLUSION 
Though the present study failed to establish an association between quadriceps CSA and 
CAF and knee extension MVIC, substantial deficits in all three measurements were 
demonstrated six-months after patellar tendon autograft ACL reconstruction, suggesting 
that current rehabilitation efforts are insufficient at removing these deficits. It appears 
that further research is necessary to determine the precise contributors to persistent 
quadriceps dysfunction. Until it is known why quadriceps dysfunction persists, it will be 
















CHAPTER 4  
NEUROMUSCULAR FATIGUE AND QUADRICEPS INHIBITION ALTER 
LOWER EXTREMITY BIOMECHANICS 
 
ABSTRACT 
Quadriceps central activation failure (CAF) occurs frequently following anterior cruciate 
ligament reconstruction (ACLr) and lingers beyond the rehabilitation period. CAF 
impairs the ability to activate the quadriceps fully and has been demonstrated to alter 
lower extremity biomechanics. Neuromuscular fatigue similarly reduces volitional 
activation and neuromechanical control strategies within the affected muscle. Individuals 
returning to activity following ACLr likely experience both quadriceps CAF and 
neuromuscular fatigue, though the effects of fatigue on muscles experiencing CAF in this 
population are unknown. This study examined the effects of neuromuscular fatigue on 
CAF following ACLr. Seventeen individuals 7-10 months post-ACLr and 16 healthy, 
control subjects participated. Subjects had quadriceps strength and the central activation 
ratio (CAR) recorded pre- and post-fatigue, which was induced via sets of double-leg 
squats. Knee sagittal and frontal plane biomechanics were recorded while subjects 
performed a dynamic landing activity pre- and post-fatigue and submitted to a standard 
inverse dynamics analysis. Statistical analysis consisted of 2x2 (time x group) repeated 
measures ANOVAs. Both groups demonstrated smaller knee flexion angles (initial 
contact [IC]: P=0.018; peak stance [PS]: P=0.002) and moments (P<0.001) post-fatigue. 
Both groups also landed with less knee abduction (IC: P=0.005; PS: P=0.017) and 
smaller abduction moments (P=0.024) following fatigue. The ACLr group was less 
flexed at PS (P=0.009) and experienced a smaller flexion moment than controls 
regardless of fatigue state (P<0.001). Following fatigue, all subjects (ACLr and control) 
demonstrated significantly lower MVIC (P<0.001) and CAR (P=0.003) values.  No 
group differences were detected for either MVIC (P=0.13) or CAR (P=0.17).  Both 
groups demonstrated quadriceps weakness and CAF following fatigue concurrent with 
altered biomechanics. These biomechanical alterations may prove injurious and have 
been linked to non-contact ACL injury risk, confirming the need to consider fatigue-
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resistance training within non-contact ACL prevention programs. Incorporation of 
fatigue-resistance within rehabilitation following ACLr does not seem necessary as 
fatigue did not worsen biomechanics in individuals after ACLr. 
INTRODUCTION 
Quadriceps weakness is a nearly universal consequence of anterior cruciate ligament 
(ACL) injury with previous reports suggesting that it may linger upwards of seven years 
post-operatively.
17
 Central activation failure (CAF) reduces volitional activation of the 
affected muscle, thereby contributing to weakness. The presence of quadriceps weakness 
along with CAF may be detrimental to those returning to activity following ACL 
reconstruction (ACLr). Following experimental knee joint effusion, which is known to 
induce quadriceps CAF, it was found that individuals landed with a smaller knee flexion 
angle and a reduced external knee flexion moment.
73
 These biomechanical alterations 
have been implicated in the non-contact ACL injury mechanism and, as such, seem 
potentially hazardous.  
Like CAF, neuromuscular fatigue also reduces voluntary activation of the affected 
musculature.
76
 Neuromuscular fatigue is an inevitable occurrence during athletic activity 
and has been demonstrated to alter lower extremity biomechanics
72, 77-79
 to the point of 
potentially increasing ACL injury risk. Gross lower extremity neuromuscular fatigue has 
been reported to increase knee extension and abduction postures and moments
79, 80
, all of 
which have been implicated in the non-contact ACL injury mechanism.  
In healthy individuals, it has been demonstrated that fatigue impairs quadriceps central 
activation and that this effect may be magnified in the presence of muscle weakness. 
Stackhouse and colleagues
11
 compared healthy elderly and young adults pre- and post-
fatigue. Prior to fatigue, elderly adults were weaker than and had greater quadriceps CAF 
compared to young adults, with this difference becoming greater following fatigue. 
There are few data to suggest how the quadriceps respond to neuromuscular fatigue 
following ACL injury/reconstruction, and those results appear conflicting. One study 
suggested that ACL-deficient limbs demonstrated greater magnitudes of quadriceps 





 A separate study, however, suggested that the quadriceps of the ACLr 
limb demonstrated greater fatigue resistance than that of the uninvolved limb.
82 
With individuals returning to activity following ACLr likely experiencing both 
quadriceps CAF and neuromuscular fatigue, it seems imperative to understand their 
combined effects so that strategies to combat the potentially hazardous consequences can 
be developed to better protect the ACLr knee from re-injury upon return to activity. The 
purpose of this study, therefore, was to determine the effects of neuromuscular fatigue on 
lower extremity strength and biomechanics in individuals with quadriceps CAF following 
ACLr compared to healthy persons. We hypothesized that, following fatigue, subjects 
would demonstrate increased knee extension and abduction angles/moments following 
fatigue and that all biomechanical changes would be greater in those following ACLr 
than in healthy subjects. Additionally, we hypothesized that subjects in the ACLr group 
would demonstrate greater quadriceps weakness and CAF prior to fatigue and reach 




Seventeen individuals who underwent ACLr 7-10 months prior to enrollment (10 male, 7 
female; age: 21.41±4.73 years; height: 1.75±0.08 m; mass: 76.52±11.85 kg) and 16 
control (5male, 11female; age: 23.38±4.11 years; 1.71±0.08 m; mass: 68.21±10.17 kg) 
subjects participated in this study. For the purpose of determining a test limb for data 
analysis, each healthy individual was assigned to an ACLr subject according to age and 
activity level. The limb corresponding to the  C r subject‘s reconstructed limb was 
designated as the control subject‘s matched limb and utilized in data analysis.  
Potential subjects were excluded if they: had a history of lower extremity surgery other 
than their recent ACL reconstruction, had suffered a lower extremity injury since 
undergoing ACL reconstruction, had current pain in either knee, underwent 
meniscectomy with their ACL reconstruction, had other ligamentous damage concurrent 
with their ACL injury, or had a known heart condition. Pregnant females were also 
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excluded. Control subjects additionally could not have a history of ACL reconstruction or 
have suffered a lower limb injury in the previous six months. This study was approved by 
the medical school institutional review board at the University of Michigan. All subjects 
provided written consent prior to participation. 
Strength and Central Activation Failure Assessment 
Quadriceps strength was assessed during the performance of a knee extension maximal 
voluntary isometric contraction (MVIC) while subjects were seated on an isokinetic 
dynamometer (Biodex System 3, Biodex Medical Systems, Shirley, NY, USA) with the 
hip flexed to 85° and the knee flexed to 90°. For the MVICs, subjects were instructed to 
extend their knee as hard as they could while watching a computer screen running a 
custom-written program (Labview 8.5, National Instruments, Austin, TX, USA) showing 
their real-time torque output. Following completion of the first MVIC trial, the program 
displayed a solid line reflecting the subject‘s peak torque value from and a dashed line set 
10% above the peak torque recorded from the initial MVIC. (Figure 3.1). For all 
subsequent trials, subjects were encouraged to reach this target torque value (dashed 
line). If subjects increased their torque during any of the subsequent trials, the height of 
the solid and dashed lines would be adjusted appropriately. Knee extension MVICs 
(minimum of three) were performed, with at least two minutes of rest in between each 
repetition, until no improvements in torque were observed by an investigator. Once each 
subject‘s knee extension torque failed to increase, the peak torque value from all recorded 
repetitions was noted and used as a threshold value for subsequent CAF assessment.  
For CAF testing, self-adhesive, stimulating electrodes (Dura-Stick II [5 cm x 9 cm] 
Chattanooga Group, Hixson, TN, USA) were applied proximally over the rectus femoris 
and distally over the vastus medialis. At the beginning of testing, the peak torque value 
recorded during the MVIC trials was inputted into the computer program. The program 
utilized this threshold (peak torque) value to determine whether or not it would trigger the 
electrical stimulator (S88 and SIU8T, GRASS Technologies, West Warwick, RI, USA) to 
deliver a stimulus (100 ms-long train, pulse duration: 600 s, delivery rate: 100 pulses 
per second, maximum voltage: 130V). Subjects were again instructed to generate enough 
torque to reach the dashed target line displayed on the screen (i.e., a value 10% greater 
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than their peak torque generated during MVIC testing). The computer program was set to 
deliver the stimulus once a subject‘s torque value reached threshold and then fell one Nm 
below their peak torque for the present trial. If a subject failed to reach the solid threshold 
line, the program would not deliver the stimulus, and the subject would be given two 
minutes of rest before the trial was repeated.  The dashed target line was set so as to be 
unreachable for the subject; however, in the event that a subject did reach the target 
value, the maximal strength value (solid threshold line) was reset and CAF testing was 
reinitiated. Three repetitions of CAF testing were performed with two minutes of rest 
provided between repetitions.  
CAF was quantified using the central activation ratio (CAR), wherein the peak torque 
generated immediately prior to the delivery of the electrical stimulus is divided by the 
peak torque generated as a result of the superimposed stimulus. Prior to the fatiguing 
exercise, three repetitions were performed with two minutes of rest provided between 
repetitions to limit the effects of fatigue on the measurement. Following the fatiguing 
exercise, three recordings were again captured, with only 30 seconds of rest provided. 
The average CAR over the three repetitions for each time point (pre- or post-fatigue) was 
used to quantify quadriceps CAF. Knee extension strength was also determined from 
these C F repetitions. The subject‘s torque value generated immediately prior to delivery 
of the electrical stimulus was recorded and divided by participant body mass (kg). The 
average value over these three repetitions was utilized to quantify strength (Nm/kg). All 
measurements were recorded bilaterally, though only data recorded in the ACLr or 
matched limb in control subjects were submitted to statistical analysis.  
Neuromuscular Fatigue 
The fatiguing exercise consisted of sets of eight double-leg squats performed to a depth 
of 90° of knee flexion followed by the performance of a dynamic landing task. Verbal 
encouragement and feedback regarding knee joint angle were provided to subjects during 
the fatiguing exercise.  
Subjects performed sets of squats until maximal fatigue was achieved, defined as the 
point at which subjects could no longer: 1) perform five consecutive repetitions to 90° of 
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knee flexion without assistance or 2) consistently reach the force platform during the 
dynamic landing task. The fatiguing exercise was also stopped if subjects reported pain in 
the ACL reconstructed knee. There was no limit on the number of squats a subject could 
perform.  
Dynamic Landing Task 
Dynamic landings were performed prior to fatigue, at maximal fatigue, and following the 
completion of each set of squats. For dynamic landings, subjects jumped forward off of 
both legs over a 17 cm box
83
 and landed on one 
limb on a force platform (OR 6-7; Advanced 
Medical Technology, Inc, Watertown, MA) 
located one meter away. Immediately upon 
landing, subjects aggressively jumped laterally 
to the opposite side. The limb on which subjects 
landed was randomly determined using a 
custom-written program displayed on a 
computer screen in front of the subject. If the 
subject was to land on his/her right limb, a light 
was displayed on the right side of the computer 
screen and the subject would jump forward, land 
on his/her right limb on the force platform and 
then laterally jump to the left (Figure 4.1) 
Subjects practiced the dynamic landing prior to 
fatigue to allow adequate familiarization with the 
task. Three good trials, defined as the proper 
limb landing completely on the force platform, were analyzed pre- and post-fatigue. In 
the event that subjects could no longer consistently reach the force platform at maximal 
fatigue, the three previous dynamic landing trials were utilized as the post-fatigue 
landings. 
Biomechanical Data Collection and Analysis  
Figure 4.1.  Dynamic landing task. 
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Subjects were outfitted with 32 precisely 
attached retro-reflective markers (Figure 
4.2) that were tracked via an 8-camera, 
high-speed (240 Hz) motion capture 
system (Vicon, Oxford Metrics, London, 
England) and from which joint rotations 
were quantified. An initial video 
recording was captured with subjects 
standing in a stationary position.
84
 This 
static recording was utilized to generate a 
kinematic model in Visual 3D (C-
Motion; Rockville, MD). The three-
dimensional marker trajectories recorded 
during each dynamic landing trial were 
processed within Visual3D to solve for 
the respective joint rotations of each frame. Rotations were calculated utilizing a Cardan 
rotation sequence
85
 and expressed relative to each subject‘s stationary position.
79
 Three-
dimensional ground reaction force (GRF) data were synchronized with the kinematic data 
and both were filtered using a zero-lag, Butterworth filter with a 12-Hz cut-off 
frequency
79
 and submitted to standard inverse dynamics analysis within Visual 3D.
86
 
Kinetic outputs were normalized to subject body mass and height
86
 and represented as 
external moments. Biomechanical data were time normalized to 100% of the stance phase 
for graphical purposes, with initial contact (IC) and toe-off equating to the time when the 
vertical GRF first exceeded and fell below 10N, respectively.
79, 80
  
IC and peak stance (PS) knee joint sagittal and frontal plane rotations over the first 50% 
of stance were calculated for each landing trial.
80
 PS joint moment data were also 
recorded in the sagittal and frontal planes at the knee. Data were analyzed during the first 
half of stance only as it is believed this is when ACL injury is most likely to occur.
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Biomechanical data were analyzed for the ACL reconstructed limb or a matched limb in 
control subjects only.  
Figure 4.2.  Retro-reflective marker placement for 




Sagittal and frontal plane knee joint angles and moments as well as CAR and MVIC were 
analyzed via 2x2 repeated measures ANOVAs. Each model had one within-subjects 
factor, fatigue state (pre- and post-fatigue) and one between-subjects factor, group (ACLr 
and control). An independent samples t-test was performed to determine if individuals in 
the ACLr group reached maximal fatigue faster than those in the control group. Sidak 
multiple comparisons procedures and univariate F-tests were utilized for all post hoc 
analyses. The -level was set a priori at P ≤ 0.05. Statistical analyses were performed 
using the Statistical Package for the Social Sciences (SPSS) software version 17.0 (SPSS, 
Inc., Chicago, IL). Effect sizes and their associated confidence intervals were calculated 
using Cohen‘s d 
23
 within Microsoft Excel 2007 (Microsoft Corporation, Redmond, WA).  
These were calculated as either 
         -            
                         
 or 
    -            -    -           
                         
  
Effect sizes were interpreted as having small (0.2-0.5), moderate (0.51-0.8), or large 





A time main effect was noted for sagittal and frontal plane knee joint angles at IC 
(sagittal P=0.018; frontal P=0.005) and at PS (sagittal P=0.002; frontal P=0.017) (Table 
4.1). Specifically, ACLr and control subjects landed in a more extended and abducted 
posture when fatigued (Figure 4.3). A group main effect was also noted indicating that 
ACLr subjects demonstrated a significantly less flexed knee angle at PS  (P=0.009) 
compared to the control subjects. No additional group main effects were noted for the 
remaining joint rotations (IC knee sagittal P=0.11; IC knee frontal P=0.83; PS knee 
frontal P=0.58). 
Significant time by group interactions were found for knee sagittal (P=0.019) plane 
angles at PS, but not for IC angles (sagittal P=0.079; frontal P=0.097) or PS knee frontal 
plane angles (P=0.222). Post hoc analyses revealed that prior to fatigue, individuals in the 
ACLr group demonstrated less knee joint flexion at peak stance compared to the control  
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Table 4.1. .Initial contact (IC) and peak stance (PS) knee joint rotations pre- and post- fatigue.  Data are 
mean±standard deviation. 
Joint Rotations (°) ACLr Control 
 Pre-Fatigue Post-Fatigue Pre-Fatigue Post-Fatigue 
IC Knee Extension/Flexion -10.3±5.5 -9.8±5.3 -14.3±4.3 -10.7±4.3 
IC Knee Adduction/Abduction -3.2±2.7 -2.8±3.1 -4.0±2.4 -2.4±2.5 
PS Knee Extension/Flexion -45.4±10.6 -44.1±6.1 -56.6±6.7 -48.2±10.9 
PS Knee Adduction/Abduction -12.2±6.8 -11.2±6.8 -13.6±6.8 -10.9±5.8 
The rotation listed first is positive 
group (P=0.001). No other significant post hoc results were detected (knee sagittal post-
fatigue P=0.19). 
Joint Moments 
Significant time (P<0.001) and group (P<0.001) main effects were detected for the 
sagittal plane knee moment (Table 4.2). Subjects in both groups demonstrated smaller 
external knee flexion moments following fatigue, with the ACLr group, regardless of 
fatigue state, experiencing smaller moments than the control subjects (Figure 4.4). There 
were time (P=0.024) but not group (P=0.2) main effects for the knee frontal plane 
moment, suggesting that regardless of group, subjects demonstrated smaller knee 
abduction moments following fatigue. 
Table 4.2.  Knee joint moments (Nm/kg*m) pre- and post-fatigue. Data are mean±standard deviation. 
Joint Moments (Nm/kg*m) ACLr Control 
 Pre-Fatigue Post-Fatigue Pre-Fatigue Post-Fatigue 
PS Knee Extension/Flexion -1.10±0.29 -1.00±0.29 -1.74±0.24 -1.20±0.37 
PS Knee Adduction/Abduction 0.29±0.15 0.28±0.18 0.43±0.19 0.31±0.16 
The moment listed first is positive 
A significant time by group interaction was identified for the knee sagittal plane moment 
(P<0.001). The ACLr group pre-fatigue had smaller external knee flexion moments than 
the control group (P<0.001).  No statistical differences were noted between groups post-
fatigue (P=0.085). 
Table 4.3.  Knee extension strength (Nm/kg) and quadriceps central activation ratio data. Data are 
mean±standard deviation. 
 ACLr Control 
 Pre-Fatigue Post-Fatigue Pre-Fatigue Post-Fatigue 
Knee Extension MVIC (Nm/kg) 2.03±0.57 1.58±0.46 2.63±0.92 1.61±0.54 
Quadriceps CAR 0.82±0.11 0.78±0.13 0.89±0.10 0.82±0.14 
 
Strength and Central Activation Ratio  
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Following fatigue, all subjects (ACLr and control) demonstrated significantly lower 
MVIC (P<0.001) (Figure 4.5) and CAR (P=0.003) (Figure 4.6) values (Table 4.3).  No 
group differences were detected for either MVIC (P=0.13) or CAR (P=0.17). There was, 
however, a significant time by group interaction for MVIC (P=0.007) only, with post hoc  
 
Figure 4.3. Pre- and post-fatigue joint rotations expressed as a percentage of the stance phase. A: ACLr 
group knee sagittal plane angle. B- control group knee sagittal plane angle. C- ACLr group knee frontal 
plane angle. D- Control group knee frontal plane angle. 
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analyses revealing that prior to fatigue, the ACLr group had significantly lower 
quadriceps strength than the control group (P=0.03). There were no post-fatigue 
differences in MVIC between groups (P=0.89). 
 
Figure 4.4. Pre- and post-fatigue joint moments expressed as a percentage of the stance phase. A: ACLr 
group knee sagittal plane moment. B- control group knee sagittal plane moment. C- ACLr group knee 




Rate of Fatigue 
There was no statistical difference in the number of squats performed to reach maximal 
fatigue between groups (ACLr: 440.94±234.84; control: 543.13±307.67; P=0.29). 
 
Figure 4.5.  Mean±standard deviation knee extension strength (Nm/kg). * indicates significant difference 
between groups prior to fatigue. † indicates time main effect. 
DISCUSSION 
Both quadriceps CAF and neuromuscular fatigue impair volitional muscle activity, 
potentially yielding hazardous lower extremity biomechanics control strategies. 
Considering that individuals returning to sports following ACLr frequently present with 
quadriceps CAF and that neuromuscular fatigue is inevitable in athletic activity, 
understanding the cumulative effects of these two impairments seems crucial so that 
strategies to counter them can be better incorporated into post-operative rehabilitation. 
This study sought to elucidate the combined effects of quadriceps CAF and 
neuromuscular fatigue on lower limb biomechanics.  
In accordance with our hypothesis, subjects demonstrated less knee flexion at IC and PS 
with concurrent reductions in the external knee flexion moment following fatigue. This 
sagittal plane biomechanical profile has been demonstrated previously in healthy adults 
following both gross lower extremity neuromuscular fatigue
79, 80
 as well as following 
isolated quadriceps and hamstrings fatigue.
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position may protect against collapse of the lower extremity on landing, increases in both 
the knee extension angle and moment have been implicated within the non-contact ACL 
injury mechanism.
33, 89
 Thus, this adaptive strategy may be hazardous. To the best of our 
knowledge, this is the first study to demonstrate these altered sagittal plane biomechanics 
in individuals following ACLr and fatigue. 
 
Figure 4.6. Mean±standard deviation quadriceps central activation ratio. *indicates significant time main 
effect. 
Both ACLr and control subjects demonstrated smaller knee abduction angles and 
abduction moments following fatigue. Previous studies have reported increases in both 
the knee abduction angle
72, 77, 79, 80
 and moment
79
 post-fatigue as well as a lack of change 
in knee frontal plane biomechanics as a result of fatigue.
78
 Our subjects may have 
developed a less aggressive landing strategy post-fatigue, one that allowed for a more 
neutral frontal plane knee angle during push-off. Alternatively, differences in the fatigue 
protocol employed between studies may account for these discrepancies. Several of these 
previous studies
77, 79
 incorporated a change of direction task into their fatiguing exercises 
which may have allowed fatigue of the out of plane hip stabilizers. As the out of plane 
hip stabilizers aid frontal plane knee control, fatigue within these muscles may precipitate 
increased knee abduction.
90
  Our fatiguing exercise consisted of a primarily sagittal plane 
motion, thus fatigue was likely limited to the quadriceps, hamstrings, and gluteus 
maximus muscles, thereby minimizing changes in knee frontal plane biomechanics 






























those reported previously are differences in the subject population utilized, with previous 
studies
79, 80
 utilizing division I athletes and the present study using a recreational athlete 
population. Previous research
91
 indicates that subject skill level and training influence 
lower extremity neuromuscular control, which may contribute to how an individual 
performs a given task, and hence, affect study outcomes.  
ACLr subjects demonstrated similar knee sagittal plane biomechanics regardless of 
fatigue state and in spite of a 22% reduction in their quadriceps strength following 
fatigue, suggesting that fatigue did not negatively influence sagittal plane biomechanics 
in the ACLr subjects to the same extent as the control group. Why this may have 
occurred is unclear. However, it seems that the ACLr group may have relied on a 
primarily hip dominant strategy
92
 to decelerate the body during landing rather than one 
utilizing the quadriceps. This control strategy, often deemed the ―quadriceps avoidance‖ 
or ―knee stiffening‖ strategy, has been demonstrated in  C  deficient and reconstructed 
individuals during walking
93, 94
 and may have translated to the dynamic activity 
employed within the present study. Relying on the hip musculature could have led to 
relatively unaltered sagittal plane knee biomechanics even in the presence of quadriceps 
fatigue. Future investigations are needed to clarify this relation between ACLr and 
biomechanics during activity. Alternatively, it is possible the ACLr subjects compensated 
using their uninjured limb during the squatting exercise, relying on the healthy limb to 
perform the majority of the work. This could have resulted in greater contralateral limb 
fatigue and, as such, relatively unchanged reconstructed limb biomechanics.  
Following fatigue, both the ACLr and control groups demonstrated reductions in the 
CAR value, indicative of more severe CAF. Previous studies have also demonstrated 
reductions in central activation following fatigue, despite differences in muscle groups 
and fatiguing protocols employed.
95, 96
 Together, these results suggest that neuromuscular 
fatigue, in part, is centrally mediated. Given the hazardous biomechanics demonstrated 
by our subjects as a result of fatigue, it seems that incorporation of training techniques to 




There were no differences in CAF between groups prior to fatigue, which is in conflict 
with our hypothesis. Several explanations for this finding are possible. First, 
rehabilitation may have restored some of the quadriceps CAF in the ACLr group, 
bringing the ACLr pre-fatigue CAR values more in line with those of the control group 
and contributing to the initial lack of difference in CAF. Second, the control group 
demonstrated an average pre-fatigue CAR of 0.89, which is below the previously 
accepted standard of 0.95 for fully activated in a normal, healthy individual.
97
 It is 
possible, however, that the magnitude of the CAR in healthy individuals is lower than 
previously reported. Recent work indicates that voluntary activation in young, healthy 
individuals may be slightly lower at 94% and 90% in the stronger and weaker limbs, 
respectively
98
. Third, as current knee injury and pain influence CAF assessment, control 
subjects were carefully screened to be free of both injury and pain at the time of testing 
(average International Knee Documentation Committee [IKDC]  score of 98.25/100), 
making it unlikely that these influenced the control subjects‘ pre-fatigue CAR values. 
Finally, it should be noted that when examining the effect sizes calculated for the CAR 
variable, both the time and group main effect values were small at -0.35 and -0.49 (Table 
4.4), respectively. These values raise the question of whether or not statistically 
significant differences in CAR measurements between these two groups or across fatigue 
states are even clinically meaningful.  
Table 4.4.  Effect sizes for time and group main effects. 
Time Main Effects Effect Size Confidence Interval 
  Lower Bound Upper Bound 
IC Knee Extension/Flexion Rotation 0.31 -1.35 1.97 
IC Knee Adduction/Abduction Rotation 0.28 -0.41 0.98 
PS Knee Extension/Flexion Rotation 0.40 -2.41 3.21 
PS Knee Adduction/Abduction Rotation 0.20 -1.21 1.61 
PS Knee Extension/Flexion Moment 0.78 0.68 0.87 
PS Knee Adduction/Abduction Moment 0.26 0.21 0.31 
Quadriceps MVIC -0.82 -1.02 -0.63 
Quadriceps CAR -0.35 -0.39 -0.32 
Group Main Effects    
    
IC Knee Extension/Flexion Rotation 0.57 -2.33 3.47 
IC Knee Adduction/Abduction Rotation 0.07 -1.63 1.78 
PS Knee Extension/Flexion Rotation 0.97 -4.38 6.33 
PS Knee Adduction/Abduction Rotation 0.10 -4.01 4.20 
PS Knee Extension/Flexion Moment 1.59 1.41 1.77 
PS Knee Adduction/Abduction Moment 0.53 0.43 0.64 
Quadriceps MVIC -0.54 -0.94 -0.15 
Quadriceps CAR -0.49 -0.57 -0.42 
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Both the ACLr and control groups required a similar number of squats to reach maximal 
fatigue. This seems counter-intuitive considering that previous research has demonstrated 
that weaker muscle fatigues more quickly than stronger muscle.
11, 99
 However, a previous 
study by Snyder-Mackler and colleagues
82
 in individuals following ACLr found the 
quadriceps in the ACLr limb to be more fatigue-resistant than that in the contralateral 
limb. These authors suggested selective Type IIb fiber atrophy in the ACLr limb 
quadriceps may have contributed to this finding.
82
 Type IIb fibers are fast twitch, non-
fatigue resistant and, as such, a lower percentage of these within the quadriceps may lend 
to a more endurant muscle. The results of morphological studies following ACLr are 
conflicting, however, with studies demonstrating both selective Type I atrophy
50
, 
selective Type II atrophy
51
, as well as a relative predominance of both.
44
 We did not 
consider quadriceps morphology within the present study and thus cannot determine if 
selective fiber type atrophy contributed to our findings.  
It is worth noting that we included individuals who underwent both patellar tendon and 
semitendinosus/gracilis autograft ACLr in this study, which may have influenced our 
results. It is unknown whether persons who are reconstructed with different graft types 
respond differently to fatigue. Future studies may be needed to elucidate the potential 
differential responses of both graft types to neuromuscular fatigue so that graft type-
specific rehabilitation strategies can be developed if necessary. 
CONCLUSION 
Both the ACLr and control groups demonstrated alterations in their knee joint 
biomechanics as well as reductions in quadriceps strength and CAR following fatigue. 
The worsening of sagittal and frontal plane biomechanics in the control subjects as a 
result of fatigue confirmed the need to perform fatigue-resistance training within ACL 
injury prevention modalities. That these neuromuscular and biomechanical changes were 
not more pronounced in the ACLr group was unexpected. Considering the important 
implications for re-injury, future studies seem necessary to further elucidate the effects of 
fatigue and CAF on lower extremity biomechanics in individuals after ACLr.  
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CHAPTER 5  
DISCUSSION 
This dissertation examined the effects of anterior cruciate ligament (ACL) injury and 
reconstruction on resultant lower extremity muscle weakness. In the first study, 
examining strength throughout the lower limb following ACL injury and reconstruction, I 
found that ACL injury lead to quadriceps, hamstrings, and ankle plantar flexor weakness, 
with the latter being sufficiently countered during post-operative rehabilitation, whereas 
quadriceps and hamstrings weakness were not restored six-months post-operatively. 
There were no hip or ankle muscle strength deficits when ACL-injured persons were 
compared to healthy individuals pre- or post-operatively, though differences existed for 
quadriceps and hamstring strength pre-operatively between ACL-injured and control 
individuals The results from this study suggested that improvements in current 
rehabilitation strategies are necessary to better target lingering quadriceps and hamstrings 
strength deficits.  
In the second study, I examined two possible contributors to quadriceps weakness, central 
activation failure (CAF) and quadriceps atrophy, following ACL reconstruction (ACLr). 
Quadriceps CAF and atrophy were not associated with reconstructed limb strength 
deficits six-months post-operatively. This finding was in spite of substantial deficits in all 
three measurements and significant side-to-side differences in strength and atrophy. Thus, 
while atrophy and CAF were present six-months post-operatively, apparently other 
unknown factors were contributing to quadriceps strength deficits following ACLr. 
Elucidating these other contributors is imperative to countering quadriceps weakness 
within this population. 
Finally, I examined the effects of quadriceps CAF and neuromuscular fatigue on knee 
joint biomechanics during landing. Compared to healthy people, individuals following 
ACLr demonstrated pre-fatigue biomechanics (reduced knee flexion angles and moments 
compared to controls) that may put them at risk for ACL re-injury. In addition, following 
fatigue both groups demonstrated potentially injurious changes in their knee joint 
biomechanics as well as impaired quadriceps strength and central activation. These 
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results corroborate that fatigue resistance training is warranted within ACL injury 
prevention strategies.  
Collectively, these studies confirmed previous research suggesting that quadriceps 
weakness lingers despite rehabilitation following ACLr.
13, 17, 27
 It is likely that until the 
contributing factors to weakness are known, attempts to fully eliminate it will prove 
difficult. In spite of investigating two of these possible contributing factors (CAF and 
atrophy) to quadriceps weakness in Chapter 3, we are currently no closer to determining 
the underlying causes of persistent quadriceps weakness following ACLr. As this was the 
first study to examine possible contributors to lingering quadriceps weakness following 
ACLr, no studies are available to which to compare our results directly. However, studies 
conducted in populations with similar quadriceps weakness suggest a clear link between 
CAF and atrophy and weakness, suggesting future studies need to be conducted to help 
confirm or refute our findings. 
The inability to restore quadriceps strength may be hazardous to individuals upon return 
to activity following ACLr, which was confirmed in Chapter 4. ACLr subjects, 
presenting with initial quadriceps weakness and CAF, demonstrated pre-fatigue 
biomechanics that have been implicated within the non-contact ACL injury 
mechanism.
33, 89
 These findings were consistent with those demonstrated after induction 
of experimental knee joint effusion
73
, which can cause quadriceps CAF.  Along with the 
control subjects, the ACLr group demonstrated potentially injurious post-fatigue knee 
joint biomechanics, reductions in quadriceps strength, and greater CAF.  These fatigue-
induced changes in biomechanics have been demonstrated in healthy people previously. 
This was the first study, however, to examine the effects of fatigue on biomechanics in 
individuals after ACLr. Our results suggested that incorporating fatigue-resistance 
training within current rehabilitation programs following ACLr may be necessary to aid 
in protecting individuals from re-injury upon return to activity post-operatively, though 
future studies confirming this are warranted. 
STRENGTHS OF THE DISSERTATION 
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Collectively, these studies lend support to the body of literature suggesting a need to 
improve current post-operative ACL rehabilitation strategies as they relate to improving 
quadriceps strength. As these studies conclude, until it is known what contributes to the 
lingering quadriceps strength deficits presenting after ACLr, they cannot be effectively 
countered during rehabilitation. Chapter 3 began to provide some insight into what those 
contributors to muscle weakness might be, suggesting that both quadriceps CAF and 
atrophy accounted for a small portion of quadriceps weakness. 
Chapter 4 provided direct biomechanical evidence that failure to restore quadriceps 
strength and central activation fully precipitates knee joint biomechanics during landing 
that have been implicated within the non-contact ACL injury mechanism. This suggested 
that the reconstruction and/or rehabilitation processes are not sufficiently reducing the 
biomechanical risk factors for re-injury when individuals return to activity.  
LIMITATIONS OF THE DISSERTATION 
Individuals undergoing both bone-patellar-tendon-bone and semitendinosus/gracilis 
autograft ACLr procedures were included within Chapters 2 and 4. The premise of these 
studies, however, was not to delineate the effects of ACL reconstruction on lower 
extremity muscle dysfunction by graft type.  
Additionally, the strength and activation measurements employed in all three chapters 
were highly dependent on the subject eliciting maximal effort during testing.  Despite the 
best efforts of the investigator and the use of visual feedback during testing, how much 
effort a subject put forth on a given trial was unknown.   
The nature of the fatiguing exercise utilized in Chapter 4 may have limited the magnitude 
of the fatigue effect in the ACL reconstructed subjects. It seemed, despite constant 
encouragement against it, that the subjects may have compensated and utilized their 
contralateral limb to their advantage during the squatting exercise. It is possible that this 
healthy limb fatigued to a greater extent than the ACL reconstructed limb, which could 
have contributed to the results demonstrated by this group.   
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1) Strength in the muscles crossing the hip and ankle joints was not different in 
anterior cruciate ligament (ACL)-injured individuals compared to healthy persons 
prior to or following surgical reconstruction. 
2) Pre-operative ankle plantar flexor strength deficits were present in the injured 
compared to the uninjured limb.  
3) Quadriceps and hamstrings strength deficits were present pre- and post-
operatively in the injured versus the uninjured limb. These deficits also were 
present pre-operatively compared to healthy individuals 
Conclusion: 
Aside from the initial injury causing ankle plantar flexor weakness, strength within the 
hip and ankle musculature did not appear to be negatively influenced by either ACL 
injury or reconstruction. These results confirmed those of previous studies demonstrating 
the presence of quadriceps and hamstrings strength deficits in the injured/reconstructed 
limb pre- and post-operatively. The quadriceps and the hamstrings are important in 
controlling lower extremity dynamic stability. Persistent weakness within these muscle 
groups may lend to potentially injurious biomechanical strategies when individuals return 
to activity following ACL reconstruction. Thus, developing rehabilitation strategies to 
more effectively counter strength deficits within the quadriceps and hamstrings 





1) Quadriceps central activation failure (CAF) and cross sectional area (CSA) were 
not significantly associated with knee extension strength six-months after ACL 
reconstruction. 
2) Peak quadriceps CSA and MVIC were significantly impaired in the injured limb 
six-months post-operatively compared to the uninjured limb. The CAR did not 
differ between limbs though the average CAR values indicated bilateral CAF was 
present.  
Conclusion: 
In spite of a lack of significant association between quadriceps CAF and CSA and knee 
extension strength, substantial deficits were noted in all three measurements six-months 
after ACL reconstruction, indicating current rehabilitation strategies are inadequate at 
removing these deficits.  
CHAPTER 4 
Findings: 
1) ACL reconstructed and control subjects landed with smaller knee flexion angles 
and moments post-fatigue, both of which have been linked with non-contact ACL 
injury risk. Further, ACL reconstructed subjects had smaller knee flexion angles 
and moments at peak stance than controls regardless of fatigue-state.  
2) Following fatigue, both groups landed with less knee abduction.  
3) Both ACL reconstructed and control subjects demonstrated reductions in 
quadriceps strength and central activation as a result of fatigue. The ACL 
reconstructed subjects had greater quadriceps weakness prior to fatigue than 
controls.   
Conclusion: 
Both the ACL reconstruction and control groups demonstrated alterations in their knee 
joint biomechanics as well as greater quadriceps weakness and CAF following fatigue. 
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These hazardous post-fatigue biomechanics confirmed the need to perform fatigue-
resistance training within ACL injury prevention modalities and suggested the need to 
explore fatigue-resistance training within rehabilitation following ACL reconstruction. 
The reduction in central activation concurrent with fatigue indicates that prevention 
strategies may benefit from improvements in central control. That these neuromuscular 
and biomechanical changes were not more pronounced in those undergoing ACL 
reconstruction was unexpected. Considering the important implications for re-injury, 
future studies seem necessary to further elucidate the effects of fatigue and CAF on lower 






CHAPTER 7  
RECOMMENDATIONS FOR FUTURE WORK 
These dissertation studies revealed the need for future work to continue in the area of 
quadriceps dysfunction following ACL injury and reconstruction. Future studies need to 
develop better means by which to target quadriceps strength, and as demonstrated in 
Chapter 2 hamstrings, strength impairments post-operatively.  
Until it is known why quadriceps impairments persist, it will be difficult to target them 
effectively during rehabilitation. Thus, future studies need to elucidate the central and/or 
peripheral contributors to quadriceps weakness. Several possible techniques not 
employed within this dissertation are the H-reflex and V-wave. The H-reflex, when 
normalized to maximal muscle activation (M-wave), allows for an assessment of net 
excitatory and inhibitory influences on alpha-motoneuron output and can provide insight 
into the influence of pre-synaptic inhibition of Ia afferents within quadriceps dysfunction 
following ACL reconstruction.
100
 The V-wave, an electrophysiological variant of the H-
reflex, provides an estimate of the level of descending motor drive to a muscle from 
supraspinal pathways in addition to reflex excitability of the motoneuron pool.
101
 These 
measurements would allow for more precise determinants of what is contributing to 
central activation failure; however, these techniques are often difficult to record within 
the quadriceps. 
There is some recent evidence to suggest following total knee arthroplasty that the 
relation between quadriceps CAF and atrophy and strength changes over the course of the 
first post-operative year. Quadriceps CAF accounts for the greatest amount of quadriceps 
weakness immediately after knee replacement, but as the patient approaches one-year 
post-operatively, this shifts towards atrophy explaining a more equal proportion of 
quadriceps weakness.
48, 49
 Longitudinal studies may be necessary following ACL 
reconstruction so that phase appropriate treatment strategies can be implemented. 
Incorporating fatigue-resistance training within current post-operative may be beneficial 
based on the results of these studies. Future work into the effects of fatigue and central 
activation failure on lower extremity biomechanics is necessary to elucidate what, if any, 
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fatigue-resistance training methods warrant inclusion within rehabilitation. These studies 
may benefit from not only inclusion of hip joint biomechanical data, yielding a more 
complete lower extremity biomechanical profile than was assessed presently, but also 
from a different fatiguing exercise. To eliminate the possibility of ACL reconstructed 
individuals compensating with their uninjured limb, it may be necessary to eliminate the 
healthy limb from the fatiguing exercise by switching to a unilateral squatting task. 




It may be beneficial to examine each of the above mentioned ideas in individuals 
undergoing either patellar tendon and semitendinosus/gracilis autograft ACL 
reconstruction procedures. It is known that each of these graft types impacts quadriceps 
and hamstrings, as well as hip adductor, strength differently, in the first 6-12 months 
post-operatively, though the effects of either graft type on muscle strength elsewhere in 
the lower extremity are unclear. Further, differential responses of individuals receiving 
each graft type to neuromuscular fatigue may occur. Unless these studies are undertaken, 





CHAPTER 8  
LITERATURE REVIEW 
This section aims to detail the: 1) anterior cruciate ligament (ACL) injury and treatment 
strategies, 2) structure and function of the ACL, 3) mechanisms of muscle weakness, and 
4) relation between neuromuscular fatigue and central activation. 
ANTERIOR CRUCIATE LIGAMENT INJURY AND TREATMENT 
The ACL is the most commonly injured knee ligament, with injuries rarely occurring in 
isolation, compounding an already lengthy and complicated recovery.
102
 The following 
sections will discuss the incidence and consequences of ACL injury as well as current 
treatment strategies.  
Anterior Cruciate Ligament Injury  
ACL injuries occur at a rate of approximately 200,000 per year in the United States
1
, with 
the majority of these occurring in individuals ages 18-45 years. Males suffer more ACL 
injuries annually than females; however, females are 2-8 times more likely to suffer an 




As of the year 2000, the estimated cost of an ACL injury (rehabilitation plus surgical 
reconstruction) was $17,000.
104
 With approximately 50,000 ACL reconstructions (ACLr) 
performed annually in the United States, the cost of ACL injury is roughly $850 
million.
105-107
 This estimate, however, does not account for the rehabilitation costs 
associated with those opting for conservative treatment following injury. In addition to 
financial costs directly associated with injury, ACL injuries precipitate many long-term 
sequelae.  
Post-traumatic osteoarthritis (OA) is a common consequence of ACL injury and develops 
in over 50% of knees approximately 5-12 years following injury.
3-5
 Despite the efforts of 
reconstruction to restore mechanical stability to the knee, OA develops regardless of the 
treatment approach (operative or conservative).
4
 In fact, it has been estimated that 70% of 
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Anterior Cruciate Ligament Injury Treatment 
Following ACL injury, individuals may opt for either surgical reconstruction followed by 
rehabilitation or the more conservative approach of rehabilitation alone. Regardless of 
treatment strategy, return to full, pre-injury functional levels is often not achieved, with 
only 36% of ACLr
108
 and 15-58% of ACL deficient
108, 109
 persons returning to full 
activity. Further, there is a high (74%) failure rate of conservative treatment
110
, with those 
individuals ultimately undergoing reconstruction.  
A variety of ACL reconstruction procedures have been utilized, though the most 





 have attempted to determine which 
reconstructive procedure yields a superior functional outcome, though variations in 
surgical procedures and functional outcomes assessment make comparison between these 
studies difficult. The number of studies showing BPTB
115
 to be superior is nearly equal to 
those concluding the hamstrings
112
 autograft is better.  Additional studies have shown 
surgical outcome to be equal among graft types.
16, 113, 114, 116-118
 
Regardless of treatment strategy, rehabilitation is imperative following ACL injury. Two 
main types of rehabilitation exist, traditional and accelerated, with the ultimate goal being 
to restore lower extremity strength and function to pre-injury levels and delay/prevent the 
onset of OA. Traditional rehabilitation often returns individuals to full activity within 8-
12 months following injury/reconstruction, whereas this time is reduced to roughly 4-6 
months with accelerated programs.
120
 Evidence demonstrating efficacy of one technique 
over the other is sparse, though it is suggested accelerated rehabilitation is as effective as 
traditional in restoring strength and function to the reconstructed limb.
121, 122
  
STRUCTURE AND FUNCTION OF THE ANTERIOR CRUCIATE LIGAMENT 
The ACL has both mechanical and somatosensory functions, serving as a passive 
stabilizer of the knee
123-125







 The following section will detail the 
mechanical and somatosensory functions of the ACL and discuss relevant anatomy.  
Mechanical Function of the Anterior Cruciate Ligament 
The ACL is comprised of a series of Type I collagen fibrils arranged into fascicles.
132, 133
 







collagen, with Type III predominating early in ligamentization following 
reconstruction.
134
 Also found within the structure of the ACL are water, ground 
substance, and elastic fibers.
133
 The orientation of fascicles is location specific, with 
centrally located fascicles arranged in linear ―waves‖ and those located in the periphery 
arranged nonlinearly, creating an accordion-like crimp to the ligament.
133, 137
 As the ACL 
is loaded, the crimp is first straightened out, allowing low loads to be applied to the 
ligament without fibril damage.
133
 As load increases, the fibrils become elongated and 
tissue stiffness increases.  
Macroscopically, the ACL is comprised of two bundles, the anteromedial (AMB) and the 
posterolateral (PLB).
138
 Because the orientation of the fibers within each bundle differs, 
each contributes to passive stability differently throughout the knee range of motion. In 
fact, a reciprocal relationship between the AMB and PLB is suggested to exist in regards 
to anterior tibial translation.
139
 When the knee is in a more extended position, the PLB 
reportedly is better able to resist anterior translation.
140, 141
 As the knee flexes, however, 
the AMB likely dominates.
140, 141
  
The ACL may also serve to limit rotation about the knee joint
133
, with the PLB providing 
greater stabilization against rotation than the AMB.
142
 Much of the support for this comes 
from studies comparing double versus single bundle reconstruction techniques. Single 
bundle techniques, in essence, reconstruct only the AMB, whereas double bundle 
procedures reconstruct both bundles. Researchers have found that resistance to both 
anterior translation and combined anterior and rotary loads was greater in those 
undergoing double bundle reconstruction, thus supporting the contention that the PLB 
provides greater support to rotary loads than the AMB.
143, 144
These results, however, may 
reflect improper surgical techniques, where the graft is oriented more vertically (i.e. the 
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11 o‘clock versus the 9-10 o‘clock position for the right knee) and should be interpreted 
with caution. 
The role of the ACL in frontal plane knee stability may depend on the integrity of the 
collateral ligaments and weightbearing status. Several studies suggest that the ACL is not 
a major stabilizer against knee frontal plane loading in the presence of an intact medial 
collateral
145-148
 or lateral collateral
149
 ligament. Additionally, Fleming et al.
124
 have 
shown that the ACL does not resist abduction/adduction loads in a non-weightbearing 
state.  
Somatosensory Function of the Anterior Cruciate Ligament  
The neural structures of the ACL are located primarily in the superficial regions of the 
ligament near the tibial attachment.
127
 The ACL receives its innervation from the 
posterior articular nerve, a branch of the tibial nerve. In addition, several other 
myelinated and unmyelinated nerve fibers are located within the ACL as well as 
mechanoreceptors and free nerve endings.  
Mechanoreceptors comprise approximately 1% of the total area of the ACL
126
 and 
function as transducers, converting a stimulus regarding mechanical deformation within 
the ligament into a neural impulse that the central nervous system (CNS) uses to interpret 
joint position, motion, and acceleration.
126, 150
 Three classifications of mechanoreceptors 
have been identified in the human ACL: Ruffini endings, Pacinian corpuscles, and Golgi 
tendon-like organs. Ruffini endings are small (6-9 m), low-threshold (highly sensitive), 
and slowly adapting  mechanoreceptors that respond to changes in intra-articular 
pressure, static joint position, and the direction, amplitude, and velocity of joint 
movement.
127, 131
 Pacinian corpuscles are low-threshold, rapidly adapting
127
 
mechanoreceptors that detect vibration
127
, signal joint acceleration and deceleration
127, 128, 
131, 151
, and fire in response to changes in pressure.
127
 Golgi tendon-like organs are large, 
high-threshold, slowly adapting mechanoreceptors that  respond to changes in tension at 
the extremes of the joint‘s range of motion.
127
   
The ACL, due to its dense mechanoreceptor population, is considered an important 
source of afference within the knee. Recent data supporting this suggest that a sensory-
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motor arc exists between the ACL and the knee musculature.
152
 Specifically, mechanical 
loading
152
 and direct electrical stimulation
153
 of the ACL increase hamstring muscle 
activity and decrease quadriceps activity, providing evidence for the afferent role of the 
ACL. It was believed initially that this reflex arc served a protective role for the ACL, 
activating the hamstrings to help stabilize the knee
154
; however, the latency of the reflex 
arc to the hamstrings (95 ms)
154
 cannot activate the hamstrings quickly enough to limit 
anterior tibial translation. It is now suggested that the reflex arc may be involved in feed 
forward control during activity.
154
 The neural pathway of this reflex is currently 




When the ACL is injured, mechanoreceptors are disrupted. Mechanoreceptor 
regeneration following ACL injury and reconstruction remains controversial, with some 





regeneration may occur by the eighth post-operative week. It also remains unclear 
whether mechanoreceptors, if able to regenerate, return to their full functional capacity. 
Recent studies by Ochi et al.
160, 161
 suggest that mechanoreceptor regeneration is possible 
and that full function is restored by 18 months post-operatively. Lack of mechanoreceptor 
regeneration and/or decreased function following ACLr purportedly contribute to muscle 
dysfucntion
162
 and diminished proprioception.
44, 163, 164
 Mechanoreceptor disruption alters 
afference to the MN 
165
, which may disrupt the reflex arc between the ACL and the 
knee musculature, altering or further impairing muscle activation.  
Free nerve endings also contribute to the somatosensory functions of the ACL and have 
been identified in the cruciate ligaments.
131
 Following ACL rupture, damage to joint 
structures (i.e. the ACL, itself) and the presence of an effusion result in stimulation of the 
nocioceptors.   The information transmitted to the CNS from the free nerve endings is 
thought to contribute to muscle dysfunction.
166
  
MUSCLE WEAKNESS:  A CONSEQUENCE OF ANTERIOR CRUCIATE 
LIGAMENT INJURY AND RECONSTRUCTION 
64 
 
The musculature surrounding the knee joint serves a protective role for both the ACL and 
other structures of the joint (e.g. articular cartilage through energy absorption on weight 
bearing). Weakness of these muscles, however, often occurs concomitantly with ACL 
injury and reconstruction
13, 141, 167
, contributing to altered gait mechanics and increased 
joint loading.
168, 169
 The presence of quadriceps and hamstrings weakness has been 
demonstrated
12-14, 17, 27, 35, 70, 170, 171
 following ACL injury and reconstruction; however, the 
effect of ACL injury on strength elsewhere in the lower extremity remains unclear.  
Despite intensive rehabilitation efforts, quadriceps weakness is nearly universal following 
ACL injury, with reports of quadriceps weakness lasting upwards of one year post-
operatively.
17, 70, 170
 Strength deficits in the injured versus uninjured limb reportedly range 
from 5-30%.
12-17
 Weakness has been demonstrated following both BPTB




 Additionally, researchers have found that quadriceps 
strength deficits occur bilaterally.
14, 35, 171
 The precise mechanism underlying quadriceps 
weakness is unknown, though AMI
31, 35, 171, 172
  and atrophy
8
 have been implicated.  





 autograft ACLr. Knee flexion strength deficits range 
from 9-13%.
14, 17, 18
 Bilateral strength deficits have been reported
14
, with hamstrings 
weakness in the reconstructed limb reportedly persisting upwards of one year post-
operatively, though contralateral strength may be restored by this time point.
173
 Donor 
site morbidity in the case of hamstring autograft reconstruction
174
 and muscle atrophy
18
 
have been suggested as possible mechanisms contributing to hamstrings weakness.  
Though little research evidence is available to support it, clinical speculation suggests 
that weakness of both the hip and ankle musculature also occurs following ACL injury. A 
study conducted by Jaramillo et al.
19
 demonstrated hip muscle weakness— extensor, 
abductor, and adductor— following knee surgery. These authors, however, examined hip 
muscle strength following a variety of surgical procedures, limiting the applicability of 
their results to an ACLr population. To date, only one study
20
 has examined the effects of 
ACLr on hip muscle strength, noting hip adductor weakness following 
semitendinosus/gracilis autograft reconstruction. These authors suggested donor site 
morbidity may contribute to weakness, though it does not likely fully explain weakness 
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due to the small cross sectional area of the gracilis.
20
 The authors further suggested that 
neurological alterations may contribute to adduction weakness.
20
 No studies have 
examined strength of the ankle joint musculature following ACL injury or reconstruction; 
however, decreased gastrocnemius activity has been demonstrated during gait
175
 in an 
ACL deficient population as well as during landing
21
 following ACLr, a finding which 
may be suggestive of muscle weakness. Additionally, clinical observation suggests 
atrophy presents in the calf musculature following ACLr.  
Biomechanical Consequences of Muscle Weakness 
Lower extremity muscle weakness following ACLr may lead to biomechanical changes 
during functional activity and, eventually, degenerative changes within the knee joint. 
Quadriceps weakness, specifically, has been linked to biomechanical adaptations, 
including decreased knee flexion excursion and internal knee extension moment during 
stance.
176, 177
 The combination of these two adaptations decreases the energy absorption 
capability of the knee musculature on weight bearing
178
, which may increase risk of 
degenerative joint disease.
177
 Additionally, quadriceps weakness has been shown to 
increase the rate of knee joint loading
179
, which may increase joint reaction forces
180
 and 
further increase the risk of joint degeneration.  Quadriceps weakness may also contribute 
to altered frontal plane knee loading, specifically increased adduction moment.
181
 
Considering that the quadriceps are important resistors of knee adduction moment
90, 182
, 
quadriceps weakness could  increase loads through the medial tibiofemoral compartment 
and possibly increase risk of OA.  
Weakness of the hip musculature has also been shown to alter biomechanics, with 
weakness of the hip abductors increasing external knee adduction moment during weight 
bearing.
183
 This may increase risk of medial tibiofemoral OA. When the stance limb hip 
abductors are weak, contralateral pelvic drop during the swing phase is increased.
184
 This 
shifts the center of mass toward the swinging limb, causing the vertical ground reaction 
force vector to pass medial to the stance limb‘s tibiofemoral joint center, which increases 





Limited attention has been paid to strength of the ankle musculature in regards to 
biomechanics. Computer modeling and forward dynamics analysis has demonstrated, 
however, that ankle plantar flexor weakness may increase hip and knee extensor work
185
, 
which could potentially decrease hip and knee flexion angles.  
MECHANISMS OF MUSCLE WEAKNESS 
Muscle Atrophy 
A possible explanation for weakness following ACL injury and reconstruction is disuse 
atrophy of the muscles of the involved limb, wherein strength deficits occur with 
inactivity following injury. Immobilization, in the form of bracing following ACL injury 
and reconstruction, can also lead to atrophy.
36
 
Recent evidence suggests, however, that quadriceps atrophy cannot sufficiently explain 
weakness.
29, 45, 47
 While not specific to an ACLr population, Mizner et al.
45
 and Petterson 
et al.
47
 found that voluntary activation failure better explains weakness than muscle 
atrophy.
47
  Following ACLr, Konishi et al.
29
 examined quadriceps torque per unit volume 
and found a reduction bilaterally compared to healthy control subjects These authors 
noted that reduced motor unit recruitment, specifically high-threshold motor units, in 
addition to muscle atrophy appear  responsible for quadriceps weakness.
29
  
Atrophy may explain hamstrings weakness in the injured compared to the uninjured limb 
6-months post-operatively following ACLr performed with ipsilateral semitendinosus 
autograft.
18
 At 12-months post-operatively, however, there were no differences between 
ACLr and healthy controls regarding hamstring muscle torque per unit volume, leading 
the authors to conclude that the same mechanisms underlying persistent quadriceps 
weakness do not explain hamstrings weakness.
18
 These results directly conflict with the 
findings of Makihara et al.
186
 who found that atrophy may explain hamstrings weakness 
upwards of 3.5 years post-operatively. These authors additionally attributed weakness to 
decreased length of the semitendinosus muscle fibers following graft harvest.
186
 Further 
research into this area appears necessary to elucidate the relationship between hamstrings 
atrophy and strength. 
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Central Activation Failure and Arthrogenic Muscle Inhibition 
Central activation failure (CAF) decreases volitional muscle contraction by failing to 
recruit all motor units or by failing to achieve maximal discharge rate from  the motor 
units that are recruited.
187
 When joint damage initiates this process, CAF is referred to as 
arthrogenic muscle inhibition (AMI).
188
 AMI is regarded as being due, at least in part, to 
altered afferent feedback from a joint.
36, 189
 As discussed previously, the healthy ACL 
houses mechanoreceptors that, under normal conditions, provide sensory feedback from 
the knee joint to the CNS relative to joint movement, position, and loading.
128
 When the 
ACL ruptures, this sends an inhibitory signal to interneurons located within the CNS, 
causing an inhibitory MN response
190
, observed as a decrease in voluntary activation of 
the musculature surrounding the affected joint. Altered afference may disrupt the gamma-
loop, further decreasing MN activity.
191-194
 Descending inhibitory signals from the 
cortex may also reduce MN excitability and minimize voluntary activation.   
Following ACL rupture, the quadriceps commonly experience AMI, though the 
magnitude of the impairment varies among studies, with reports ranging from 8-45%.
31, 
35, 75, 171, 172
 Additionally, AMI has been reported in the unaffected limb following ACL 
injury
195, 196
 and reportedly ranges from 7-26%, which is nearly equivalent to the 
magnitude of impairment in the injured limb in some individuals.
31, 35, 171
  While studies 
have shown that reconstruction and rehabilitation following ACL injury reduce the 
severity of AMI, they do not appear to eliminate it. In fact, Urbach et al.
171
 demonstrated 
bilateral AMI of 15% in the injured and 16% in the uninjured limbs, respectively, two 
years post-operatively.  
It is believed that AMI is a natural process designed to protect the injured joint from 
further damage by limiting its mobility, though the effects of AMI may be more harmful 
than beneficial. AMI has been suggested to precipitate weakness
197
 and possibly 
atrophy
198
 of the affected limb, which may alter biomechanics, possibly initiating 
degenerative changes within the joint. That AMI persists beyond the rehabilitative phase 
suggests effective treatments to combat it have yet to be determined. Hurley and 
Newham
198
, however, have found that strength gains are still possible in the presence of 
AMI, leading these authors to conclude that additional factors (i.e. altered proprioception 
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stemming from the neurophysiologic mechanisms of AMI) may contribute to the 
initiation and progression of joint degeneration.  
Mechanisms of Arthrogenic Muscle Inhibition 
Pre-Synaptic Inhibition 
Pre-synaptic inhibition generally occurs following decreased neurotransmitter release 
from the pre-synaptic terminal.
199
 Primary afferent depolarization (PAD) interneurons are 
involved in this process
200
, synapsing with primary afferents containing GABA receptors. 
When GABAa receptors are activated, this causes an efflux of chloride ions and, 
therefore, PAD. PAD decreases the amplitude of the action potential, which reduces 
calcium influx into the pre-synaptic terminal, thereby decreasing neurotransmitter release 
into the synaptic cleft.
201
 It has been suggested that activation of GABAb receptors 
directly interferes with voltage-gated calcium channels, reducing calcium influx into the 
pre-synaptic terminal
202
; however, the role of GABAb receptors in pre-synaptic inhibition 




It has been demonstrated previously that pre-synaptic inhibition contributes to quadriceps 
AMI following induction of an experimental knee joint effusion. 
205
 Though the precise 
mechanism underlying pre-synaptic inhibition in AMI is unknown, it is suggested that 
GABA-ergic interneurons may be involved.
205
 Increased afferent input may occur in the 
presence of joint effusion and GABA-ergic interneurons may serve as a gating 
mechanism for this increased afference, reducing excitatory input to the injured 
muscle.
205
 This may contribute to AMI in the presence of knee joint effusion following 
ACL injury and reconstruction.  
Reciprocal Inhibition 
Reciprocal inhibition is a process wherein inhibitory Ia interneurons receive an excitatory 
stimulus from Ia afferents.
190
 The axons of these Ia interneurons create a heterogenic 
synapse with the MN of antagonistic musculature, sending an inhibitory stimulus to the 
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MN. Reciprocal inhibition, therefore, ultimately results in antagonist muscle inhibition. 
This process may also be mediated by Renshaw cells.
206
  
The precise role of reciprocal inhibition within quadriceps AMI is currently unknown; 
however, as Ia interneurons receive input from joint afferents
207
, it is possible that a 
change in afference would activate the Ia interneuron, possibly contributing to AMI. Ia 
inhibition could reduce the efficacy of afferent transmission, decreasing efferent output, 
and, therefore, volitional muscle contraction.   
Reciprocal inhibition has  been suggested as mediating AMI in other muscles, 
specifically the hamstrings.
208
 A study examining chronic ankle instability reported 
bilateral hamstrings AMI, with the authors suggesting that soleus inhibition leads to 
quadriceps facilitation, which they also reported. Quadriceps facilitation could, through 
reciprocal inhibition, cause hamstrings inhibition.
208
 Considering that both the quadriceps 
and hamstrings send and receive neural projections to/from the ankle plantar flexor and 
dorsiflexor muscles
41
, it seems plausible that altered Ia afferent transmission from the 
injured ankle could lead to altered muscle activation at the knee and that  knee injury 
could precipitate altered ankle muscle activity. Similar neural projections that occur 
between the knee and ankle muscles have been shown in animals between the rectus 
femoris and its hip synergists (e.g. sartorius)
26
, suggesting that altered afferent output 
following knee injury may alter activity and generate weakness of the hip musculature, 
though this has not been demonstrated.  
Recurrent Inhibition 
Recurrent inhibition results in agonist inhibition and antagonist facilitation and may be 
mediated by Renshaw cells. An antidromic potential from an MN excites the Renshaw 
cell, which then sends an inhibitory stimulus back to the original MN. Because 
Renshaw cells also synapse with Ia interneurons, inhibitory stimuli are concurrently 
projected to synergistic muscles.
209
 It has been suggested that Renshaw cells are 
preferentially activated by large motoneurons, making recurrent inhibition more likely in 





Experimental knee joint effusion has been demonstrated to cause AMI.
57, 211
 Further, 
Renshaw cell activation has been demonstrated following experimental knee joint 
effusion.
212
 Thus, Renshaw cells are suggested to contribute to AMI and may serve as  a 
gating mechanism
212





Non-reciprocal inhibition likely originates within the Golgi tendon organ (GTO). The 
GTO houses Ib afferents, which synapse with Ib interneurons. These interneurons 
generate both excitatory and inhibitory signals, producing antagonist excitation and 
causing homonymous and synergistic MN inhibition.
188
  
Non-reciprocal inhibition has been found to contribute to AMI. Iles et al.
211
 induced 
experimental knee joint effusion and measured the magnitude of Ib inhibition at rest and 
during quadriceps contraction. In the presence of effusion, non-reciprocal inhibition 
increased compared to a non-effused state. The authors hypothesized that non-reciprocal 
inhibition may decrease volitional control of the injured joint, preventing further 
injury.
211
 This decrease in volitional control may occur through stimulation of Ruffini 
endings in the presence of effusion.
214
 Ruffini endings project an afferent stimulus to Ib 
interneurons, which may decrease voluntary muscle activity.
215
  
Tonic Descending Inhibition  
Tonic descending inhibition (TDI) is a mechanism through which the brain stem can 
control afferent input. TDI serves to inhibit increases in afferent information to the 
central nervous system.
216, 217
 In the presence of joint pathology, however, spinal neurons 
decrease their threshold to afferent input, enhancing the effects of efferent inhibitory 
drive and making the spinal neurons more susceptible to peripheral feedback.
218
TDI has 
been implicated within AMI, and is suggested to contribute to the bilateral inhibition seen 
following joint injury
36
 as cells within the spinal cord receive input from both the 






The gamma-loop consists of MN activation of intrafusil fibers within the muscle 
spindle, which lowers the firing threshold of Ia afferents, causing MN firing. The 
precise cause of gamma-loop dysfunction has yet to be determined, but two possible 
theories have been proposed. The first was reported by Hagbarth et al.
220
, wherein the 
authors induced a partial nerve block of the deep peroneal nerve and found reduced 
volitional motor unit firing rates that could be countered by muscle vibration. The second 
mechanism is that intrafusil fibers experience fatigue similarly to extrafusil fibers. During 
sustained isometric contractions, it has been demonstrated that afferent firing rates 
decrease progressively with time and this decline is inversely proportional to EMG 
activity. The authors attributed decreased afferent firing to fatigue of the fusimotor 
system, leading to withdraw of MN activity and disfacilitaton of the MN.
221
  
Previous studies have found that altered afferent activity, which occurs following ACL 
rupture, may lead to abnormal gamma efferent activity.
193, 194
 In a recent series of studies 
by Konishi et al.
29, 191-194
, these authors have suggested that this loss of afference 
following ACL injury leads to gamma-loop dysfunction and that the combined effects of 
altered afferent and efferent activity may explain both unilateral and bilateral quadriceps 
weakness following ACL injury and reconstruction. However, these authors utilized 
prolonged vibration of the patellar tendon, which may stimulate the GTO. As discussed 
previously, the GTO houses Ib afferents, which, when they synapse with Ib interneurons, 
mediate non-reciprocal inhibition. As non-reciprocal inhibition causes agonist inhibition 
(i.e. the quadriceps in the case of the patellar tendon), Ib afferent activation due to 
patellar tendon vibration may help to explain the quadriceps weakness demonstrated in 
these studies. 
METHODS OF ASSESSING MUSCLE DYSFUNCTION 
Muscle Atrophy Assessment 
Multiple methods exist for non-invasive measurement of human skeletal muscle atrophy. 
Ultrasound was an early, preferred technique
222
 for the assessment of superficial 
muscles
223
; however, due to the limited abilities of ultrasound (e.g.: poor resolution and 
72 
 
inability to control slice thickness)
222
, computed tomography (CT) and magnetic 
resonance (MR) imaging have become the preferred methods.   
CT scans utilize a series of x-rays to generate a soft tissue image. An x-ray beam is 
passed through a person to a detector located on the other side of the body segment.
224
 
The x-ray beam and detector move along the tissue and a series of measurements are 
taken with the x-ray beam at different angles.
224
 These data are reconstructed to allow for 
the creation of an image representing the soft tissue scanned.
224
 MR imaging operates on 
the principles of magnetic fields, wherein protons spin about an internal axis creating a 
magnetic dipole moment.
225
 When placed in a strong magnetic field, slightly more than 
half of the magnetic dipoles orient with the external magnetic field.
225
 The magnetic 
dipoles oriented with the external field are cancelled out by the dipoles oriented opposite 
to the external field, and an MR image is generated by the extra dipoles, the ones that 
have not been cancelled out.
225
  
MR imaging offers several advantages to other imaging techniques for assessing muscle 
atrophy. Firstly, MR imaging uses non-ionizing radiation and has no known adverse 
physiological effects.
225
 Because a series of images is required to accurately calculate 
muscle cross sectional area (CSA)
226
, these features make MR imaging preferable. 
Additionally, the time required to obtain multiple MR images is less than that required to 
obtain multiple images using CT, allowing muscle CSA assessment in a more time and 
cost-effective manner.
226
 Lastly, the soft tissue images obtained from MR techniques are 
more detailed than those obtained from CT
222
 and have not been demonstrated to over-
estimate muscle CSA, as often occurs with CT scans.
222, 227
  
Atrophy is often quantified as either muscle volume
7, 8
 or CSA.
7, 8, 44, 45
 After a CT or MR 
image is obtained, the contours of a muscle are traced in each image in which the muscle 
is present
7, 8
 and then submitted to a computer program which calculates volume or CSA. 
A study by Williams and colleagues
7
 determined that both muscle volume and CSA 
equally predict muscle atrophy in the quadriceps. CSA has been shown to be more 
strongly related to quadriceps strength than volume
228
 and, thus, has been suggested as an 





Muscle Strength Assessment 
Several methods exist for assessing muscle strength. Clinically, strength is typically 
assessed using manual muscle testing or hand held dynamometry, though both methods 
may be limited by the strength of the examiner. Though not always clinically accessible, 
isokinetic dynamometry is the gold standard. Isokinetic dynamometry allows for three 
types of strength assessment: isometric, concentric, and eccentric.  
Isometric strength assesses a muscle‘s ability to produce static force.
229
 This method is 
advantageous when the joint range of motion is limited by injury or immobilization. 
Isometric strength assessment, however, only indicates strength at the particular point in 
the range of motion where the test is occurring and, as such, is not a functional, dynamic 
measure.  
Concentric and eccentric strength measures assess dynamic strength, with concentric 
being the more commonly utilized method.
230
 Testing of both concentric and eccentric 
strength has been performed at a variety of movement velocities ranging from 30-
300º/s.
231-234
 It has been suggested that lower movement velocities (i.e.: 60º/s) are more 
useful for testing concentric strength as force output declines with increasing contraction 
speed..
230
 Eccentric strength does not change with regards to movement velocity and is 




In order to determine a force decrement following injury, a baseline (pre-injury) 
measurement is required. As a pre-injury measurement may be lacking, clinicians often 
perform a bilateral comparison. Several studies, however, have demonstrated AMI in the 
contralateral limb following injury.
195, 196
 Thus, the contralateral limb may not be an ideal 
comparison. Additionally, the magnitude of the volitional muscle contraction is 
dependent not only on the strength of the targeted muscle, but also on factors such as 
pain, motivation, and agonist-antagonist co-contraction, all of which can lead to an 
underestimation of strength. 
Muscle strength is often quantified by either force (N) or torque (Nm) and normalized to 
individual body mass so that strength can be compared across individuals. When strength 
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is assessed using dynamometry, torque may be the more appropriate parameter to report 
as the rotational strength of the muscle is what is being tested.
230
  
Arthrogenic Muscle Inhibition Assessment 
Burst Superimposition 
The burst superimposition technique involves the application of a train of electrical 
stimuli during the performance of a maximum voluntary isometric contraction (MVIC).  
This technique indicates the level of volitional activation a person is capable of achieving 
versus what would be possible if no inhibition were present. When the torque signal 
generated by the person during MVIC is visualized, a spike in force production can be 
observed at the time the stimulus is delivered 
(Figure 1). The percent difference between this 
spike and the torque level immediately prior to 
the spike is known as a central activation ratio 
(CAR)
187
 and is used to quantify CAF, or AMI. 
Because the stimulus is delivered proximal to 
the neuromuscular junction, Merton
235
 
suggested that any increase in force output 
following stimulation indicated that full MN 
pool activation had not been achieved and, thus, 
indicated central activation failure. As with any MVIC technique, this method requires 
the generation of a true maximal contraction, as submaximal contractions have been 
demonstrated to over-estimate CAF/AMI.
236
  
CAR is calculated by the following equation (Eq. 1):   
Eq. 1          
    
                  
       
where MVIC is the mean torque value and Superimposed Burst is the maximum value 
elicited via the electrical stimulus. Applying equation 1 yields an uncorrected CAR value, 
which, according to Stackhouse et al.
237
 provides an overestimation of central activation. 
In a study comparing central activation at varying percentages of MVIC, it was found 
Figure 8.1. Schematic of CAR measurement. 
The arrow indicates the point at which the 
stimulus was delivered. CAR is calculated by 




that the relationship between CAR and MVIC is curvilinear, wherein CAR values are 
higher than their equivalent voluntary activation values.
237
 For example, at 25% MVIC, a 
linear relationship would yield a CAR of 25; however, these authors found at 25% 
MVIC, the CAR value was approximately 40.
237
 Thus, it was concluded that CAR over-
estimates central activation, thereby underestimating AMI. The authors posit that the 
overestimation may be due to the duration of the train of stimuli delivered, and that full 
summation of force cannot be generated during the short train duration.
237
 
To correct for this overestimation, an equation (Eq. 2) was developed to produce a 
corrected CAR value (CARc)
237, 238
: 
Eq. 2                             
where y is the CAR value obtained in equation 1. 
Equation 2 is solved using the quadratic formula and 
then divided by 100 to obtain CARc.  
Interpolated Twitch Technique 
In the interpolated twitch technique, an electrical pulse 
is superimposed on top of an MVIC, but there are two 
key differences between this and the burst 
superimposition technique. First, the electrical pulse is 
comprised of different parameters and is usually a 
singlet or a doublet of pulses rather than a train. 
Second, the equation used to calculate central activation 
is different and requires the elicitation of a resting 
twitch force (Figure 2) (Eq. 3)
239
: 
Eq. 3    
         
                   
              
       
where superimposed twitch is the maximum value 
elicited via the electrical stimulus superimposed over 
Figure 8.2. Schematic of ITT. 
Arrows indicate delivery of the 
stimulus. A) stimulus delivered at 
rest. B) stimulus delivered over top 




the MVIC and control twitch is the maximum value elicited by the twitch at rest.  
Several studies have examined the efficacy of the CAR and ITT techniques as well as the 
number of stimuli required to accurately quantify CAF/AMI. Bampouras et al.
240
 found 
that the level of activation obtained with the ITT method is similar regardless of the 
number of stimuli delivered. These findings directly contradict those of Lloyd et al.
241
 
and Behm et al.
242
 who found that a train of electrical stimuli was more effective than 
using singlets or doublets of pulses when using the ITT method of quantification. Behm 
et al.
242
 concluded that as long as a train of stimuli is delivered, both the ITT and CAR 
methods are equally effective at quantifying CAF/AMI. 
H-reflex and M-wave 
Both the Hoffman 
reflex (H-reflex) 
and M-wave are 




is applied directly 
over a motor 
nerve
100






diameter Ia afferent 
fibers are 
selectively recruited 
and action potentials generated along their axons.
244
 These action potentials travel from 
the point of stimulation to the spinal cord, where they produce excitatory postsynaptic 
potentials, which, in turn, give rise to efferent potentials traveling toward the muscle. 
These efferent action potentials are recorded in the muscle via electromyography (EMG) 
Figure 3. H-reflex and M-wave pathway. The solid line represents the MN axon 
and the dashed line represents the Ia afferent axon. If a low-intensity 
percutaneous stimulus is delivered to a mixed nerve (1),  Ia afferents are 
selectively recruited and action potentials within these fibers travel toward the 
spinal cord (2). Ia action potentials transmitted to the spinal cord synapse with 
interneurons and send action potentials toward the muscle belly via the MN (3). 
These action potentials are recorded in the muscle belly as an H-reflex via EMG 
electrodes (open circles). As the stimulus intensity is increased, MN are 
recruited at the point of stimulation and action potentials travel to the muscle 
belly where they are recorded via EMG electrodes as an M-wave(4). Action 
potentials generated in the MN at the point of stimulation also travel 
antidromically toward the spinal cord (4*), colliding with the action potentials 
generated within the Ia fibers, thereby cancelling out the H-reflex signal. 
Modified from Aagaard, P., Simonsen, E. B., Andersen, J. L., Magnusson, P., & 
Dyhre-Poulsen, P. (2002). Neural adaptation to resistance training: changes in 




assessment as an H-reflex. As the intensity of the percutaneous stimulus utilized to 
generate an H-reflex is increased, it continues to stimulate the Ia afferents while also 
resulting in direct stimulation of the MN. This direct MN stimulation produces an M-
wave that can be recorded via EMG assessment.  
The peak-to-peak maximum H-reflex is representative of the portion of the MN pool 
capable of being excited
100
, while the peak-to-peak M-wave is an estimate of maximal 
muscle activation.
245
 The intra- and inter-session reliability have been demonstrated to be 
high
246
 for these measurements, though they have several important limitations. The H-
reflex is not recordable in all individuals and the amplitude of both measurements is 
sensitive to body position. It has been suggested that individuals maintain a supine body 
position, with the knee flexed to 15°, the arms resting at the sides with the palms facing 
up, and the head and eyes facing directly forward to minimize the effects of variable body 
position on the measurement.
247
 Additionally, the H-reflex measurement is only an 
estimate of MN excitability and may be influenced by other factors (e.g.: presynaptic Ia 
inhibition, Renshaw cell activity, and Ib inhibitory interneurons) that cannot be accounted 
for with this measurement.
248, 249
 The influence of these other factors on H-reflex 
amplitude may be minimized when the measurement is elicited with the muscle at rest.
248
  
The H-reflex technique also does not account for the influence of muscle spindle activity 
on MN excitability.
250
 During voluntary movement, muscle spindles modulate muscle 
activity and, therefore, MN output. 
V-wave 
The V-wave is a physiological variant of the H-reflex that has been shown to reflect the 
level of descending, efferent, neural drive to a muscle from spinal and/or supraspinal 
MNs during a voluntary muscle contraction.
101
 During M-wave elicitation, action 
potentials produced at the point of stimulation along the MN travel both 
orthodromically toward the muscle and antidromically to the spinal cord (Figure 4). 
Further, Ia afferents continue to be generated, producing H-reflex signals. As the 
antidromic potentials approach the spinal cord, they collide with the H-reflex signal 
traveling toward the muscle, cancelling out the H-reflex. When the percutaneous stimulus 
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is superimposed on an MVIC, however, the antidromic action potentials that would 
normally prevent the H-reflex signal from passing to the muscle are, themselves, 
cancelled out by the descending, orthodromic action potentials generated as a result of 
voluntary muscle contraction. This allows the H-reflex signal to once again pass through 
to the muscle
101
, where the signal is then recorded as a V-wave. 
NEUROMUSCULAR FATIGUE AND CENTRAL ACTIVATION 
Neuromuscular fatigue is a decrease in force-generating capability induced by exercise.
76
 
It is both a peripheral and a central process. Peripheral fatigue encompasses any structure 
distal to the neuromuscular junction
251
 and is often regarded as fatigue within the muscle, 
itself, due to altered metabolics or muscle damage.
252
 Central fatigue, which will be 
detailed below, occurs when the activity within spinal and supraspinal structures 
responsible for neural drive to a muscle is reduced.
76, 251
 
Figure 4. V-wave pathway. The solid line represents the MN axon, the dashed line represents 
the Ia afferent axon, and the dotted line represents the efferent axon. When a supramaximal, 
percutaneous stimulus is applied over a mixed nerve (1), an efferent motor response is generated 
due to activation of MN via descending pathways from the motor cortex (5). The efferent 
impulses collide with the antidromic action potentials (4*), allowing the Ia afferent signal to 
pass through the spinal cord to the muscle (23).  This signal is recorded in the muscle belly via 
EMG electrodes (open circles) as an H-reflex. Modified from Aagaard, P., Simonsen, E. B., 
Andersen, J. L., Magnusson, P., & Dyhre-Poulsen, P. (2002). Neural adaptation to resistance 





During persistent muscle contraction, input from Ia, Ib, III, and IV afferents is altered. 
During a sustained MVIC, Ia firing rates decline with time, ultimately reducing input to 
MN and decreasing force generation.
221
 The role of Ib afferents remains speculative and 
it is believed that either decreased sensitization of Ib afferents or attenuation of their 
inhibitory effects occurs during fatiguing exercise. This belief stems from the fact that 
MN firing continues during fatigue, though at a reduced capacity. If Ib-induced non-
reciprocal inhibition occurred during MVIC, MN firing in the muscle generating the 
contraction would not occur. The role of groups III and IV (nociceptive) afferents is 
unclear, though it is believed they respond to the metabolic changes that occur locally 
with fatigue
253, 254
, which leads to an inhibitory effect on Ia afferent activity, altering 









 have proposed two possible mechanisms by which supraspinal fatigue 
may operate. First, motor cortex output decreases, possibly due to changes in 
corticospinal neurons or input to these neurons.
256
 While changes in corticospinal 
neuronal activity have been demonstrated during fatigue, fatigue may also occur in the 
absence of these changes.
257, 258
 Thus, while corticospinal neuron activity may contribute 
to supraspinal fatigue, it cannot fully explain it. Second, motor cortex output remains 
constant, but becomes less effective and MNs become less responsive to descending 
input, a response consistent with MN inhibition.
256
  
Contributions of Fatigue to Anterior Cruciate Ligament Injury 







 Also emerging out 
of these studies have been several important biomechanical risk factors, namely what 
both Ireland
265
 and Hewett et al.
266
 have described as increased hip internal rotation and 
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adduction combined with knee extension, abduction, and external rotation postures and 
moments.  
Neuromuscular fatigue, an essentially inevitable occurrence during athletic activity, also 
purportedly increases ACL injury risk.
267, 268
 Lower extremity neuromuscular fatigue, 
specifically, has been shown to alter neuromuscular control strategy and generate lower 




Following gross lower extremity fatigue, several alterations consistent with the 
aforementioned biomechanical risk factors have been reported. Specifically, fatigue leads 
to increases in hip internal rotation
80




, and internal 
rotation
77, 80, 269





 moments as well as anterior tibial shear.
77, 78
  
Specific adaptations linked with non-contact ACL injury risk have also been 
demonstrated following isolated muscle fatigue. Nyland and colleagues
72
 have 
demonstrated  that isolated quadriceps fatigue increased knee extension angle and 
moment.  
Relationship Between Arthrogenic Muscle Inhibition and Fatigue 
As discussed previously, both AMI and neuromuscular fatigue are central and peripheral 
processes, which ultimately lead to a decrease in voluntary muscle activation. Previous 
research has demonstrated that volitional control is reduced both with muscle weakness 
and fatigue.
10, 257
Thus, it seems the relationship between AMI and fatigue is additive, 
wherein fatigue would further impair central drive to the musculature.   
Neuromuscular fatigue impairs not only the affected limb, but also alters the 
neuromuscular control strategy of the contralateral limb in unilateral fatigue.
270
 The 
proposed mechanisms underlying this cross-over effect of fatigue may help to explain the 
relationship between fatigue and AMI. Group III and IV afferents are purportedly 
sensitive to the metabolic changes that occur locally with fatigue.
253, 254
 The response of 
group III and IV afferents to these metabolic products leads to an inhibitory effect on Ia 
81 
 




Studies examining AMI have found that preferential atrophy may occur
36, 189
, which may 
further explain the relationship between muscle fatigue and inhibition, though evidence 
regarding which phenotype is affected is conflicting. Stokes and Young
189
, for example, 
reported that atrophy of either Type I or Type II fibers may occur. These and other 
authors
36
, however, have also reported that an increase in type II fiber frequency occurs 
with AMI. Given that Type II fibers are non-fatigue resistant, this could increase muscle 
fatigability. Along these lines, Young
36
 reported selective atrophy of Type I fibers in 
ACL deficient people, a population where AMI is prevalent. This selective Type I 
atrophy could also increase muscle fatigability.  Consistent with these findings are those 
examining muscle phenotype and selective atrophy following ACL rupture. Both 
selective Type I
44, 50
 and Type II
44, 51
 atrophy have been reported. More research is 
needed into this area to determine the role of muscle phenotype changes after ACL injury 
and with AMI; however, it is important to consider that muscle phenotype may play a 
crucial role in muscle fatigability and, thus, warrants consideration as a link between 
fatigue and AMI. 
Clinical speculation suggests that neuromuscular fatigue may be implicated in re-injury 
following ACLr. As discussed previously, neuromuscular fatigue may increase non-
contact ACL injury risk by altering the biomechanical profile of the fatigued individual. 
Considering that AMI is prevalent in those returning to activity following ACLr, and that 
fatigue and AMI may be additive processes which are each capable of altering 
biomechanics, it seems that the relationship between fatigue and AMI ought to be 
studied. If these two processes, fatigue and AMI, are additive and the relationship can be 
elucidated, then better rehabilitation strategies can be developed to counter these 





Knowledge regarding the neuromuscular consequences of ACL injury is limited. 
Elucidating the magnitude of weakness in the muscles proximal and distal to the knee, 
the mechanisms underlying persistent quadriceps weakness, and how fatigue impacts 
CAF and what the combined effects of fatigue and central activation are on 
neuromechanics will aid researchers and clinicians in understanding ACL injury and 




 IRB CONSENT FORM 
 
UNIVERSITY OF MICHIGAN 
CONSENT TO BE PART OF A RESEARCH STUDY 
 
Information About This form 
 
You, or your child, may be eligible to take part in a research study.  This form gives you 
important information about the study.  It describes the purpose of the study, and the risks 
and possible benefits of participating in the study. Parents or legal guardians who are 
giving permission for a child, please note:  in the sections that follow the word ‗you‘ 
refers to ‗your child.‘ 
 
Please take time to review this information carefully.  After you have finished, you 
should talk to the researchers about the study and ask them any questions you have.  You 
may also wish to talk to others (for example, your friends, family, or other doctors) about 
your participation in this study.   If you decide to take part in the study, you will be asked 
to sign this form.  Before you sign this form, be sure you understand what the study is 
about, including the risks and possible benefits to you. 
 
1.  General Information About This Study AND the RESEARCHERS 
 
1.1  Study title:  
Neuromechanical Dysfunction Associated with ACL Injury 
 
1.2  Company or agency sponsoring the study:  
This study is funded by The University of Michigan Bone and Joint Injury Prevention & 
Rehabilitation Center. Additional funding is provided by the National Institutes of 
Health. 
 
1.3  Names, degrees, and affiliations of the researchers conducting the study:  
Riann Palmieri-Smith, PhD, ATC – University of Michigan, Division of Kinesiology 
Kathryn Antle, MS – University of Michigan, Department of Orthopedics 
Kimberly Becker, PT – University of Michigan, MedSport 
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Catherine Brandon, MD – University of Michigan, Department of Radiology 
Scott McLean, PhD - University of Michigan, Division of Kinesiology 
Daryl Montie, DPT, CSCS, MA – University of Michigan, MedSport 
Abbey Thomas, MEd – University of Michigan, Division of Kinesiology 
Ganapriya Venkatasubramanian – University of Michigan, Division of Kinesiology 
Edward Wojtys, MD – University of Michigan, Department of Orthopedics 
Jennifer Kreinbrink, BS – University of Michigan, Department of Orthopedics 
 
2.  PURPOSE OF THis STUDY 
 
2.1  Study purpose:  
Thigh muscle weakness often accompanies anterior cruciate ligament (ACL) injury.  This 
study is designed to examine how thigh muscle weakness that accompanies ACL injury 
affects lower body positions and forces.  We will also examine whether electrical 
stimulation therapy can improve thigh muscle strength.   
 
3.  Information About STUDY participants (SUBJECTS) 
 
Taking part in this study is completely voluntary.  You do not have to participate if you 
don't want to.  You may also leave the study at any time.  If you leave the study before it 
is finished, there will be no penalty to you, and you will not lose any benefits to which 
you are otherwise entitled.   
 
3.1  Who can take part in this study? 
259 subjects between the ages of 14-35 will be recruited to participate.  All study 
participants cannot have any previous history of serious knee injury (other than the 
current ACL tear) or surgery and cannot have a cardiac demand-type pacemaker. 
Furthermore, volunteers who are females and are pregnant are not eligible to participate.  
In addition to the criteria above, volunteers with ACL injury also cannot have any injury 
to any other knee ligament besides the ACL rupture and healthy volunteers cannot have 
any current knee pain and/or have had any lower body injury in the previous 6 months.  It 
is very important that you accurately report your medical history.  
 
3.2  How many people (subjects) are expected to take part in this study? 
We will enroll 214 participants in this part of the study and 45 participants in another part 




Picture 1.  Muscle Strength Test 
 Picture 2.  Knee Looseness Testing 
 
4.  information about study participation  
 
4.1  What will happen to me in this study?   
If you agree to participate in this study, you will be asked to report to the MedSport 
Clinic located in Domino Farms for testing. You will be asked to participate in a 
minimum of two testing sessions and a maximum of three testing sessions.  If you are a 
volunteer that has torn your ACL, you will be asked to report for testing prior to your 
surgery, ~6 months following your surgery, and in some cases ~8 months to 1 year 
following your surgery.  If you are a healthy, uninjured volunteer you will be asked to 
report for up to 3 sessions approximately 6 months apart.  We will schedule these session 
on days/times that are convenient for you.   
 
At the first testing session, your muscle strength, the looseness of your knee joints, and a 
measure of the swelling in your knees will be taken.  Additionally, you will be asked to 
fill out a questionnaire that asks questions about your pain level and functional abilities.   
 
Measures of Muscle Strength:  Two large 
pads will be placed on the front of both of 
your thighs and secured with bandages.  Once 
all of the pads are attached to your leg, you 
will be positioned in a device that measures 
muscle strength.  You will be asked to sit in a 
chair attached to the device with your knees 
bent (Picture 1).  Once you are positioned in 
the device, you will be asked to kick your leg 
out against a pad as hard as you can.  As soon 
as you feel comfortable with the kick, the 
researchers will apply a group of shocks to the skin of your thigh while you are resting.  
We will deliver the shocks thru the pads we attached earlier.  In order to help you get use 
to the shocks, we will start giving them to you at a low level and will then increase the 
level in small amounts. We eventually need the level of the shocks to reach 150 volts 
each (if these shock were delivered separately they would feel like a shock of static 
electricity like when you walk across a carpet and touch a door knob, except a shock of 
static electricity can reach up to 1,000 volts) The series of 10 shocks will last less than 1 
second and are delivered very close together, so you shouldn‘t be able to feel individual 
shocks.  The group of shocks will allow your muscle to contract even when you are 
resting.  These shocks may be slightly uncomfortable, the discomfort you experience in 
the muscle is normal.  If at anytime during the procedures you feel as if the shocks are 
too strong and you don‘t want to continue, please notify the researchers immediately.   




       Picture 3.  Jump Landing Task.  
 
Picture 4. Forward Hop 
you can.  Once the researchers see that you are contracting as hard as you can by 
watching the computer screen (usually in about 2 seconds), they will deliver the series of 
shocks on top of your muscle.  This technique, where we deliver shocks on top of a 
muscle contraction, will be repeated 3 times for each leg.   
 
Measure of looseness of your knee joint:  In order to see how loose your knees are, we 
will place each knee into a device, one at a time.  You will be asked to lay on your back 
and we will place a pad under both of your legs.  The device will be secured to your leg, 
at the ankle and calf, by Velcro straps (see picture 2).  Once your knee is in the device, 
the investigators will pull a handle on the device, which causes the shin bone to move 
forward.  The investigators will pull on the handle 3 times for each knee.   
 
Measure of knee swelling:  We will assess how much fluid is in your knee by wrapping 
a cloth measuring tape around your kneecap.  We will do this on both knees. 
 
At the second and third (if applicable) 
testing sessions, you will repeat all of the 
tests done in the first session and will also 
be asked to complete several jump 
landings before and after being fatigued 
and 10 forward hops.   
 
Jump Landings:  The jump landing tasks 
will include both double and single leg 
take-offs. 
Upon 
landing, you will be required to quickly jump to the left, 
right or straight up. You will be informed in which direction 
to jump by a light (Picture 3). The first light (L1) is fixed to 
the left and in front of a force plate (similar to a scale that 
measures forces), If this light comes on, you will land on 
the left foot only and then jump to the right. A second light 
(L2) will be similarly positioned to the right of the force 
plates, and will require you to land on the right foot only 
and jump to the left. A third light (L3) will be placed 
between the two force plates. When this light comes on you 
will be required to land on both feet and jump straight up.  
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The researchers will demonstrate the jump landings before you are asked to do it.   
 
Following the initial jump landing trials, you will again be required to perform the above 
tasks, only this time while being exposed to a general fatigue protocol. Specifically, you 
will be asked to perform continuous sets of three single or double leg squats between the 
jump trials.  You will alternate between squats and jumps until fatigue is reached, being 
defined as the point when you can no longer perform three squats in succession. You will 
be able to place the non-fatigued leg on a platform for stability during the single leg 
squats.  From our previous work, we expect that you will be able to perform 
approximately 50 jump trials (150 squats) prior to maximum fatigue.  
 
During all the of the jump landing you will have 28 reflective markers attached to your 
body, which will enable us to measure the movements of your lower body. The markers 
will be secured directly to the skin using adhesive tape and will not cause you any 
discomfort. As some markers are required to be attached to the thigh and hips, you will 
be asked to wear bicycle shorts and sports brassier during testing.  
 
Forward Hops:  The forward hop requires you to jump and land on a single leg.  We 
will ask you to complete the hop for both legs.  Before you hop, you will be asked to 
stand on the leg we are testing (picture 4), with your hands on your hips.  When you are 
ready, you will be asked to jump forward as far as you can and stick the landing, if 
possible.  You will be asked to hop 5 times for each leg.  
 
Measures of brain and spinal cord output:  For these tests we will obtain measures of 
brain and spinal cord function known as the H-reflex, M-wave, and, V-wave. To obtain 
the H-reflex and M-wave one small area, on both legs, will be shaved, rubbed gently with 
sand paper, and cleaned with isopropyl alcohol.  Four round stickers (electrodes) will be 
applied to this area and an additional electrode will be applied to the bone on the inside of 
your ankle.  These electrodes will be outlined with a black marker to ensure they are in 
the same place throughout the entire testing session.  Next, you will be given a small 
round disc to place near your groin. A diagram will be provided to demonstrate the 
correct placement.  Additionally, we will ask you to place a large rubber electrode on 
your buttocks.   Several measurements will be taken while you are lying down.  These 
measurements include a 1-millisecond shock.  The intensity of this shock will vary 
depending on which response is being elicited.  Lower intensities (50-100V) will be 
needed to obtain an H-reflex where higher intensities (100-200V) are needed to elicit an 
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M-wave.  The shocks in this study feel similar to a shock of static electricity, like when 
you are walking across a carpet and then touch a door knob, except the voltage is much 
lower (A shock of static electricity can provide up to thousands of volts of electricity).  
To obtain the V-wave, the same technique utilized to gather the H-reflex and M-wave 
will be used, except that you will be asked to contract your quadriceps, by kicking out 
your leg, as hard as you can against resistance.  The shocks will be applied atop of the 
quadriceps contraction.   
 
4.2  How much of my time will be needed to take part in this study?   
The first testing session will last approximately 1.5 hours, while the second and third 
testing session will take approximately 2.5 hours.   
 
4.3 When will my participation in the study be over?  
Most subjects will complete their part of the study within 1 year.  The entire study is 
expected to last about 5 years.   
 
5.  information about RISKS and benefits  
 
5.1  What risks will I face by taking part in the study?  What will the researchers do 
to protect me against these risks? 
 
The known or expected risks are:  
 You may experience some discomfort when the electrical shocks are applied to 
you skin. In order to make the shocks as comfortable as possible, large pads will 
be used to apply the shocks.   
 You may experience muscle soreness after performing repeated muscle 
contractions.  You will be offered ice bags following the experiment to minimize 
the chances of muscle soreness.    
 You may suffer a joint or muscle injury during the study when performing the 
landing tasks.  Dr. Palmieri-Smith, the lead researcher on this study, is a certified 
athletic trainer equipped with the knowledge to evaluate and manage 
musculoskeletal injuries. Thus, if an injury were to occur Dr. Palmieri-Smith 
would manage the condition and refer you to a physician for further evaluation.   
 You may suffer a muscle or tendon injury when performing the repeated muscle 
contractions.  Dr. Palmieri-Smith, the lead researcher on this study, is a certified 
athletic trainer equipped with the knowledge to evaluate and manage 
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musculoskeletal injuries. Thus, if an injury were to occur, Dr. Palmieri-Smith 
would manage the condition and refer you to a physician for further evaluation.   
 There is also the potential risk of loss of confidentiality through participation in 
this study.   
Every effort will be made to keep your information confidential, however, this 
cannot be guaranteed.  Some of the questions we will ask you as part of this study 
may make you feel uncomfortable.  You may refuse to answer any of the 
questions and you may take a break at any time during the study.  You may stop 
your participation in this study at any time. 
 As with any research study, there may be additional risks that are unknown or 
unexpected. 
 
5.2  What happens if I get hurt, become sick, or have other problems as a result of 
this research? 
 
The researchers have taken steps to minimize the risks of this study.  Even so, you may 
still have problems or side effects, even when the researchers are careful to avoid them. 
Please tell the researchers listed in Section 10 about any injuries, side effects, or other 
problems that you have during this study.  You should also tell your regular doctors. 
5.3  If I take part in this study, can I also participate in other studies? 
 
 Being in more than one research study at the same time, or even at different times, may 
increase the risks to you.  It may also affect the results of the studies.  You should not 
take part in more than one study without approval from the researchers involved in each 
study.   
 
5.4  How could I benefit if I take part in this study?  How could others benefit?   
 
You may not receive any personal benefits from being in this study. Your participation 
will be of benefit to medical science.  
 
5.5  Will the researchers tell me if they learn of new information that could change 
my willingness to stay in this study? 
 
Yes, the researchers will tell you if they learn of important new information that may 
change your willingness to stay in this study. If new information is provided to you after 
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you have joined the study, it is possible that you may be asked to sign a new consent 
form that includes the new information. 
 
 
6.  Other options  
 
6.1  If I decide not to take part in this study, what other options do I have? 
Since your participation is voluntary, you may decide not to take part in the study at any 
time without penalty.  Your only other option is not to participate. 
 
7.  ENDING THE STUDY 
 
7.1  If I want to stop participating in the study, what should I do? 
 
You are free to leave the study at any time.  If you leave the study before it is finished, 
there will be no penalty to you. You will not lose any benefits to which you may 
otherwise be entitled.  If you choose to tell the researchers why you are leaving the study, 
your reasons for leaving may be kept as part of the study record. If you decide to leave 
the study before it is finished, please tell one of the persons listed in Section 10 ―Contact 
Information‖ (below). 
 
7.2  Could there be any harm to me if I decide to leave the study before it is 
finished?  
No harm will occur if you decide to leave the study early. 
 
7.3  Could the researchers take me out of the study even if I want to continue to 
participate? 
 
Yes. There are many reasons why the researchers may need to end your participation in 
the study.  Some examples are: 
 
 The researcher believes that it is not in your best interest to stay in the study. 
 You become ineligible to participate. 
 Your condition changes and you need treatment that is not allowed while you are 
taking part in the study. 
 You do not follow instructions from the researchers. 
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 The study is suspended or canceled. 
 
 
8.  Financial Information 
 
8.1  Who will pay for the costs of the study? Will I or my health plan be billed for 
any costs of the study?   
The study will pay for research-related items or services that are provided only because 
you are in the study.  If you are not sure what these are, see Section 4.1 above or ask the 
researchers for a list.  If you get a bill you think is wrong, call the researchers‘ number 
listed in section 10.1. 
 
You or your health plan will pay for all the things you would have paid for even if you 
were not in the study, like: 
 Health care given during the study as part of your regular care 
 Items or services needed to give you study drugs or devices 
 Monitoring for side effects or other problems 
 Treatment of complications  
 Deductibles or co-pays for these items or services. 
If you do not have a health plan, or if you think your health plan may not cover these 
costs during the study, please talk to the researchers listed in Section 10 below or call 
your health plan‘s medical reviewer. 
 
By signing this form, you do not give up your right to seek payment if you are harmed as 
a result of being in this study. 
 
8.2  Will I be paid or given anything for taking part in this study? 
You will receive $25 for each session in which you participate.  You will receive this 
payment in the mail approximately 4 weeks after each testing session.   
 
 
8.3  Who could profit or financially benefit from the study results? 





9.  confidentiality of subject records and authorization to release your protected 
health information  
 
The information below describes how your privacy and the confidentiality of your 
research records will be protected in this study. 
 
9.1  How will the researchers protect my privacy? 
We will put the information collected about you during the study into a research record.  
This research record will not show your name, but will have codes entered in it, that will 
allow the information to be linked to you.  However, we will keep your research record 
confidential, to the extent provided by federal, state, and local law.  We will not allow 
anyone to see your record, other than people who have a right to see it.  You will not be 
identified in any reports from this study.   
 
9.2  What information about me could be seen by the researchers or by other 
people?  Why?  Who might see it? 
 
Signing this form gives the researchers your permission to obtain, use, and share 
information about you for this study, and is required in order for you to take part in the 
study.  Information about you may be obtained from any hospital, doctor, and other 
health care provider involved in your care, including: 
 Hospital/doctor's office records, including test results (X-rays, blood tests, 
urine tests, etc.) 
 Mental health care records (except psychotherapy notes not kept with your 
medical records) 
 Alcohol/substance abuse treatment records 
 Your AIDS/HIV status 
 All records relating to your ACL injury, the treatment you have received, and 
your response to the treatment 
 Billing information 
 
There are many reasons why information about you may be used or seen by the 




 The researchers may need the information to make sure you can take part in 
the study.   
 
 The researchers may need the information to check your test results or look 
for side effects.   
 
 University, Food and Drug Administration (FDA), and/or other government 
officials may need the information to make sure that the study is done in a 
safe and proper manner.    
 
 Study sponsors or funders, or safety monitors or committees, may need the 
information to:  
o Make sure the study is done safely and properly 
o Learn more about side effects  
o Analyze the results of the study  
  
 Insurance companies or other organizations may need the information in order 
to pay your medical bills or other costs of your participation in the study. 
 
 The researchers may need to use the information to create a databank of 
information about your condition or its treatment. 
 
 Information about your study participation may be included in your regular 
UMHS medical record. 
 
 If you receive any payments for taking part in this study, the University of 
Michigan accounting department may need your name, address, social 
security number, payment amount, and related information for tax reporting 
purposes.  
 
 Federal or State law may require the study team to give information to 
government agencies. For example, to prevent harm to you or others, or for 




The results of this study may be published or presented at a scientific meeting.  If your 
name and pictures will be used in any publications or presentation, the researchers will 
ask for your separate written permission.   
 
9.3  What happens to information about me after the study is over or if I cancel my 
permission? 
 
As a rule, the researchers will not continue to use or disclose information about you, but 
will keep it secure until it is destroyed.  Sometimes, it may be necessary for information 
about you to continue to be used or disclosed, even after you have canceled your 
permission or the study is over.  Examples of reasons for this include: 
 
 To avoid losing study results that have already included your information  
 To provide limited information for research, education, or other activities  (This 
information would not include your name, social security number, or anything 
else that could let others know who you are.)  
 To help University and government officials make sure that the study was 
conducted properly 
 
As long as your information is kept within the University of Michigan Health System, it 
is protected by the Health System‘s privacy policies.  For more information about these 
policies, ask for a copy of the University of Michigan Notice of Privacy Practices.  This 
information is also available on the web at http://www.med.umich.edu/hipaa/npp.htm. 
Note that once your information has been shared with others as described under Question 
9.2, it may no longer be protected by the privacy regulations of the federal Health 
Insurance Portability and Accountability Act of 1996 (HIPAA).   
 
9.4  When does my permission expire?   
 
Your permission expires at the end of the study, unless you cancel it sooner. You may 
cancel your permission at any time by writing to the researchers listed in Section 10 
"Contact Information" (below).   
 
 
10.  Contact Information 
 




Please contact the researchers listed below to: 
 
 Obtain more information about the study 
 Ask a question about the study procedures or treatments 
 Talk about study-related costs to you or your health plan  
 Report an illness, injury, or other problem (you may also need to tell your regular 
doctors) 
 Leave the study before it is finished 
 Express a concern about the study 
 
Principal Investigator: Riann Palmieri-Smith, Ph.D., ATC 
Mailing Address: 4745G CCRB, School of Kinesiology, University of Michigan, 
401 Washtenaw Avenue, Ann Arbor, MI, 48109-2214 
Telephone: 734-615-3154 
 
You may also express a concern about a study by contacting the Institutional Review 
Board listed below, or by calling the University of Michigan Compliance Help Line at 1-
888-296-2481. 
 
 University of Michigan Medical School Institutional Review Board (IRBMED) 
Argus I 
517 W. William 




e-mail: irbmed@umich.edu  
 
If you are concerned about a possible violation of your privacy, contact the University of 




When you call or write about a concern, please provide as much information as possible, 
including the name of the researcher, the IRBMED number (at the top of this form), and 
details about the problem.  This will help University officials to look into your concern.  
When reporting a concern, you do not have to give your name unless you want to. 
 
11.  record of Information provided 
 
11.1  What documents will be given to me? 
 
Your signature in the next section means that you have received copies of all of the 
following documents: 
 
 This "Consent to be Part of a Research Study" document.  (Note: In addition to the 
copy you receive, copies of this document will be stored in a separate confidential 
research file and may be entered into your regular University of Michigan 
medical record.) 





I understand the information printed on this form.  I have discussed this study, its risks 
and potential benefits, and my other choices with ____________________.  My questions 
so far have been answered.  I understand that if I have more questions or concerns about 
the study or my participation as a research subject, I may contact one of the people listed 
in Section 10 (above).  I understand that I will receive a copy of this form at the time I 
sign it and later upon request.  I understand that if my ability to consent for myself 
changes, either I or my legal representative may be asked to re-consent prior to my 
continued participation in this study. 
 
Signature of Subject: ____________________________________ Date: _____________ 
 
Name (Print legal name):   __________________________________________________ 
 
Patient ID:  Date of Birth: ____________________ 
 
Legal Representative (if applicable): 
Signature of Person #1 Legally 
Authorized to Give Consent__________________________________ Date: __________ 
Name (Print legal name):     ____________ Phone: _____________ 
Address:   ________________________________ 
Check Relationship to Subject: 
Parent  Spouse  Child  Sibling  Legal Guardian Other: __________________ 
 
Signature of Person #2 Legally 
Authorized to Give Consent__________________________________ Date: __________ 
Name (Print legal name):     ____________ Phone: _____________ 
Address:   ________________________________ 
Check Relationship to Subject: 
Parent  Spouse  Child  Sibling  Legal Guardian Other: __________________ 
 
If this consent is for a child who is a ward of the state (for example a foster child), 
please tell the study team immediately. The researchers may need to contact the 
IRBMED. 







Principal Investigator (or Designee): 
I have given this research subject (or his/her legally authorized representative, if 
applicable) information about this study that I believe is accurate and complete.  The 
subject has indicated that he or she understands the nature of the study and the risks and 
benefits of participating. 
 
Name:   Title: 
_________________________________ 
 
























 DATA COLLECTION MATERIALS 
COLLECTION FORMS
 
Figure B.1. Circumference and effusion data collection form for aims 1-3. Testing sessions were pre-
operative and/or post-operatively, as appropriate. Knee effusion and thigh circumference were recorded in 





Figure B.2. Quadriceps central activation failure data collection form. Test session was post-operative 





Figure B.3. Data collection sheet for Chapter4 dynamic landing trials. R denotes right limb, L denotes left 




























































AIM 1 SUPPLEMENTAL DATA 




































13 M R 16 1.71 78.84 Basketball 
Did not 
recall  
None STG 67 7 1 9 56.32 83.91 
15 F R 14 1.74 61.23 Basketball Non-contact Medial PT 30 9 2 9 45.98 97.7 
16 F L 15 1.67 81.65 Softball 
Non-contact, 
running 
Medial‡ PT 46 6 2 4 51.72 68.97 
18 M R 23 1.8 86.18 Soccer 
Non-contact, 
cutting 
 ateral‡ PT 320 7 5 5 71.26 60.92 
21 F L 15 1.85 61.23 Volleyball 
Landing 
from hit 
Medial‡ PT 48 10 1 5 11.49 85.06 





None PT 39 10 4 4 43.68 81.61 
23 F L 27 1.57 52.16 Soccer 
Non-contact, 
cutting 
None PT 56 5 2 7 27.59 80.46 
24 F L 19 1.84 84.37 Snowboarding Non-contact 
Lateral & 
Medial 
PT 277 7 4 8 66.67 90.8 
26 M R 15 1.75 63.5 Soccer Non-contact Lateral§ PT 49 9 2 7 45.98 74.71 
31 M L 20 1.85 81.65 Soccer Non-contact None PT 54 4 9 7 48.28 87.76 
32 F R 17 1.57 61.23 Gymnastics Landing  ateral‡ PT 39 9 4 7 52.87 81.61 
34 M L 17 1.73 61.23 Soccer Cutting Lateral§ PT 63 9 3 6 40.23 72.41 





STG 106 9 5 6 79.31 94.25 
36 M R 28 1.65 88.45 Basketball 
Landing 
from jump 
Lateral PT 70 7 2 5 54.02 57.47 
M= male; F= female; L= left; R= right; PT= patellar tendon; STG= semitendinosus/gracilis; IKDC= International Knee Documentation Society  
* As dictated by the subject 
 †Meniscal damage was determined from diagnostic MRI report. ‡Indicates subject had meniscal debridement/repair concurrent with ACL reconstruction. 
§Indicates subject had meniscectomy concurrent with ACL reconstruction. All other subjects had no treatment of meniscal injury. ǁTegner scale is scored from 0-10, 









Table C.2. Control Subject Demographic Data. 
Subject ID Sex Age Height (m) Mass (kg) Tegner Score* IKDC Score† 
C1 F 24 1.7 64.41 10 100 
C2 M 20 1.83 88.45 5 97.7 
C3 F 22 1.7 61.23 9 95.4 
C4 M 32 1.74 80 7 100 
C5 M 22 1.88 81.65 6 100 
C6 M 23 1.8 98.43 7 100 
C7 F 30 1.63 48.54 9 100 
 C9 F 24 1.63 56.7 6 93.1 
C10 F 25 1.8 86.18 6 100 
C11 M 27 1.91 77.11 6 100 
C12 M 25 1.78 83.91 6 94.25 
C13 F 25 1.63 65.77 6 94.25 
C14 F 21 1.8 70.31 7 100 
C15 M 28 1.78 72.57 5 100 
C16 1 23 1.68 63.5 7 100 











Table C.3. Pre-operative ACL-Injured Subject Knee Effusion and Thigh Circumference Data. 
 Knee Effusion (cm) Thigh Circumference (cm)* 
 Suprapatellar† Mid-Patella 6 cm 12 cm 18 cm 
Subject ID Injured Uninjured    Injured Uninjured Injured Uninjured Injured Uninjured Injured Uninjured 
13 40.0 37.7 37.7 41.0 43.9 44.1 49.1 50.0 53.4 55.0 
15 36.9 36.0 36.0 35.7 39.0 39.9 43.9 44.2 49.7 50.5 
16 45.5 44.1 43.0 41.9 49.2 49.2 58.5 56.5 61.3 61.0 
18 40.0 40.3 39.6 39.7 42.9 43.5 50.4 50.2 56.3 56.2 
21 37.5 37.1 36.3 36.0 37.7 39.2 40.7 43.5 44.2 47.3 
22 40.5 40.2 38.0 37.2 44.4 44.4 50.0 50.3 54.4 55.0 
23 35.0 35.0 34.3 33.9 36.8 38.0 42.2 43.3 46.5 47.9 
24 39.0 40.6 38.8 39.5 42.5 45.5 49.0 51.7 54.0 56.5 
26 35.2 36.2 34.9 36.0 37.0 39.0 42.3 45.0 46.5 49.0 
31 38.5 39.0 39.0 38.3 41.2 43.1 46.2 48.8 49.8 52.7 
32 37.9 38.0 35.9 36.5 41.0 42.3 46.5 50.0 52.5 56.0 
34 37.5 38.2 37.0 35.8 39.5 42.9 44.5 49.0 48.0 51.5 
35 44.0 44.4 41.0 41.0 48.5 49.7 56.0 56.0 60.0 61.8 
36 43.3 42.1 39.1 39.6 49.0 47.5 60.2 58.4 62.2 61.6 
*Measured 6, 12, and 18 cm proximal to the superior pole of the patella with the subject in supine and the knee resting in approximately 10° of flexion on a 
bolster. 












Table C.4. Post-operative ACL-injured Subject Knee Effusion and Thigh Circumference Data. 
 Knee Effusion (cm) Thigh Circumference (cm)* 
 Suprapatellar† Mid-Patella 6 cm 12 cm 18 cm 
Subject ID Injured Uninjured    Injured Uninjured Injured Uninjured Injured Uninjured Injured Uninjured 
13 39.8 40.3 36.8 37.5 43.3 44.9 48.8 51.9 53.7 56.2 
15 36.2 37.0 35.2 35.6 39.0 41.0 44.0 45.5 49.9 51.0 
16 47.0 44.0 45.0 41.3 52.4 50.0 60.3 59.0 63.0 62.0 
18 38.0 37.8 38.1 38.5 40.9 41.1 48.0 48.0 54.2 52.9 
21 39.0 38.7 37.6 36.7 40.0 42.0 43.5 45.4 47.5 50.4 
22 39.1 40.0 37.3 37.1 43.8 43.8 50.0 50.5 52.4 54.9 
23 35.0 36.2 34.0 33.5 38.0 39.0 42.5 44.0 47.0 49.7 
24 48.0 41.0 48.5 39.9 42.2 45.5 49.0 52.0 53.0 56.0 
26 36.7 38.5 35.8 36.4 41.5 43.0 46.0 48.5 50.5 53.2 
31 39.0 38.9 39.0 38.3 42.0 43.2 48.5 49.7 52.0 53.8 
32 38.0 38.0 36.4 36.0 41.6 42.9 47.5 49.0 53.0 54.0 
34 39.2 39.2 36.8 36.8 42.0 43.8 47.1 49.7 50.8 53.5 
35 45.3 45.3 42.0 42.0 50.5 52.0 57.4 59.1 64.5 63.4 
36 43.2 43.0 39.8 40.5 49.0 48.5 57.3 58.0 63.2 64.0 
*Measured 6, 12, and 18 cm proximal to the superior pole of the patella with the subject in supine and the knee resting in approximately 10° of flexion on a 
bolster. 














Table C.5. Pre-operative ACL-injured Subject Calf Girth Data (cm). 
 5 cm Proximal 10 cm Proximal Maximum 5 cm Distal 10 cm Distal 
Subject ID Injured Uninjured    Injured Uninjured Injured Uninjured Injured Uninjured Injured Uninjured 
13 36.7 38.0 34.0 33.8 39.1 39.0 35.2 34.0 30.0 29.8 
15 35.5 36.2 32.5 32.3 37.4 37.6 34.0 32.9 29.5 28.2 
16 42.1 40.8 39.2 38.2 44.0 42.9 39.5 39.0 33.0 31.1 
18 37.6 37.5 37.0 36.3 39.8 39.2 35.1 34.4 28.4 27.6 
21 31.8 32.3 33.1 32.0 34.7 34.9 32.5 34.3 27.5 28.9 
22 36.5 35.0 36.3 34.4 38.7 38.2 33.7 34.3 29.7 29.3 
23 33.9 32.3 30.2 30.4 35.0 35.8 30.0 32.4 26.0 27.3 
24 36.8 36.8 33.2 33.8 37.1 38.1 34.0 35.6 28.4 29.9 
26 32.0 34.4 31.2 33.3 33.5 36.6 32.2 34.7 28.8 29.5 
31 34.5 36.0 32.8 33.7 37.5 38.8 34.2 33.3 29.0 28.3 
32 35.0 35.5 33.4 33.0 36.5 37.0 32.2 32.0 27.8 27.5 
34 34.9 37.0 33.2 33.9 37.0 39.8 34.5 36.3 28.2 29.1 
35 42.9 40.5 38.0 37.7 41.5 41.8 35.0 35.7 30.8 31.2 
36 39.5 38.7 36.8 35.9 41.1 39.7 34.6 35.3 30.0 29.5 
Measurements were taken with the subject lying in a supine position and the knee flexed so the foot was flat on the table. The distance from the lateral knee joint 
line to the tip of the lateral malleolus was measured. A mark was placed one-third of the way from the lateral knee joint line to the lateral malleolus to signify the 














Table C.6. Post-operative ACL-injured Subject Calf Girth Data (cm). 
Measurements were taken with the subject lying in supine and the knee flexed so the foot was flat on the table. The distance from the lateral knee joint line to the 
tip of the lateral malleolus was measured. One-third of this distance was determined and a mark 1/3 of the way from the lateral joint line to the lateral malleolus 








 5 cm Proximal 10 cm Proximal Maximum 5 cm Distal 10 cm Distal 
Subject ID Injured Uninjured    Injured Uninjured Injured Uninjured Injured Uninjured Injured Uninjured 
13 36.5 38.7 34.8 35.4 39.0 39.5 36.5 34.4 31.8 30.2 
15 35.2 36.5 31.8 32.5 37.0 38.2 34.5 33.5 29.6 28.5 
16 44.0 42.5 41.5 38.6 43.5 43.3 38.0 38.9 31.2 32.0 
18 36.7 36.8 34.4 34.2 37.4 37.8 32.3 31.9 26.5 27.2 
21 36.0 35.1 33.9 33.3 36.6 37.0 33.5 35.2 28.5 31.0 
22 37.2 37.0 33.8 33.0 37.4 37.8 32.7 32.5 28.3 28.4 
23 34.0 34.5 29.8 31.0 35.5 36.5 31.9 32.7 26.7 27.4 
24 32.5 36.9 33.8 34.0 37.5 39.0 34.9 35.3 30.0 30.2 
26 34.3 35.0 32.0 33.0 37.0 38.0 34.5 35.3 28.8 30.0 
31 35.4 37.2 33.0 33.3 37.2 38.5 33.1 32.7 28.1 27.8 
32 35.5 36.5 33.0 33.0 36.1 36.5 32.2 31.9 27.5 27.6 
34 38.4 37.6 34.4 33.9 39.0 39.7 35.0 35.5 29.0 29.4 
35 43.5 42.0 39.6 39.3 44.5 43.4 37.2 37.5 33.1 32.0 










Table C.7. Control Subject Knee Effusion and Thigh Circumference Data. 
 Knee Effusion (cm) Thigh Circumference (cm)* 
 Suprapatellar† Mid-Patella 6 cm 12 cm 18 cm 
Subject 
ID 
Test Limb Contralateral 
Limb 
Test Limb Contralateral 
Limb 
Test Limb Contralateral 
Limb 
Test Limb Contralateral 
Limb 
Test Limb Contralateral 
Limb 
C1 37.5 36.9 36.0 35.6 41.1 40.4 47.8 46.7 53.7 53.0 
C2 41.5 42.2 41.4 41.1 47.5 46.5 51.8 51.3 55.5 56.0 
C3 37.0 36.5 36.2 35.8 40.5 39.9 45.1 44.9 50.0 49.0 
C4 40.0 40.0 38.8 39.1 44.2 44.0 50.0 49.8 55.0 54.2 
C5 35.0 34.6 34.0 34.1 39.5 38.5 44.6 43.2 48.2 47.0 
C6 40.3 39.5 37.4 37.9 41.9 42.8 47.8 49.0 54.0 53.2 
C7 35.0 34.6 34.0 34.1 39.5 38.5 44.6 43.2 48.2 47.0 
C9 34.3 35.8 33.8 34.0 38.3 39.4 44.5 46.3 50.6 51.0 
C10 43.1 42.5 40.2 40.4 48.2 47.0 52.2 51.7 57.3 57.0 
C11 37.0 37.0 36.9 37.4 40.3 40.4 46.8 46.5 50.6 50.0 
C12 41.0 40.5 39.0 39.1 47.3 46.8 51.9 52.7 55.8 56.5 
C13 38.1 37.5 36.9 36.4 43.1 42.1 49.0 48.2 53.0 52.4 
C14 39.5 39.0 38.5 37.5 42.0 41.0 45.2 44.0 49.0 48.5 
C15 38.0 37.1 37.7 36.4 42.5 42.0 48.5 46.7 52.5 51.6 
C16 36.6 37.8 36.5 36.3 41.5 43.5 48.5 50.5 54.4 54.5 
*Measured 6, 12, and 18 cm proximal to the superior pole of the patella with the subject in supine and the knee resting in approximately 10° of flexion on a 
bolster. 











Table C.8. Control Subject Calf Girth Measurements (cm). 
Measurements were taken with the subject lying in supine and the knee flexed so the foot was flat on the table. The distance from the lateral knee joint line to the 
tip of the lateral malleolus was measured. One-third of this distance was determined and a mark 1/3 of the way from the lateral joint line to the lateral malleolus 






 5 cm Proximal 10 cm Proximal Maximum 5 cm Distal 10 cm Distal 
Subject 
ID 
Test Limb Contralateral 
Limb 
Test Limb Contralateral 
Limb 
Test Limb Contralateral 
Limb 
Test Limb Contralateral 
Limb 
Test Limb Contralateral 
Limb 
C1 34.8 34.1 31.0 30.5 36.0 36.3 33.5 32.4 28.0 27.5 
C2 39.1 39.3 35.5 36.8 37.3 34.2 31.8 29.6 27.3 26.0 
C3 36.6 35.5 31.6 31.0 38.1 37.7 36.0 35.5 28.9 29.5 
C4 35.2 35.2 38.6 36.8 38.6 38.0 38.5 38.5 32.0 32.2 
C5 32.0 32.8 30.5 30.4 35.2 34.7 30.4 29.8 25.7 25.5 
C6 36.0 36.1 34.7 35.2 38.8 38.1 35.7 35.8 31.7 31.5 
C7 32.0 32.8 30.5 30.4 35.2 34.7 30.4 29.8 25.7 25.5 
C9 32.0 32.8 30.5 31.7 34.4 34.8 30.6 31.2 25.4 26.8 
C10 41.7 41.5 36.7 38.8 41.3 41.8 38.2 37.3 32.5 32.7 
C11 35.4 35.0 31.5 31.2 37.7 37.3 34.5 35.3 28.1 29.0 
C12 37.5 36.1 36.9 36.8 40.4 39.8 36.4 36.8 30.7 30.8 
C13 34.1 34.4 32.9 33.0 37.9 38.2 35.2 25.7 28.5 27.8 
C14 35.8 37.2 33.6 34.2 36.5 37.0 32.5 31.9 28.8 27.7 
C15 36.5 35.1 33.0 32.6 37.0 36.5 33.2 31.3 28.0 26.0 








Table C.9. Pre-operative ACL-injured subject strength data (Nm/kg). 












Hip Abductors Hip Adductors Hip Flexors Hip Extensors 
Subj. 
ID 
I U I U I U I U I U I U I U I U 
13 0.63 1.16 0.53 0.63 0.49 0.46 0.25 0.39 0.53 0.46 0.56 0.81 1.16 1.02 1.16 0.49 
15 1.08 1.58 0.77 0.90 0.41 0.45 0.14 0.27 0.45 0.36 0.81 0.86 0.54 0.63 0.99 0.59 
16 1.12 1.29 0.75 1.05 0.41 0.41 0.30 0.20 0.47 0.00 0.47 0.61 0.85 0.88 0.88 0.78 
18 1.22 1.22 1.03 1.89 0.58 0.26 0.39 0.32 0.00 0.48 0.71 0.55 1.00 0.83 0.96 1.28 
21 0.63 1.17 0.36 1.04 0.41 0.77 0.32 0.23 0.86 0.90 0.86 1.08 0.77 0.59 0.59 0.77 
22 2.40 3.01 1.08 1.33 0.68 0.86 0.36 0.25 1.36 1.18 1.15 1.29 1.44 1.51 1.83 1.79 
23 1.49 2.70 0.95 1.11 0.37 0.42 0.27 0.32 1.38 1.06 1.17 1.11 1.01 1.49 2.17 1.11 
24 2.26 2.10 1.28 1.41 0.46 0.43 0.33 0.36 1.28 0.89 0.85 0.75 1.28 1.25 1.44 1.41 
26 0.81 2.45 0.67 1.24 0.42 0.56 0.28 0.35 0.87 0.92 0.55 0.77 1.10 1.01 0.87 0.85 
31 0.90 2.22 0.77 0.99 0.20 0.40 0.27 0.35 0.65 0.52 0.52 0.59 1.27 1.13 1.82 1.19 
32 1.52 1.86 0.64 1.01 0.81 0.91 0.20 0.19 0.83 0.98 0.85 0.86 1.31 1.38 1.27 0.84 
34 1.31 2.30 0.92 1.25 0.82 1.08 0.17 0.28 0.74 0.88 0.51 0.77 1.44 1.44 1.98 1.84 
35 1.95 2.18 0.71 1.09 0.44 0.49 0.12 0.13 0.56 0.60 0.76 0.56 1.43 1.06 1.59 1.43 








Table C.10. Post-operative ACL-injured subjects strength data (Nm/kg). 












Hip Abductors Hip Adductors Hip Flexors Hip Extensors 
Subj. 
ID 
I U I U I U I U I U I U I U I U 
13 1.36 2.15 0.84 1.16 0.76 0.63 0.25 0.24 0.81 0.86 0.67 0.96 1.73 1.67 1.94 1.47 
15 1.56 1.86 1.03 0.84 0.87 0.66 0.18 0.14 0.72 0.50 0.76 0.81 1.06 1.02 1.56 1.52 
16 1.24 1.18 0.84 0.97 0.58 0.29 0.23 0.20 0.70 0.68 0.69 0.76 1.46 1.00 1.14 1.20 
18 2.28 1.81 1.10 1.00 0.93 0.77 0.38 0.31 0.75 0.69 0.96 1.00 0.76 1.11 1.32 1.39 
21 1.21 1.78 0.71 0.87 0.86 0.55 0.19 0.15 0.70 0.64 1.03 0.89 1.04 1.23 1.09 1.29 
22 1.90 2.93 0.99 1.13 0.65 0.83 0.24 0.30 1.08 0.95 0.95 0.97 1.62 1.38 2.14 1.54 
23 1.95 3.16 1.51 1.75 1.24 1.23 0.26 0.29 1.23 1.09 1.01 0.96 1.89 2.29 2.50 2.89 
24 1.38 3.10 1.38 1.30 0.58 0.60 0.32 0.31 1.05 0.88 0.92 0.92 1.41 1.51 1.83 1.62 
26 1.16 2.81 1.09 1.33 0.79 0.92 0.42 0.48 1.08 1.13 1.20 0.90 1.65 1.68 1.27 1.26 
31 0.77 1.27 0.72 0.88 0.90 0.61 0.32 0.29 0.86 0.81 1.03 0.88 1.13 1.13 1.83 1.68 
32 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
34 2.09 2.44 1.11 1.39 1.13 0.94 0.29 0.33 0.83 0.72 0.67 0.79 2.37 2.28 1.67 2.51 
35 1.46 2.18 0.73 0.99 0.65 0.54 0.24 0.19 0.78 0.73 0.56 0.61 1.40 1.63 1.68 1.60 










Table C.11. Control subject strength data (Nm/kg). 









Hip Abductors Hip Adductors Hip Flexors Hip Extensors 
Subj. 
ID 
T C T C T C T C T C T C T C T C 
C1 1.41 1.46 1.05 1.00 0.60 0.70 0.23 0.26 0.92 0.85 0.62 0.75 2.83 1.93 1.49 1.01 
C2 1.42 1.54 0.75 0.78 0.51 0.51 0.35 0.34 0.60 0.78 0.48 0.55 1.02 1.01 0.74 1.22 
C3 2.01 2.31 1.33 1.21 1.03 1.38 0.43 0.37 0.92 0.78 0.75 0.80 1.16 1.23 1.67 1.48 
C4 1.66 2.10 0.85 0.82 0.45 0.53 0.37 0.47 0.60 0.83 0.79 0.64 1.43 1.05 1.18 1.08 
C5 1.99 1.40 0.93 0.82 0.15 0.18 0.11 0.14 0.66 0.39 0.75 0.49 1.31 1.22 1.29 1.34 
C6 1.63 1.76 0.92 1.11 0.33 0.12 0.22 0.09 0.66 0.54 0.13 0.21 0.93 0.94 0.36 0.72 
C7 2.30 2.10 1.25 1.25 1.38 0.85 0.22 0.26 1.19 1.63 1.14 1.03 1.66 1.87 1.49 1.55 
C9 1.22 1.24 0.90 0.67 0.37 0.46 0.26 0.20 0.73 0.94 0.75 0.82 0.59 0.62 1.26 1.38 
C10 1.72 1.96 0.85 1.04 0.70 1.05 0.16 0.21 0.89 0.68 0.31 0.38 1.41 1.43 1.59 0.21 
C11 1.73 1.54 0.81 0.86 0.54 0.63 0.30 0.34 0.65 0.83 0.62 0.70 1.11 0.88 0.99 1.14 
C12 2.44 2.03 1.43 1.21 0.91 1.10 0.33 0.28 0.75 0.65 0.51 0.56 1.74 1.66 1.15 1.68 
C13 1.12 1.14 0.69 0.68 0.25 0.27 0.16 0.17 0.65 0.58 0.45 0.54 0.76 0.65 0.97 0.94 
C14 1.41 1.51 0.90 0.81 0.75 0.78 0.26 0.25 0.90 0.96 0.87 0.86 1.89 1.17 1.71 1.35 
C15 0.24 2.47 1.21 1.24 1.06 1.21 0.36 0.31 1.32 1.48 0.69 0.86 1.64 2.18 1.93 2.04 








AIM 1 STATISTICAL OUTPUT 
 
General Linear Model- ACL-injured vs. control at pre-op 
Tests of Between-Subjects Effects 
Source Dependent Variable 
Type III Sum of 
Squares df 
Mean 







pre-op injured limb knee extensor strength (Nm/kg) 1.226a 1 1.226 5.138 .032 5.138 .589 
pre-op injured limb knee flexor strength (Nm/kg) .234c 1 .234 4.353 .047 4.353 .521 
pre-op injured limb ankle plantar flexor strength 
(Nm/kg) 
.255d 1 .255 3.088 .090 3.088 .396 
pre-op injured limb ankle dorsiflexor strength 
(Nm/kg) 
.001e 1 .001 .101 .754 .101 .061 
pre-op injured limb hip abductor strength (Nm/kg) .029f 1 .029 .255 .618 .255 .078 
pre-op injured limb hip adductor strength (Nm/kg) .046g 1 .046 .808 .377 .808 .140 








pre-op injured limb hip extensor strength (Nm/kg) .164i 1 .164 .669 .421 .669 .124 
Intercept pre-op injured limb knee extensor strength (Nm/kg) 68.124 1 68.124 285.485 .000 285.485 1.000 
pre-op injured limb knee flexor strength (Nm/kg) 23.158 1 23.158 431.003 .000 431.003 1.000 
pre-op injured limb ankle plantar flexor strength 
(Nm/kg) 
10.387 1 10.387 125.760 .000 125.760 1.000 
pre-op injured limb ankle dorsiflexor strength 
(Nm/kg) 
2.040 1 2.040 328.392 .000 328.392 1.000 
pre-op injured limb hip abductor strength (Nm/kg) 18.536 1 18.536 165.512 .000 165.512 1.000 
pre-op injured limb hip adductor strength (Nm/kg) 13.776 1 13.776 244.501 .000 244.501 1.000 
pre-op injured limb hip flexor strength (Nm/kg) 47.106 1 47.106 212.165 .000 212.165 1.000 
pre-op injured limb hip extensor strength (Nm/kg) 50.063 1 50.063 203.614 .000 203.614 1.000 
Group pre-op injured limb knee extensor strength (Nm/kg) 1.226 1 1.226 5.138 .032 5.138 .589 
pre-op injured limb knee flexor strength (Nm/kg) .234 1 .234 4.353 .047 4.353 .521 
pre-op injured limb ankle plantar flexor strength 
(Nm/kg) 








pre-op injured limb ankle dorsiflexor strength 
(Nm/kg) 
.001 1 .001 .101 .754 .101 .061 
pre-op injured limb hip abductor strength (Nm/kg) .029 1 .029 .255 .618 .255 .078 
pre-op injured limb hip adductor strength (Nm/kg) .046 1 .046 .808 .377 .808 .140 
pre-op injured limb hip flexor strength (Nm/kg) .470 1 .470 2.118 .157 2.118 .289 
pre-op injured limb hip extensor strength (Nm/kg) .164 1 .164 .669 .421 .669 .124 
Error pre-op injured limb knee extensor strength (Nm/kg) 6.443 27 .239     
pre-op injured limb knee flexor strength (Nm/kg) 1.451 27 .054     
pre-op injured limb ankle plantar flexor strength 
(Nm/kg) 
2.230 27 .083 
    
pre-op injured limb ankle dorsiflexor strength 
(Nm/kg) 
.168 27 .006 
    
pre-op injured limb hip abductor strength (Nm/kg) 3.024 27 .112     
pre-op injured limb hip adductor strength (Nm/kg) 1.521 27 .056     








pre-op injured limb hip extensor strength (Nm/kg) 6.638 27 .246     
Total pre-op injured limb knee extensor strength (Nm/kg) 76.507 29      
pre-op injured limb knee flexor strength (Nm/kg) 25.031 29      
pre-op injured limb ankle plantar flexor strength 
(Nm/kg) 
12.997 29 
     
pre-op injured limb ankle dorsiflexor strength 
(Nm/kg) 
2.213 29 
     
pre-op injured limb hip abductor strength (Nm/kg) 21.660 29      
pre-op injured limb hip adductor strength (Nm/kg) 15.305 29      
pre-op injured limb hip flexor strength (Nm/kg) 53.953 29      
pre-op injured limb hip extensor strength (Nm/kg) 56.727 29      
Corrected Total pre-op injured limb knee extensor strength (Nm/kg) 7.669 28      
pre-op injured limb knee flexor strength (Nm/kg) 1.685 28      
pre-op injured limb ankle plantar flexor strength 
(Nm/kg) 
2.485 28 








pre-op injured limb ankle dorsiflexor strength 
(Nm/kg) 
.168 28 
     
pre-op injured limb hip abductor strength (Nm/kg) 3.052 28      
pre-op injured limb hip adductor strength (Nm/kg) 1.567 28      
pre-op injured limb hip flexor strength (Nm/kg) 6.465 28      
pre-op injured limb hip extensor strength (Nm/kg) 6.803 28      
 
Univariate Tests 
Dependent Variable Sum of Squares df Mean Square F Sig. Noncent. Parameter Observed Powera 
pre-op injured limb knee extensor strength (Nm/kg) Contrast 1.226 1 1.226 5.138 .032 5.138 .589 
Error 6.443 27 .239     
pre-op injured limb knee flexor strength (Nm/kg) Contrast .234 1 .234 4.353 .047 4.353 .521 
Error 1.451 27 .054     








Error 2.230 27 .083     
pre-op injured limb ankle dorsiflexor strength (Nm/kg) Contrast .001 1 .001 .101 .754 .101 .061 
Error .168 27 .006     
pre-op injured limb hip abductor strength (Nm/kg) Contrast .029 1 .029 .255 .618 .255 .078 
Error 3.024 27 .112     
pre-op injured limb hip adductor strength (Nm/kg) Contrast .046 1 .046 .808 .377 .808 .140 
Error 1.521 27 .056     
pre-op injured limb hip flexor strength (Nm/kg) Contrast .470 1 .470 2.118 .157 2.118 .289 
Error 5.995 27 .222     
pre-op injured limb hip extensor strength (Nm/kg) Contrast .164 1 .164 .669 .421 .669 .124 












General Linear Model- ACL-reconstructed vs. control at post-op 
Tests of Between-Subjects Effects 
Source Dependent Variable 
Type III Sum of 
Squares df 
Mean 











 1 .942 3.664 .066 3.664 .455 
post-op injured limb knee flexor strength .023c 1 .023 .259 .615 .259 .078 
Post_Inj_Ank_PF .047d 1 .047 .424 .520 .424 .096 
Post_Inj_Ank_DF .002e 1 .002 .247 .623 .247 .077 
Post_Inj_Hip_Abd .001f 1 .001 .013 .910 .013 .051 
Post_Inj_Hip_Add .152g 1 .152 2.137 .155 2.137 .292 
Post_Inj_Hip_Flex .000h 1 .000 .001 .975 .001 .050 
Post_Inj_Hip_Ext .795i 1 .795 2.642 .116 2.642 .348 
Intercept post-op injured limb knee extensor strength 
(Nm/kg) 








post-op injured limb knee flexor strength 26.469 1 26.469 299.772 .000 299.772 1.000 
Post_Inj_Ank_PF 15.553 1 15.553 141.733 .000 141.733 1.000 
Post_Inj_Ank_DF 1.985 1 1.985 251.248 .000 251.248 1.000 
Post_Inj_Hip_Abd 19.729 1 19.729 242.281 .000 242.281 1.000 
Post_Inj_Hip_Add 15.120 1 15.120 212.191 .000 212.191 1.000 
Post_Inj_Hip_Flex 56.707 1 56.707 162.638 .000 162.638 1.000 
Post_Inj_Hip_Ext 57.181 1 57.181 189.964 .000 189.964 1.000 
Group post-op injured limb knee extensor strength 
(Nm/kg) 
.942 1 .942 3.664 .066 3.664 .455 
post-op injured limb knee flexor strength .023 1 .023 .259 .615 .259 .078 
Post_Inj_Ank_PF .047 1 .047 .424 .520 .424 .096 
Post_Inj_Ank_DF .002 1 .002 .247 .623 .247 .077 
Post_Inj_Hip_Abd .001 1 .001 .013 .910 .013 .051 








Post_Inj_Hip_Flex .000 1 .000 .001 .975 .001 .050 
Post_Inj_Hip_Ext .795 1 .795 2.642 .116 2.642 .348 
Error post-op injured limb knee extensor strength 
(Nm/kg) 
6.945 27 .257 
    
post-op injured limb knee flexor strength 2.384 27 .088     
Post_Inj_Ank_PF 2.963 27 .110     
Post_Inj_Ank_DF .213 27 .008     
Post_Inj_Hip_Abd 2.199 27 .081     
Post_Inj_Hip_Add 1.924 27 .071     
Post_Inj_Hip_Flex 9.414 27 .349     
Post_Inj_Hip_Ext 8.127 27 .301     
Total post-op injured limb knee extensor strength 
(Nm/kg) 
78.930 29 
     
post-op injured limb knee flexor strength 28.961 29      








Post_Inj_Ank_DF 2.207 29      
Post_Inj_Hip_Abd 21.963 29      
Post_Inj_Hip_Add 17.110 29      
Post_Inj_Hip_Flex 66.198 29      
Post_Inj_Hip_Ext 65.706 29      
Corrected Total post-op injured limb knee extensor strength 
(Nm/kg) 
7.887 28 
     
post-op injured limb knee flexor strength 2.407 28      
Post_Inj_Ank_PF 3.009 28      
Post_Inj_Ank_DF .215 28      
Post_Inj_Hip_Abd 2.200 28      
Post_Inj_Hip_Add 2.076 28      
Post_Inj_Hip_Flex 9.414 28      










Dependent Variable Sum of Squares df Mean Square F Sig. Noncent. Parameter Observed Powera 
post-op injured limb knee extensor strength (Nm/kg) Contrast .942 1 .942 3.664 .066 3.664 .455 
Error 6.945 27 .257     
post-op injured limb knee flexor strength Contrast .023 1 .023 .259 .615 .259 .078 
Error 2.384 27 .088     
Post_Inj_Ank_PF Contrast .047 1 .047 .424 .520 .424 .096 
Error 2.963 27 .110     
Post_Inj_Ank_DF Contrast .002 1 .002 .247 .623 .247 .077 
Error .213 27 .008     
Post_Inj_Hip_Abd Contrast .001 1 .001 .013 .910 .013 .051 
Error 2.199 27 .081     
Post_Inj_Hip_Add Contrast .152 1 .152 2.137 .155 2.137 .292 








Post_Inj_Hip_Flex Contrast .000 1 .000 .001 .975 .001 .050 
Error 9.414 27 .349     
Post_Inj_Hip_Ext Contrast .795 1 .795 2.642 .116 2.642 .348 









Source Measure Type III Sum of Squares df Mean Square F Sig. Noncent. Parameter Observed Powera 
time KE Sphericity Assumed .087 1 .087 .199 .663 .199 .070 
Greenhouse-Geisser .087 1.000 .087 .199 .663 .199 .070 
Huynh-Feldt .087 1.000 .087 .199 .663 .199 .070 
Lower-bound .087 1.000 .087 .199 .663 .199 .070 
KF Sphericity Assumed .004 1 .004 .036 .852 .036 .054 
Greenhouse-Geisser .004 1.000 .004 .036 .852 .036 .054 
Huynh-Feldt .004 1.000 .004 .036 .852 .036 .054 
Lower-bound .004 1.000 .004 .036 .852 .036 .054 
APF Sphericity Assumed .401 1 .401 2.893 .113 2.893 .351 
Greenhouse-Geisser .401 1.000 .401 2.893 .113 2.893 .351 
Huynh-Feldt .401 1.000 .401 2.893 .113 2.893 .351 
Lower-bound .401 1.000 .401 2.893 .113 2.893 .351 
ADF Sphericity Assumed .007 1 .007 1.029 .329 1.029 .156 
Greenhouse-Geisser .007 1.000 .007 1.029 .329 1.029 .156 








Lower-bound .007 1.000 .007 1.029 .329 1.029 .156 
HAb Sphericity Assumed .024 1 .024 .188 .671 .188 .069 
Greenhouse-Geisser .024 1.000 .024 .188 .671 .188 .069 
Huynh-Feldt .024 1.000 .024 .188 .671 .188 .069 
Lower-bound .024 1.000 .024 .188 .671 .188 .069 
HAd Sphericity Assumed .010 1 .010 .100 .757 .100 .060 
Greenhouse-Geisser .010 1.000 .010 .100 .757 .100 .060 
Huynh-Feldt .010 1.000 .010 .100 .757 .100 .060 
Lower-bound .010 1.000 .010 .100 .757 .100 .060 
HF Sphericity Assumed .978 1 .978 3.279 .093 3.279 .389 
Greenhouse-Geisser .978 1.000 .978 3.279 .093 3.279 .389 
Huynh-Feldt .978 1.000 .978 3.279 .093 3.279 .389 








HE Sphericity Assumed 1.126 1 1.126 4.522 .053 4.522 .503 
Greenhouse-Geisser 1.126 1.000 1.126 4.522 .053 4.522 .503 
Huynh-Feldt 1.126 1.000 1.126 4.522 .053 4.522 .503 
Lower-bound 1.126 1.000 1.126 4.522 .053 4.522 .503 
Error(time) KE Sphericity Assumed 5.693 13 .438     
Greenhouse-Geisser 5.693 13.000 .438     
Huynh-Feldt 5.693 13.000 .438     
Lower-bound 5.693 13.000 .438     
KF Sphericity Assumed 1.533 13 .118     
Greenhouse-Geisser 1.533 13.000 .118     
Huynh-Feldt 1.533 13.000 .118     
Lower-bound 1.533 13.000 .118     
APF Sphericity Assumed 1.803 13 .139     








Huynh-Feldt 1.803 13.000 .139     
Lower-bound 1.803 13.000 .139     
ADF Sphericity Assumed .092 13 .007     
Greenhouse-Geisser .092 13.000 .007     
Huynh-Feldt .092 13.000 .007     
Lower-bound .092 13.000 .007     
HAb Sphericity Assumed 1.658 13 .128     
Greenhouse-Geisser 1.658 13.000 .128     
Huynh-Feldt 1.658 13.000 .128     
Lower-bound 1.658 13.000 .128     
HAd Sphericity Assumed 1.343 13 .103     
Greenhouse-Geisser 1.343 13.000 .103     
Huynh-Feldt 1.343 13.000 .103     








HF Sphericity Assumed 3.877 13 .298     
Greenhouse-Geisser 3.877 13.000 .298     
Huynh-Feldt 3.877 13.000 .298     
Lower-bound 3.877 13.000 .298     
HE Sphericity Assumed 3.236 13 .249     
Greenhouse-Geisser 3.236 13.000 .249     
Huynh-Feldt 3.236 13.000 .249     
Lower-bound 3.236 13.000 .249     
leg KE Sphericity Assumed 5.896 1 5.896 25.635 .000 25.635 .997 
Greenhouse-Geisser 5.896 1.000 5.896 25.635 .000 25.635 .997 
Huynh-Feldt 5.896 1.000 5.896 25.635 .000 25.635 .997 
Lower-bound 5.896 1.000 5.896 25.635 .000 25.635 .997 
KF Sphericity Assumed .702 1 .702 39.395 .000 39.395 1.000 








Huynh-Feldt .702 1.000 .702 39.395 .000 39.395 1.000 
Lower-bound .702 1.000 .702 39.395 .000 39.395 1.000 
APF Sphericity Assumed 6.429E-5 1 6.429E-5 .005 .946 .005 .050 
Greenhouse-Geisser 6.429E-5 1.000 6.429E-5 .005 .946 .005 .050 
Huynh-Feldt 6.429E-5 1.000 6.429E-5 .005 .946 .005 .050 
Lower-bound 6.429E-5 1.000 6.429E-5 .005 .946 .005 .050 
ADF Sphericity Assumed .000 1 .000 .140 .714 .140 .064 
Greenhouse-Geisser .000 1.000 .000 .140 .714 .140 .064 
Huynh-Feldt .000 1.000 .000 .140 .714 .140 .064 
Lower-bound .000 1.000 .000 .140 .714 .140 .064 
HAb Sphericity Assumed .027 1 .027 1.127 .308 1.127 .166 
Greenhouse-Geisser .027 1.000 .027 1.127 .308 1.127 .166 
Huynh-Feldt .027 1.000 .027 1.127 .308 1.127 .166 








HAd Sphericity Assumed .059 1 .059 2.334 .151 2.334 .294 
Greenhouse-Geisser .059 1.000 .059 2.334 .151 2.334 .294 
Huynh-Feldt .059 1.000 .059 2.334 .151 2.334 .294 
Lower-bound .059 1.000 .059 2.334 .151 2.334 .294 
HF Sphericity Assumed .000 1 .000 .005 .943 .005 .051 
Greenhouse-Geisser .000 1.000 .000 .005 .943 .005 .051 
Huynh-Feldt .000 1.000 .000 .005 .943 .005 .051 
Lower-bound .000 1.000 .000 .005 .943 .005 .051 
HE Sphericity Assumed .237 1 .237 3.712 .076 3.712 .430 
Greenhouse-Geisser .237 1.000 .237 3.712 .076 3.712 .430 
Huynh-Feldt .237 1.000 .237 3.712 .076 3.712 .430 
Lower-bound .237 1.000 .237 3.712 .076 3.712 .430 
Error(leg) KE Sphericity Assumed 2.990 13 .230     








Huynh-Feldt 2.990 13.000 .230     
Lower-bound 2.990 13.000 .230     
KF Sphericity Assumed .232 13 .018     
Greenhouse-Geisser .232 13.000 .018     
Huynh-Feldt .232 13.000 .018     
Lower-bound .232 13.000 .018     
APF Sphericity Assumed .175 13 .013     
Greenhouse-Geisser .175 13.000 .013     
Huynh-Feldt .175 13.000 .013     
Lower-bound .175 13.000 .013     
ADF Sphericity Assumed .033 13 .003     
Greenhouse-Geisser .033 13.000 .003     
Huynh-Feldt .033 13.000 .003     








HAb Sphericity Assumed .317 13 .024     
Greenhouse-Geisser .317 13.000 .024     
Huynh-Feldt .317 13.000 .024     
Lower-bound .317 13.000 .024     
HAd Sphericity Assumed .329 13 .025     
Greenhouse-Geisser .329 13.000 .025     
Huynh-Feldt .329 13.000 .025     
Lower-bound .329 13.000 .025     
HF Sphericity Assumed .284 13 .022     
Greenhouse-Geisser .284 13.000 .022     
Huynh-Feldt .284 13.000 .022     
Lower-bound .284 13.000 .022     
HE Sphericity Assumed .829 13 .064     








Huynh-Feldt .829 13.000 .064     
Lower-bound .829 13.000 .064     
time * leg KE Sphericity Assumed .011 1 .011 .103 .754 .103 .060 
Greenhouse-Geisser .011 1.000 .011 .103 .754 .103 .060 
Huynh-Feldt .011 1.000 .011 .103 .754 .103 .060 
Lower-bound .011 1.000 .011 .103 .754 .103 .060 
KF Sphericity Assumed .158 1 .158 7.633 .016 7.633 .724 
Greenhouse-Geisser .158 1.000 .158 7.633 .016 7.633 .724 
Huynh-Feldt .158 1.000 .158 7.633 .016 7.633 .724 
Lower-bound .158 1.000 .158 7.633 .016 7.633 .724 
APF Sphericity Assumed .136 1 .136 9.777 .008 9.777 .824 
Greenhouse-Geisser .136 1.000 .136 9.777 .008 9.777 .824 
Huynh-Feldt .136 1.000 .136 9.777 .008 9.777 .824 








ADF Sphericity Assumed .003 1 .003 1.653 .221 1.653 .222 
Greenhouse-Geisser .003 1.000 .003 1.653 .221 1.653 .222 
Huynh-Feldt .003 1.000 .003 1.653 .221 1.653 .222 
Lower-bound .003 1.000 .003 1.653 .221 1.653 .222 
HAb Sphericity Assumed .001 1 .001 .087 .773 .087 .059 
Greenhouse-Geisser .001 1.000 .001 .087 .773 .087 .059 
Huynh-Feldt .001 1.000 .001 .087 .773 .087 .059 
Lower-bound .001 1.000 .001 .087 .773 .087 .059 
HAd Sphericity Assumed .021 1 .021 1.881 .193 1.881 .246 
Greenhouse-Geisser .021 1.000 .021 1.881 .193 1.881 .246 
Huynh-Feldt .021 1.000 .021 1.881 .193 1.881 .246 
Lower-bound .021 1.000 .021 1.881 .193 1.881 .246 
HF Sphericity Assumed .004 1 .004 .152 .703 .152 .065 








Huynh-Feldt .004 1.000 .004 .152 .703 .152 .065 
Lower-bound .004 1.000 .004 .152 .703 .152 .065 
HE Sphericity Assumed .148 1 .148 2.148 .167 2.148 .274 
Greenhouse-Geisser .148 1.000 .148 2.148 .167 2.148 .274 
Huynh-Feldt .148 1.000 .148 2.148 .167 2.148 .274 
Lower-bound .148 1.000 .148 2.148 .167 2.148 .274 
Error(time*leg) KE Sphericity Assumed 1.412 13 .109     
Greenhouse-Geisser 1.412 13.000 .109     
Huynh-Feldt 1.412 13.000 .109     
Lower-bound 1.412 13.000 .109     
KF Sphericity Assumed .268 13 .021     
Greenhouse-Geisser .268 13.000 .021     
Huynh-Feldt .268 13.000 .021     








APF Sphericity Assumed .181 13 .014     
Greenhouse-Geisser .181 13.000 .014     
Huynh-Feldt .181 13.000 .014     
Lower-bound .181 13.000 .014     
ADF Sphericity Assumed .027 13 .002     
Greenhouse-Geisser .027 13.000 .002     
Huynh-Feldt .027 13.000 .002     
Lower-bound .027 13.000 .002     
HAb Sphericity Assumed .181 13 .014     
Greenhouse-Geisser .181 13.000 .014     
Huynh-Feldt .181 13.000 .014     
Lower-bound .181 13.000 .014     
HAd Sphericity Assumed .144 13 .011     
























Huynh-Feldt .144 13.000 .011     
Lower-bound .144 13.000 .011     
HF Sphericity Assumed .323 13 .025     
Greenhouse-Geisser .323 13.000 .025     
Huynh-Feldt .323 13.000 .025     
Lower-bound .323 13.000 .025     
HE Sphericity Assumed .897 13 .069     
Greenhouse-Geisser .897 13.000 .069     
Huynh-Feldt .897 13.000 .069     








General Linear Model- ACL-injured Pre-op vs. Post-op (2x2 limb x time) ANOVAs 
Tests of Within-Subjects Effects 
T-Test- Post-Hoc paired samples t-tests for hamstrings and ankle plantar flexors 
 
Paired Samples Statistics 
 Mean N Std. Deviation Std. Error Mean 
Pair 1 pre-op injured limb knee flexor strength (Nm/kg) .8043 14 .23530 .06289 
post-op injured limb knee flexor strength .9279 14 .35659 .09530 
Pair 2 pre-op healthy limb knee flexor strength (Nm/kg) 1.1343 14 .29244 .07816 
Post_Un_Kn_Flex 1.0457 14 .39081 .10445 
Pair 3 pre-op injured limb ankle plantar flexor strength (Nm/kg) .5050 14 .17204 .04598 
Post_Inj_Ank_PF .7729 14 .29319 .07836 
Pair 4 pre-op healthy limb ankle plantar flexor strength (Nm/kg) .6014 14 .25331 .06770 
























pre-op injured limb knee flexor strength (Nm/kg) - post-op 
injured limb knee flexor strength 
-
.12357 





pre-op healthy limb knee flexor strength (Nm/kg) - 
Post_Un_Kn_Flex 
.08857 .44218 .11818 -.16673 .34388 .749 13 .467 
Pair 
3 

























AIM 2 SUPPLEMENTAL DATA 



























1 M L 16 1.83 79.38 Football 
Tackled from 
behind 
9 8 80.46 Lateral 31 
2 F L 29 1.73 104.33 Softball 
Slipped on 
home plate 
7 4 80.46 Medial 135 
4 F L 15 1.65 59.78 Basketball 
Running 
straight ahead 
9 7 100 Medial‡ 47 
5 F R 14 1.74 61.23 Basketball 
Not specified/ 
non-contact 
9 9 97.7 Medial 30 
6 F L 15 1.68 81.65 Softball Running 7 4 68.97 Medial‡ 46 
7 M L 29 1.75 77.11 
Ultimate 
Frisbee 
Cutting 10 7 81.61 None 39 
8 M L 19 1.84 84.37 Snowboarding 
Not specified/ 
non-contact 




9 F L 15 1.85 61.23 Volleyball 
Landing from 
hit 
10 5 85.06 Medial‡ 48 
11 F L 27 1.57 52.16 Soccer Cutting 5 7 80.46 None 56 
12 F L 20 1.73 70.31 Basketball pivoting 7 5 71.26 None 222 
13 M R 28 1.65 88.45 Basketball 
Landing from 
jump 
7 5 57.47 Lateral 70 
14 M L 26 1.78 72.57 Soccer Planting 9 9 88.51 Medial‡ 320 
M= male; F= female; L= left; R= right; * As dictated by the subject 
†Meniscal damage was determined from each subject‘s diagnostic MRI report 








                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
Table C.13. Knee effusion and thigh circumference data. 
 Knee Effusion (cm) Thigh Circumference (cm)* 
 Suprapatellar† Mid-Patella 6 cm 12 cm 18 cm 
Subject ID Injured Uninjured    Injured Uninjured Injured Uninjured Injured Uninjured Injured Uninjured 
1 41.6 39.8 41.8 39.7 43.8 45.5 49.2 51.2 54.8 57.2 
2 44.5 50.5 47.1 42.7 54.0 52.0 60.8 59.5 65.7 64.7 
4 37.5 35.6 37.1 34.2 40.0 40.3 45.5 47.2 51.4 51.8 
5 36.2 35.2 37.0 35.6 39.0 41.0 44.0 45.5 49.9 51.0 
6 47.0 45.0 44.0 41.3 52.4 50.0 60.3 59.0 63.0 62.0 
7 39.1 37.3 40.0 37.1 43.8 43.8 50.0 50.5 52.4 54.9 
8 48.0 48.5 41.0 39.9 42.2 45.5 49.0 52.0 53.0 56.0 
9 39.0 37.6 38.7 36.7 40.0 42.0 43.5 45.4 47.5 50.4 
11 35.0 34.0 36.2 33.5 38.0 39.0 42.5 44.0 47.0 49.7 
12 41.0 37.3 40.7 38.0 43.0 44.0 48.8 50.0 54.0 54.1 
13 43.2 39.8 43.0 40.5 49.0 48.5 57.3 58.0 63.2 64.0 
14 45.1 36.1 40.0 37.6 36.7 48.7 42.2 37.3 45.8 36.0 
*Measurements were taken 6, 12, and 18 cm proximal to the superior pole of the patella 
†Measured 1 cm proximal to the superior pole of the patella with the subject in supine 
Table C.14. Quadriceps strength (Nm/kg) and central activation ratio data. 
 Knee Extension MVIC 
(Nm/kg) 
Quadriceps CAR 
Subject ID Injured Uninjured Injured Uninjured 
1 1.57 2.58 0.65 0.70 
2 1.62 2.52 0.84 0.93 
4 1.96 3.24 0.97 0.97 
5 2.06 1.88 0.79 0.76 
6 1.31 1.58 0.65 0.68 
7 3.21 4.02 0.96 0.99 
8 2.18 3.79 0.65 0.83 
9 1.44 1.28 0.89 0.77 
11 2.58 4.34 1.00 1.00 
12 1.65 2.45 0.86 0.89 
13 1.73 3.15 0.73 0.96 








Table C.15. Quadriceps cross sectional area (cm²) data.  
 Injured Limb   Uninjured Limb 
Subject ID VL RF VM VI Quad VL RF VM VI Quad 
1 29.53 8.27 12.2 27.03 77.03 30.85 14.02 14.67 32.36 91.89 
2 27.68 10.07 10.12 23.03 70.9 32.85 8.89 13.46 27.52 82.72 
4 21.83 7.54 8.55 21.35 59.27 22.18 8.93 10.85 21.55 66.51 
5 16.83 6.63 9.14 16.23 48.81 21.18 5.96 10.31 18.81 56.27 
6 33.27 9.01 13.58 21.77 77.63 30.69 8.96 17.74 25.28 82.67 
7 26.84 9 12.56 24.3 72.7 27.7 11.91 12.32 29.24 81.17 
8 35.02 11.69 12.62 28.02 87.35 50.67 9.79 17.47 39.17 117.11 
9 17.63 5.61 10.46 15.91 49.61 19.93 5.78 15.68 21.34 62.73 
11 13.03 4.06 5.51 18 40.4 19.86 6.88 9.49 22.63 58.85 
12 19.14 7.68 8.01 17.05 51.86 26.62 9.65 12.5 20.18 68.94 
13 36.75 16.81 10.15 38.21 101.92 45.35 10.44 19.69 38.67 114.41 
14 23.87 9.52 12.13 35.56 81.08 29.79 11.82 13.89 35.52 91.02 
VL= vastus lateralis; RF= rectus femoris; VM= vastus medialis; VI= vastus intermedius; Quad= overall muscle cross sectional area (e.g., sum total of individual 










AIM 2 STATISTICAL OUTPUT 




Model Variables Entered Variables Removed Method 
1 Injured limb peak CAR across 3 trials
a
 . Enter 
2 Injured limb overall peak quad CSA across all slices
a
 . Enter 
a. All requested variables entered. 




Model R R Square 
Adjusted R 
Square 











 .157 .072 .51991 .157 1.856 1 10 .203 
2 .404
b
 .164 -.022 .54573 .007 .076 1 9 .789 
a. Predictors: (Constant), Injured limb peak CAR across 3 trials 
b. Predictors: (Constant), Injured limb peak CAR across 3 trials, Injured limb overall peak quad CSA across all slices 












Model Sum of Squares df Mean Square F Sig. 
1 Regression .502 1 .502 1.856 .203
a
 
Residual 2.703 10 .270   
Total 3.205 11    
2 Regression .524 2 .262 .880 .448
b
 
Residual 2.680 9 .298   
Total 3.205 11    
a. Predictors: (Constant), Injured limb peak CAR across 3 trials 
b. Predictors: (Constant), Injured limb peak CAR across 3 trials, Injured limb overall peak quad CSA across all slices 














Unstandardized Coefficients Standardized Coefficients 
t Sig. B Std. Error Beta 
1 (Constant) .557 1.044  .533 .605 
Injured limb peak CAR across 3 trials 1.692 1.242 .396 1.362 .203 
2 (Constant) .240 1.586  .152 .883 
Injured limb peak CAR across 3 trials 1.851 1.425 .433 1.299 .226 
Injured limb overall peak quad CSA across all slices .003 .010 .092 .276 .789 


















1 Injured limb overall peak 
quad CSA across all slices 
.092
a
 .276 .789 .092 .837 
a. Predictors in the Model: (Constant), Injured limb peak CAR across 3 trials 





 Minimum Maximum Mean Std. Deviation N 
Predicted Value 1.6534 2.2374 1.9642 .21832 12 
Residual -.58180 1.01468 .00000 .49363 12 
Std. Predicted Value -1.423 1.251 .000 1.000 12 
Std. Residual -1.066 1.859 .000 .905 12 









General Linear Model 
Within-Subjects Factors 
Measure leg Dependent Variable 
MVIC 1 Inj_MVIC 
2 Un_MVIC 
CAR 1 Inj_CAR 
2 Un_CAR 













 Mean Std. Deviation N 
Injured limb peak MVIC across 3 trials (Nm/kg) 1.9642 .53976 12 
Un_MVIC 2.8067 .95597 12 
Injured limb peak CAR across 3 trials .8317 .12619 12 
Un_CAR .7883 .13953 12 
Injured limb overall peak quad CSA across all slices 68.2133 18.35317 12 









Tests of Within-Subjects Effects 
Univariate Tests 
Source Measure Type III Sum of Squares df Mean Square F Sig. Noncent. Parameter Observed Powera 
leg MVIC Sphericity Assumed 4.259 1 4.259 21.140 .001 21.140 .986 
Greenhouse-Geisser 4.259 1.000 4.259 21.140 .001 21.140 .986 
Huynh-Feldt 4.259 1.000 4.259 21.140 .001 21.140 .986 
Lower-bound 4.259 1.000 4.259 21.140 .001 21.140 .986 
CAR Sphericity Assumed .011 1 .011 1.175 .301 1.175 .168 
Greenhouse-Geisser .011 1.000 .011 1.175 .301 1.175 .168 
Huynh-Feldt .011 1.000 .011 1.175 .301 1.175 .168 
Lower-bound .011 1.000 .011 1.175 .301 1.175 .168 
QUAD Sphericity Assumed 1010.493 1 1010.493 45.417 .000 45.417 1.000 
Greenhouse-Geisser 1010.493 1.000 1010.493 45.417 .000 45.417 1.000 








Lower-bound 1010.493 1.000 1010.493 45.417 .000 45.417 1.000 
Error(leg) MVIC Sphericity Assumed 2.216 11 .201     
Greenhouse-Geisser 2.216 11.000 .201     
Huynh-Feldt 2.216 11.000 .201     
Lower-bound 2.216 11.000 .201     
CAR Sphericity Assumed .105 11 .010     
Greenhouse-Geisser .105 11.000 .010     
Huynh-Feldt .105 11.000 .010     
Lower-bound .105 11.000 .010     
QUAD Sphericity Assumed 244.741 11 22.249     
Greenhouse-Geisser 244.741 11.000 22.249     
Huynh-Feldt 244.741 11.000 22.249     
Lower-bound 244.741 11.000 22.249     









Tests of Between-Subjects Effects 
Transformed Variable:Average 
Source Measure Type III Sum of Squares df Mean Square F Sig. Noncent. Parameter Observed Powera 
Intercept MVIC 136.565 1 136.565 136.054 .000 136.054 1.000 
CAR 15.746 1 15.746 610.111 .000 610.111 1.000 
QUAD 133929.630 1 133929.630 186.570 .000 186.570 1.000 
Error MVIC 11.041 11 1.004     
CAR .284 11 .026     
QUAD 7896.370 11 717.852     












Estimated Marginal Means 
1. Grand Mean 
Measure Mean Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
MVIC 2.385 .205 1.935 2.836 
CAR .810 .033 .738 .882 












Measure leg Mean Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
MVIC 1 1.964 .156 1.621 2.307 
2 2.807 .276 2.199 3.414 
CAR 1 .832 .036 .751 .912 
2 .788 .040 .700 .877 
QUAD 1 68.213 5.298 56.552 79.874 












AIM 3 SUPPLEMENTAL DATA 





























1 F R 23 1.6 74.84 sledding 
put foot out 
to stop sled 
None PT 249 9 7 81.68 
3 M L 16 1.78 89.81 basketball 
going up for 
layup 
Medial PT 65 10 9 65.52 
4 F L 22 1.7 77.11 skiing turning  None PT 93 8 8 89.66 
8 M R 26 1.75 75.92 soccer cutting  Lateral§ PT 56 5 2 81.61 
9 M R 17 1.78 58.97 soccer cutting None PT 42 9 9 n/a 
10 M R 18 1.91 83.91 football spin move  None PT 24 9 7 90.8 
11 M R 16 1.8 81.65 football tackled Lateral PT 48 10 9 90.8 
12 F L 29 1.73 104.33 softball 
stretched to 
beat throw  
Medial PT 135 7 4 80.46 
13 M R 27 1.7 65.77 
ultimate 
Frisbee 
cutting  None PT 12 10 10 100 




Lateral‡ STG 196 9 5 72.41 
19 M R 26 1.8 77.11 skiing turning None STG 51 7 3 55.17 
20 M L 25 1.78 67.59 soccer cutting  None STG 136 7 6 79.31 
22 F L 27 1.57 63.5 softball 
stepped in 
hole running 
None STG 50 6 7 89.66 
23 F R 16 1.71 78.84 basketball 
playing 
defense 
None STG 67 9 9 90.8 
24 F R 14 1.74 61.23 basketball cutting  Medial PT 29 9 9 97.7 
26 M L 21 1.85 81.65 soccer cutting  None STG 55 9 7 82.76 
28 F R 19 1.73 68.04 soccer cutting 
Lateral & 
Medial‡ 
PT 47 9 8 93.1 
M= male; F= female; L= left; R= right; PT= patellar tendon; STG= semitendinosus/gracilis; IKDC= International Knee Documentation Society  
* As dictated by the subject 
 †Meniscal damage was determined from diagnostic MRI report. ‡Indicates subject had meniscal debridement/repair concurrent with ACL reconstruction. 
§Indicates subject had meniscectomy concurrent with ACL reconstruction. All other subjects had no treatment of meniscal injury. ǁTegner scale is scored from 0-10, 









Table C.17. Control subject demographic data. 
Subject ID Sex Age Height (m) Mass (kg) Tegner Score* IKDC Score† 
C1 M 30 1.75 68.04 6 100 
C2 F 19 1.7 62.14 5 94.25 
C3 F 23 1.6 61.23 7 100 
C5 F 20 1.7 69.4 6 94.25 
C6 M 19 1.75 88.9 4 96.55 
C8 F 20 1.68 72.57 5 100 
C9 F 28 1.63 70.31 6 100 
C10 M 27 1.91 77.11 6 100 
C11 F 18 1.6 56.7 5 100 
C12 M 20 1.71 61.23 7 100 
C13 F 30 1.63 49.9 7 100 
C14 F 23 1.7 61.23 5 98.85 
C18 F 25 1.8 86.18 6 100 
C19 F 21 1.8 70.31 5 100 
C20 M 28 1.78 72.57 5 100 
C21 F 23 1.68 63.5 7 100 













Table C.18. ACLr subject knee effusion and thigh circumference data. 
 Knee Effusion (cm) Thigh Circumference (cm)* 
 Suprapatellar† Mid-Patella 6 cm 12 cm 18 cm 
Subject ID Injured Uninjured    Injured Uninjured Injured Uninjured Injured Uninjured Injured Uninjured 
1 41.8 38.7 39.1 42.0 45.7 46.9 53.8 53.5 57.8 56.6 
3 44.5 40.8 42.2 44.3 47.3 47.8 53.4 54.5 57.5 58.6 
4 44.5 40.0 40.7 43.0 48.0 47.4 54.0 55.2 61.4 61.9 
8 37.4 36.0 36.5 36.5 38.8 39.8 44.8 45.6 50.5 51.1 
9 34.4 34.3 35.1 33.8 36.4 37.2 41.7 42.5 46.1 46.8 
10 38.8 37.9 38.9 38.5 41.5 41.0 49.0 47.8 53.4 53.0 
11 41.1 38.4 38.0 40.5 46.3 47.0 55.5 55.1 60.2 59.5 
12 44.5 42.7 50.5 47.1 54.0 52.0 60.8 59.5 65.7 64.7 
13 36.1 36.0 35.7 36.0 40.0 39.0 47.1 47.0 51.8 52.4 
18 42.5 40.5 40.5 42.9 44.9 46.2 49.2 52.0 55.5 57.0 
19 39.5 37.9 37.5 40.9 40.7 43.8 45.7 50.0 50.6 54.3 
20 34.0 33.4 33.0 34.0 37.0 37.7 42.1 44.4 48.0 50.3 
22 43.2 40.5 41.0 44.2 46.6 48.4 54.5 55.0 59.8 60.8 
23 39.8 37.5 36.8 40.3 43.3 44.9 48.8 51.9 53.7 56.2 
24 36.2 35.6 35.2 37.0 39.0 41.0 44.0 45.5 49.9 51.0 
26 39.0 38.3 39.0 38.9 42.0 43.2 48.5 49.7 52.0 53.8 
28 38.2 40.5 56.0 38.5 41.0 54.5 44.0 46.0 50.4 52.0 
*Measurements were taken 6, 12, and 18 cm proximal to the superior pole of the patella 










Table C.19. ACLr calf girth data (cm). 
 5 cm Proximal 10 cm Proximal Maximum 5 cm Distal 10 cm Distal 
Subject ID Injured Uninjured    Injured Uninjured Injured Uninjured Injured Uninjured Injured Uninjured 
1 40.8 40.0 38.8 38.0 41.1 41.5 34.2 35.7 28.8 30.5 
3 42.0 42.0 38.2 37.7 42.5 44.6 37.5 38.0 31.2 31.0 
4 39.2 40.2 36.5 37.1 41.2 40.8 35.9 34.3 31.0 29.2 
8 35.1 35.3 32.5 32.8 37.2 36.8 31.2 33.0 27.4 27.8 
9 33.4 32.3 30.7 31.2 35.0 34.3 31.8 33.0 26.0 27.4 
10 36.6 38.2 33.5 33.7 38.0 38.4 38.3 34.3 30.5 30.5 
11 38.8 39.9 36.4 46.5 41.4 42.0 36.0 38.6 29.0 29.9 
12 48.4 45.6 47.2 43.8 46.5 46.9 40.0 39.8 33.1 33.4 
13 33.0 34.0 31.0 30.8 35.7 35.6 31.4 31.7 28.2 28.2 
18 39.5 42.0 36.9 37.5 41.4 43.0 38.9 38.2 31.3 31.0 
19 38.6 38.2 33.9 34.0 40.7 41.0 37.9 37.0 29.5 30.4 
20 32.9 32.8 28.9 29.3 34.3 35.4 31.3 31.5 26.1 27.3 
22 42.0 41.0 36.0 37.3 41.4 40.1 37.7 38.3 32.0 32.1 
23 36.5 38.7 34.8 35.4 39.0 39.5 36.5 34.4 31.8 30.2 
24 35.2 36.5 31.8 32.5 37.0 38.2 34.5 33.5 29.6 28.5 
26 35.4 37.2 33.0 33.3 37.2 38.5 33.1 32.7 28.1 27.8 
28 50.2 40.5 36.9 36.2 40.8 40.4 36.0 37.1 30.2 30.2 
Measurements were taken with the subject lying in supine and the knee flexed so the foot was flat on the table. The distance from the lateral knee joint line to the 
tip of the lateral malleolus was measured. One-third of this distance was determined and a mark 1/3 of the way from the lateral joint line to the lateral malleolus 










Table C.20. Control subject knee effusion and thigh circumference data. 
 Knee Effusion (cm) Thigh Circumference (cm)* 
 Suprapatellar† Mid-Patella 6 cm 12 cm 18 cm 
Subject 
ID 
Test Limb Contralateral  
Limb 
   Test Limb Contralateral  
Limb 
Test Limb Contralateral  
Limb 
Test Limb Contralateral  
Limb 
Test Limb Contralateral  
Limb 
C1 35.7 36.5 36.0 36.3 39.5 41.0 45.5 47.0 49.5 51.2 
C2 47.5 37.4 36.4 36.7 41.0 39.5 45.2 43.9 51.0 49.2 
C3 37.3 38.5 35.8 36.8 42.7 43.0 49.9 50.4 53.5 51.8 
C5 40.3 40.5 37.9 39.5 45.5 46.0 53.0 52.7 56.5 56.0 
C6 43.8 42.6 41.1 40.5 49.3 49.2 56.9 56.0 60.6 60.4 
C8 44.0 44.4 41.0 41.2 48.7 49.0 54.1 54.4 59.7 58.2 
C9 42.7 42.1 39.3 39.8 46.9 47.5 51.5 52.7 56.0 55.7 
C10 37.0 37.0 36.9 37.4 40.3 40.4 46.8 46.5 50.6 50.0 
C11 36.0 35.7 35.0 35.5 41.0 39.0 46.3 45.0 49.8 48.6 
C12 34.1 33.8 33.6 33.3 39.0 38.5 45.5 44.3 48.1 48.3 
C13 33.8 33.9 33.5 33.3 38.3 38.5 42.5 44.5 46.4 46.4 
C14 38.2 37.8 36.8 36.6 42.0 41.0 45.5 44.8 51.0 50.3 
C18 42.5 43.1 40.4 40.2 47.0 48.2 51.7 52.2 57.0 57.3 
C19 39.5 39.0 38.5 37.5 42.0 41.0 45.2 44.0 49.0 48.5 
C20 37.1 38.0 36.4 37.7 42.0 42.5 46.7 48.5 51.6 52.5 
C21 36.6 37.8 36.5 36.3 41.5 43.5 48.5 50.5 54.4 54.5 
*Measurements were taken 6, 12, and 18 cm proximal to the superior pole of the patella 










Table C.21. Control subject calf girth data (cm). 
 5 cm Proximal 10 cm Proximal Maximum 5 cm Distal 10 cm Distal 
Subject 
ID 
Test Limb Contralateral 
Limb 
   Test Limb Contralateral 
Limb 
Test Limb Contralateral 
Limb 
Test Limb Contralateral 
Limb 
Test Limb Contralateral 
Limb 
C1 35.5 35.8 32.0 33.0 36.8 37.9 31.0 33.5 26.1 27.7 
C2 34.0 34.8 33.0 32.7 33.5 32.9 29.8 28.8 24.3 24.3 
C3 34.7 35.9 31.8 32.8 36.9 37.5 33.4 33.0 27.6 27.7 
C5 38.0 38.6 35.2 35.5 38.3 38.0 33.1 33.0 27.0 27.1 
C6 41.8 42.7 38.8 40.0 43.2 43.4 37.8 37.9 32.9 32.0 
C8 43.3 44.0 39.9 38.4 42.2 43.4 38.2 38.7 33.3 33.8 
C9 36.5 36.5 34.8 33.4 38.7 37.8 35.6 34.8 29.5 28.9 
C10 35.4 35.0 31.5 31.2 37.7 37.3 34.5 35.3 28.1 29.0 
C11 33.5 35.5 32.0 32.0 36.3 35.7 33.1 30.6 27.0 24.8 
C12 32.0 32.7 32.2 30.6 35.7 35.2 31.8 29.6 27.2 25.6 
C13 32.0 32.8 30.0 30.0 33.8 34.5 28.5 28.5 25.0 24.9 
C14 36.6 36.0 33.9 33.0 37.9 38.0 35.8 35.4 31.1 31.0 
C18 41.5 41.7 38.8 36.7 41.8 41.3 37.3 38.2 32.7 32.5 
C19 35.8 37.2 33.6 34.2 36.5 37.0 32.5 31.9 28.8 27.7 
C20 35.1 36.5 32.6 33.0 36.5 37.0 31.3 33.2 26.0 28.0 
C21 36.0 37.8 33.3 33.6 37.0 38.3 33.9 33.4 28.5 28.8 
Measurements were taken with the subject lying in supine and the knee flexed so the foot was flat on the table. The distance from the lateral knee joint line to the 
tip of the lateral malleolus was measured. One-third of this distance was determined and a mark 1/3 of the way from the lateral joint line to the lateral malleolus 









Table C.22. ACLr subject pre- and post-fatigue joint rotation (degrees) data. 
 IC Knee Sagittal Rotation IC Knee Frontal Rotation PS Knee Sagittal Rotation PS Knee Frontal Rotation 
 Pre-Fatigue Post-Fatigue Pre-Fatigue Post-Fatigue Pre-Fatigue Post-Fatigue Pre-Fatigue Post-Fatigue 
Subject ID I U I U I U I U I U I U I U I U 
1 -11.86 -7.66 -12.45 4.23 -2.63 -53.43 -1.91 24.64 -45.42 -11.06 -43.75 2.54 -2.63 4.21 -4.75 1.97 
3 -20.75 -9.65 -5.92 6.61 -4.30 -41.44 1.44 26.42 -40.72 -7.98 -43.14 7.03 -7.16 6.61 -5.30 6.93 
4 -7.49 -19.64 -11.39 4.41 -1.08 -58.22 -2.98 4.41 -47.43 -14.42 -39.15 -0.77 -11.55 -4.28 -9.55 -6.78 
8 -8.08 -16.89 -3.46 -3.87 -1.51 -61.06 -0.81 -2.70 -49.71 -10.20 -48.56 -3.60 -7.77 -13.69 -5.74 -13.19 
9 -15.58 -17.22 -10.60 -2.89 -3.61 -56.21 -1.98 -2.89 -54.28 -10.70 -52.22 -3.33 -13.74 -12.11 -9.97 -13.54 
10 -6.83 -10.37 -8.31 -1.48 1.49 -47.01 1.19 -0.80 -36.06 -8.32 -42.37 -0.28 -5.90 -6.93 -6.27 -4.07 
11 -16.43 -17.70 -18.09 -6.45 -7.49 -60.95 -5.65 -6.45 -56.88 -12.99 -50.21 -4.14 -17.64 -18.20 -14.70 -14.48 
12 -10.30 -15.28 -8.93 -5.04 -4.94 -55.09 -4.38 -4.19 -36.50 -14.57 -36.31 -5.05 -7.48 -8.58 -7.49 -9.09 
13 -16.59 -29.77 -19.83 -0.57 -8.00 -70.61 -9.88 -0.57 -50.66 -23.57 -53.44 1.48 -15.52 -8.83 -18.63 -6.61 
18 -11.52 -12.87 -11.55 -2.23 -5.96 -65.09 -7.88 -1.95 -42.49 -12.95 -49.04 -3.37 -15.88 -11.96 -27.59 -13.13 
19 -0.29 -1.30 1.47 -0.19 -3.65 -58.88 -2.43 -0.19 -22.89 3.50 -32.72 1.39 -14.51 -10.89 -15.26 -5.28 
20 -12.31 0.15 -9.34 1.91 -2.51 -47.06 -1.55 1.91 -72.60 0.97 -47.02 3.91 -24.62 -19.60 -12.71 -14.17 
22 -12.90 -16.16 -14.81 -3.52 -1.07 -45.40 -1.14 1.91 -37.28 -16.55 -37.07 -3.10 -7.35 -6.85 -4.42 -5.76 
23 -6.02 -12.64 -10.62 -2.70 -3.40 -63.47 -4.21 -2.70 -46.23 -14.77 -49.99 -2.67 -9.02 -10.71 -8.68 -10.03 
24 -12.37 -22.00 -11.48 -4.96 -5.79 -65.48 -5.13 -4.96 -48.34 -24.28 -42.32 -5.72 -23.37 -15.21 -23.75 -12.95 
26 -1.40 -7.78 -3.59 -0.82 1.13 -65.29 0.72 -0.82 -40.44 -6.17 -37.22 -0.31 -8.60 -12.54 -8.41 -8.68 
28 -5.00 -25.41 -6.94 -5.47 -1.88 -65.93 -0.89 -4.82 -44.44 -25.29 -44.67 -3.16 -13.77 -14.42 -7.74 -10.77 
IC= initial contact; PS= peak stance 
I= injured; U= uninjured 









Table C.23. Control subject pre- and post-fatigue joint rotation (degrees) data. 
 IC Knee Sagittal Rotation IC Knee Frontal Rotation PS Knee Sagittal Rotation PS Knee Frontal Rotation 
 Pre-Fatigue Post-Fatigue Pre-Fatigue Post-Fatigue Pre-Fatigue Post-Fatigue Pre-Fatigue Post-Fatigue 
Subject ID T C T C T C T C T C T C T C T C 
C1 -11.97 -11.06 -5.44 -9.07 -6.53 -52.93 -3.78 -6.53 -61.20 -63.43 -51.39 -52.93 -18.45 -23.00 -14.48 -10.39 
C2 -13.95 -17.31 -14.28 -5.24 -3.61 -45.49 -3.53 -3.61 -53.89 -56.17 -52.47 -45.49 -16.84 -12.84 -17.67 -13.57 
C3 -11.20 -16.89 -13.44 -34.63 0.94 -54.97 1.15 0.94 -45.75 -49.76 -50.27 -54.97 -13.20 -11.15 -13.89 -4.73 
C5 -12.26 -12.00 -7.17 -9.37 -1.84 -42.39 -1.20 -1.84 -57.20 -49.34 -50.69 -42.39 -10.27 -9.28 -6.69 -6.79 
C6 -12.40 -10.23 -18.75 -10.43 -2.65 -65.58 -1.55 -2.65 -70.26 -68.39 -74.22 -65.58 -13.83 -14.05 -10.04 -8.11 
C8 -16.79 -11.36 -11.41 -14.17 -6.53 -42.42 -5.93 -6.53 -56.95 -48.11 -39.87 -42.42 -17.83 -19.07 -7.45 -13.69 
C9 -23.54 -16.38 -16.85 -14.43 -2.57 -51.02 -2.57 -2.57 -55.39 -51.90 -52.04 -51.02 -8.36 -9.66 -6.05 -9.66 
C10 -16.65 -20.16 -12.99 -12.73 -2.70 -48.84 -2.68 -2.70 -50.90 -50.26 -47.35 -48.84 -17.96 -10.14 -15.20 -12.86 
C11 -14.42 -11.31 -11.76 -3.05 -0.95 -36.68 1.71 -0.95 -63.23 -57.15 -49.05 -36.68 -7.64 -10.58 -6.89 -3.38 
C12 -16.03 -13.04 -3.05 -10.74 1.09 -58.83 1.40 1.09 -55.05 -62.60 -36.68 -58.83 -8.37 -6.82 -5.79 -6.21 
C13 -22.98 -19.95 -9.84 -20.72 -6.07 -63.43 -5.05 -6.07 -69.41 -60.21 -56.88 -63.43 -7.79 -11.56 -8.05 -10.69 
C14 -10.40 -7.02 -7.07 -4.40 -0.87 -43.45 -0.82 -0.87 -52.14 -40.18 -36.03 -43.45 -20.05 -16.11 -13.30 -15.41 
C18 -11.94 -16.74 -6.93 -18.39 -6.50 -43.21 -6.25 -6.50 -50.32 -51.80 -36.91 -43.21 -25.67 -22.54 -18.19 -17.97 
C19 -12.59 -16.48 -8.69 -19.01 -3.30 -57.66 -1.96 -3.30 -53.40 -66.68 -28.61 -57.66 -6.09 -11.79 -3.47 -14.91 
C20 -6.83 -10.15 -8.58 -3.40 2.46 -49.59 2.92 2.46 -52.25 -57.21 -48.70 -49.59 -2.03 -5.14 -4.48 -7.91 
C21 -14.87 -10.44 -14.18 -9.48 -1.99 -56.37 -1.99 -1.99 -58.65 -61.86 -59.28 -56.37 -23.74 -16.27 -23.18 -13.40 
IC= initial contact; PS= peak stance 
T=test limb; C= contralateral limb 










Table C.24. ACLr subjects pre- and post-fatigue external joint moments (Nm/kg*m). 
 PS Knee Sagittal Moment PS Knee Frontal Moment 
 Pre-Fatigue Post-Fatigue Pre-Fatigue Post-Fatigue 
Subject ID I U I U I U I U 
1 -0.80 -1.11 -0.58 0.46 -0.19 -0.27 -0.24 -0.25 
3 -1.22 -0.83 -0.92 1.12 -0.14 -0.27 -0.15 -0.35 
4 -1.15 -1.46 -0.84 0.57 -0.72 -0.13 -0.53 -0.18 
8 -1.06 -1.62 -1.11 0.12 -0.20 -0.48 -0.14 -0.45 
9 -1.49 -2.13 -1.22 0.32 -0.34 -0.17 -0.18 -0.20 
10 -1.32 -1.87 -1.30 0.18 -0.11 -0.28 -0.09 -0.30 
11 -1.16 -1.24 -0.93 0.19 -0.34 -0.33 -0.29 -0.31 
12 -0.97 -1.46 -1.32 0.43 -0.50 -0.25 -0.34 -0.23 
13 -1.64 -2.14 -1.39 0.03 -0.37 -0.60 -0.75 -0.38 
18 -1.03 -1.51 -1.06 -0.01 -0.27 -0.36 -0.16 -0.64 
19 -0.56 -1.56 -0.46 0.05 -0.15 -0.33 -0.13 -0.26 
20 -1.21 -1.66 -1.24 0.32 -0.20 -0.22 -0.16 -0.11 
22 -1.03 -2.12 -0.77 0.61 -0.23 -0.40 -0.20 -0.26 
23 -1.25 -2.02 -1.30 0.16 -0.18 -0.39 -0.13 -0.22 
24 -0.93 -1.97 -0.96 0.07 -0.29 -0.58 -0.48 -0.55 
26 -0.57 -1.30 -0.53 0.20 -0.30 -0.31 -0.51 -0.27 
28 -1.32 -2.31 -0.99 0.26 -0.45 -0.70 -0.28 -0.65 
PS= peak stance 
I= injured; U= uninjured 











Table C.25. Control subjects pre- and post-fatigue external joint moments (Nm/kg*m). 
 PS Knee Sagittal Moment PS Knee Frontal Moment 
 Pre-Fatigue Post-Fatigue Pre-Fatigue Post-Fatigue 
Subject ID T C T C T C T C 
C1 -1.54 -1.53 0.07 -1.10 -0.61 -0.62 -0.40 -0.40 
C2 -1.95 -1.86 0.06 -1.65 -0.51 -0.77 -0.37 -0.60 
C3 -2.15 -2.29 0.14 -1.62 -0.31 -0.71 -0.16 -0.45 
C5 -1.57 -1.40 0.29 -0.95 -0.26 -0.43 -0.15 -0.50 
C6 -1.89 -1.79 0.27 -1.53 -0.45 -0.57 -0.16 -0.30 
C8 -1.88 -1.10 0.08 -1.01 -0.40 -0.30 -0.45 -0.21 
C9 -1.76 -1.53 0.10 -1.21 -0.34 -0.35 -0.44 -0.40 
C10 -1.40 -1.38 0.20 -1.47 -0.26 -0.23 -0.21 -0.22 
C11 -1.75 -1.47 0.39 -1.03 -0.07 -0.77 -0.20 -0.33 
C12 -1.92 -1.73 0.09 -1.68 -0.41 -0.17 -0.43 -0.23 
C13 -1.98 -1.86 0.10 -1.68 -0.62 -0.60 -0.56 -0.43 
C14 -1.85 -1.63 0.06 -1.06 -0.52 -0.62 -0.30 -0.32 
C18 -1.28 -1.56 0.32 -0.80 -0.79 -0.48 -0.33 -0.36 
C19 -1.51 -1.50 0.03 -1.03 -0.41 -0.28 -0.15 -0.24 
C20 -1.56 -1.66 0.44 -0.94 -0.16 -0.22 -0.11 -0.39 
C21 -1.81 -1.88 0.20 -1.52 -0.70 -0.39 -0.59 -0.13 
PS= peak stance 
T= test limb; C= contralateral limb 










Table C.26. ACLr subjects pre- and post-fatigue knee extension strength (Nm/kg) and central activation ratio data. 
 Knee Extension MVIC (Nm/kg) Quadriceps CAR 
 Pre-Fatigue Post-Fatigue Pre-Fatigue Post-Fatigue 
Subject ID Injured Uninjured Injured Uninjured Injured Uninjured Injured Uninjured 
1 1.47 2.27 1.50 1.72 0.75 0.89 0.76 0.85 
3 1.84 2.35 1.21 1.21 0.67 0.82 0.62 0.66 
4 1.85 2.03 1.09 1.11 0.80 0.77 0.67 0.58 
8 2.34 3.28 1.71 2.19 0.95 0.98 0.92 0.97 
9 2.37 3.17 2.09 3.01 0.97 0.95 0.96 0.95 
10 2.15 3.24 2.09 1.95 0.83 0.96 0.79 0.81 
11 2.68 3.03 1.98 2.73 0.95 0.92 0.92 0.90 
12 1.23 2.64 1.26 2.10 0.89 0.96 0.88 0.95 
13 3.10 4.25 1.96 3.17 0.85 0.95 0.77 0.87 
18 1.36 2.28 1.19 1.24 0.59 0.67 0.56 0.54 
19 2.06 4.15 1.46 2.43 0.86 0.89 0.74 0.77 
20 2.91 2.88 2.50 1.82 0.86 0.85 0.89 0.78 
22 1.93 2.39 1.14 1.30 0.83 0.83 0.75 0.71 
23 1.54 1.54 1.86 1.10 0.67 0.67 0.69 0.72 
24 1.48 1.48 0.80 1.15 0.75 0.68 0.69 0.66 
26 1.55 3.57 1.29 1.58 0.74 0.96 0.66 0.84 










Table C.27. Control subjects pre- and post-fatigue knee extension strength (Nm/kg) and central activation ratio data. 
 Knee Extension MVIC (Nm/kg) Quadriceps CAR 
 Pre-Fatigue Post-Fatigue Pre-Fatigue Post-Fatigue 
Subject ID Test Limb Contralateral Test Limb Contralateral Test Limb Contralateral Test Limb Contralateral 
C1 1.71 1.71 1.46 0.98 0.66 0.67 0.90 0.76 
C2 1.52 1.80 1.09 1.44 0.72 0.80 0.68 0.74 
C3 2.05 2.10 1.39 1.67 0.83 0.88 0.76 0.82 
C5 2.62 2.42 0.93 1.12 0.86 0.90 0.50 0.61 
C6 3.76 3.86 2.02 2.72 0.89 0.86 0.65 0.79 
C8 1.81 1.82 1.30 1.27 0.93 0.99 0.96 0.95 
C9 2.77 2.72 1.97 2.09 1.00 0.99 0.96 0.98 
C10 3.15 3.44 2.53 2.61 0.97 0.99 0.94 0.98 
C11 2.75 2.21 1.38 1.11 0.95 0.92 0.74 0.76 
C12 2.11 2.21 2.15 1.98 0.82 0.82 0.84 0.96 
C13 5.04 3.37 2.67 2.00 0.99 1.00 0.97 0.98 
C14 2.04 2.66 1.11 1.59 0.98 0.99 0.95 0.92 
C18 1.57 1.98 1.40 1.61 0.95 0.97 0.97 0.95 
C19 3.12 2.84 1.55 1.19 0.90 0.90 0.79 0.67 
C20 3.02 3.09 0.94 1.54 0.94 0.91 0.70 0.86 

















AIM 3 STATISTICAL OUTPUT 
General Linear Model- 2x2 Repeated Measures (Group x Time) ANOVA 
Within-Subjects Factors 
Measure time Dependent Variable 
IC_KS_ROT 1 Pre_IC_Inj_KSrot 
2 Post_IC_Inj_KSrot 
IC_KF_ROT 1 Pre_IC_Inj_KFrot 
2 Post_IC_Inj_KFrot 
PS_KS_ROT 1 Pre_Inj_KSrot 
2 Post_Inj_KSrot 
PS_KF_ROT 1 Pre_Inj_KFrot 
2 Post_Inj_KFrot 









PS_KF_TRQ 1 Pre_Inj_KFtrq 
2 Post_Inj_KFtrq 
MVIC_AVG 1 Avg_MVIC 
2 Avg_MVIC_Post 
CAR_AVG 1 Avg_CAR 
2 Avg_CAR_Post 
 
Tests of Within-Subjects Effects 
Univariate Tests 
Source Measure Type III Sum of Squares df Mean Square F Sig. Noncent. Parameter Observed Powera 
time IC_KS_ROT Sphericity Assumed 73.760 1 73.760 6.261 .018 6.261 .679 
Greenhouse-Geisser 73.760 1.000 73.760 6.261 .018 6.261 .679 
Huynh-Feldt 73.760 1.000 73.760 6.261 .018 6.261 .679 








IC_KF_ROT Sphericity Assumed 18.670 1 18.670 8.939 .005 8.939 .825 
Greenhouse-Geisser 18.670 1.000 18.670 8.939 .005 8.939 .825 
Huynh-Feldt 18.670 1.000 18.670 8.939 .005 8.939 .825 
Lower-bound 18.670 1.000 18.670 8.939 .005 8.939 .825 
PS_KS_ROT Sphericity Assumed 398.619 1 398.619 11.744 .002 11.744 .913 
Greenhouse-Geisser 398.619 1.000 398.619 11.744 .002 11.744 .913 
Huynh-Feldt 398.619 1.000 398.619 11.744 .002 11.744 .913 
Lower-bound 398.619 1.000 398.619 11.744 .002 11.744 .913 
PS_KF_ROT Sphericity Assumed 54.035 1 54.035 6.334 .017 6.334 .684 
Greenhouse-Geisser 54.035 1.000 54.035 6.334 .017 6.334 .684 
Huynh-Feldt 54.035 1.000 54.035 6.334 .017 6.334 .684 
Lower-bound 54.035 1.000 54.035 6.334 .017 6.334 .684 








Greenhouse-Geisser 1.706 1.000 1.706 44.943 .000 44.943 1.000 
Huynh-Feldt 1.706 1.000 1.706 44.943 .000 44.943 1.000 
Lower-bound 1.706 1.000 1.706 44.943 .000 44.943 1.000 
PS_KF_TRQ Sphericity Assumed .065 1 .065 5.638 .024 5.638 .633 
Greenhouse-Geisser .065 1.000 .065 5.638 .024 5.638 .633 
Huynh-Feldt .065 1.000 .065 5.638 .024 5.638 .633 
Lower-bound .065 1.000 .065 5.638 .024 5.638 .633 
MVIC_AVG Sphericity Assumed 8.981 1 8.981 54.296 .000 54.296 1.000 
Greenhouse-Geisser 8.981 1.000 8.981 54.296 .000 54.296 1.000 
Huynh-Feldt 8.981 1.000 8.981 54.296 .000 54.296 1.000 
Lower-bound 8.981 1.000 8.981 54.296 .000 54.296 1.000 
CAR_AVG Sphericity Assumed .056 1 .056 10.517 .003 10.517 .881 








Huynh-Feldt .056 1.000 .056 10.517 .003 10.517 .881 
Lower-bound .056 1.000 .056 10.517 .003 10.517 .881 
time * Group IC_KS_ROT Sphericity Assumed 38.796 1 38.796 3.293 .079 3.293 .420 
Greenhouse-Geisser 38.796 1.000 38.796 3.293 .079 3.293 .420 
Huynh-Feldt 38.796 1.000 38.796 3.293 .079 3.293 .420 
Lower-bound 38.796 1.000 38.796 3.293 .079 3.293 .420 
IC_KF_ROT Sphericity Assumed 6.124 1 6.124 2.932 .097 2.932 .382 
Greenhouse-Geisser 6.124 1.000 6.124 2.932 .097 2.932 .382 
Huynh-Feldt 6.124 1.000 6.124 2.932 .097 2.932 .382 
Lower-bound 6.124 1.000 6.124 2.932 .097 2.932 .382 
PS_KS_ROT Sphericity Assumed 208.273 1 208.273 6.136 .019 6.136 .670 
Greenhouse-Geisser 208.273 1.000 208.273 6.136 .019 6.136 .670 
Huynh-Feldt 208.273 1.000 208.273 6.136 .019 6.136 .670 








PS_KF_ROT Sphericity Assumed 13.228 1 13.228 1.551 .222 1.551 .226 
Greenhouse-Geisser 13.228 1.000 13.228 1.551 .222 1.551 .226 
Huynh-Feldt 13.228 1.000 13.228 1.551 .222 1.551 .226 
Lower-bound 13.228 1.000 13.228 1.551 .222 1.551 .226 
PS_KS_TRQ Sphericity Assumed .772 1 .772 20.338 .000 20.338 .992 
Greenhouse-Geisser .772 1.000 .772 20.338 .000 20.338 .992 
Huynh-Feldt .772 1.000 .772 20.338 .000 20.338 .992 
Lower-bound .772 1.000 .772 20.338 .000 20.338 .992 
PS_KF_TRQ Sphericity Assumed .041 1 .041 3.560 .069 3.560 .448 
Greenhouse-Geisser .041 1.000 .041 3.560 .069 3.560 .448 
Huynh-Feldt .041 1.000 .041 3.560 .069 3.560 .448 
Lower-bound .041 1.000 .041 3.560 .069 3.560 .448 
MVIC_AVG Sphericity Assumed 1.369 1 1.369 8.273 .007 8.273 .796 








Huynh-Feldt 1.369 1.000 1.369 8.273 .007 8.273 .796 
Lower-bound 1.369 1.000 1.369 8.273 .007 8.273 .796 
CAR_AVG Sphericity Assumed .005 1 .005 .980 .330 .980 .160 
Greenhouse-Geisser .005 1.000 .005 .980 .330 .980 .160 
Huynh-Feldt .005 1.000 .005 .980 .330 .980 .160 
Lower-bound .005 1.000 .005 .980 .330 .980 .160 
Error(time) IC_KS_ROT Sphericity Assumed 365.225 31 11.781     
Greenhouse-Geisser 365.225 31.000 11.781     
Huynh-Feldt 365.225 31.000 11.781     
Lower-bound 365.225 31.000 11.781     
IC_KF_ROT Sphericity Assumed 64.745 31 2.089     
Greenhouse-Geisser 64.745 31.000 2.089     
Huynh-Feldt 64.745 31.000 2.089     








PS_KS_ROT Sphericity Assumed 1052.169 31 33.941     
Greenhouse-Geisser 1052.169 31.000 33.941     
Huynh-Feldt 1052.169 31.000 33.941     
Lower-bound 1052.169 31.000 33.941     
PS_KF_ROT Sphericity Assumed 264.449 31 8.531     
Greenhouse-Geisser 264.449 31.000 8.531     
Huynh-Feldt 264.449 31.000 8.531     
Lower-bound 264.449 31.000 8.531     
PS_KS_TRQ Sphericity Assumed 1.177 31 .038     
Greenhouse-Geisser 1.177 31.000 .038     
Huynh-Feldt 1.177 31.000 .038     
Lower-bound 1.177 31.000 .038     
PS_KF_TRQ Sphericity Assumed .360 31 .012     








Huynh-Feldt .360 31.000 .012     
Lower-bound .360 31.000 .012     
MVIC_AVG Sphericity Assumed 5.128 31 .165     
Greenhouse-Geisser 5.128 31.000 .165     
Huynh-Feldt 5.128 31.000 .165     
Lower-bound 5.128 31.000 .165     
CAR_AVG Sphericity Assumed .166 31 .005     
Greenhouse-Geisser .166 31.000 .005     
Huynh-Feldt .166 31.000 .005     
Lower-bound .166 31.000 .005     












2. Group ACLr or Control 
Univariate Tests 
Measure Sum of Squares df Mean Square F Sig. Noncent. Parameter Observed Powera 
IC_KS_ROT Contrast 48.698 1 48.698 2.702 .110 2.702 .357 
Error 558.710 31 18.023     
IC_KF_ROT Contrast .285 1 .285 .046 .832 .046 .055 
Error 192.648 31 6.214     
PS_KS_ROT Contrast 480.651 1 480.651 7.817 .009 7.817 .773 
Error 1906.117 31 61.488     
PS_KF_ROT Contrast 2.860 1 2.860 .079 .780 .079 .059 
Error 1120.230 31 36.136     
PS_KS_TRQ Contrast 1.457 1 1.457 20.762 .000 20.762 .993 
Error 2.176 31 .070     








Error .750 31 .024     
MVIC_AVG Contrast .809 1 .809 2.439 .128 2.439 .328 
Error 10.275 31 .331     
CAR_AVG Contrast .024 1 .024 2.012 .166 2.012 .280 
Error .371 31 .012     
The F tests the effect of Group ACLr or Control. This test is based on the linearly independent pairwise comparisons among the estimated marginal means. 


















4. Group ACLr or Control * time 
Measure Group ACLr or Control time Mean Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
IC_KS_ROT ACLr 1 -10.336 1.203 -12.789 -7.884 
2 -9.755 1.169 -12.140 -7.370 
control 1 -14.301 1.240 -16.829 -11.773 
2 -10.652 1.205 -13.110 -8.194 
IC_KF_ROT ACLr 1 -3.247 .620 -4.511 -1.983 
2 -2.792 .686 -4.191 -1.394 
control 1 -4.043 .639 -5.345 -2.740 
2 -2.369 .707 -3.810 -.927 
PS_KS_ROT ACLr 1 -45.434 2.167 -49.854 -41.013 








control 1 -56.624 2.234 -61.181 -52.068 
2 -48.152 2.195 -52.628 -43.677 
PS_KF_ROT ACLr 1 -12.148 1.556 -15.321 -8.975 
2 -11.233 1.527 -14.348 -8.118 
control 1 -13.632 1.604 -16.903 -10.362 
2 -10.926 1.574 -14.137 -7.715 
PS_KS_TRQ ACLr 1 -1.101 .064 -1.231 -.970 
2 -.995 .080 -1.158 -.832 
control 1 -1.738 .066 -1.872 -1.603 
2 -1.199 .082 -1.368 -1.031 
PS_KF_TRQ ACLr 1 -.293 .043 -.380 -.206 
2 -.280 .041 -.365 -.195 
control 1 -.426 .044 -.516 -.337 








MVIC_AVG ACLr 1 2.031 .185 1.654 2.409 
2 1.581 .120 1.336 1.827 
control 1 2.632 .191 2.243 3.022 
2 1.606 .124 1.353 1.859 
CAR_AVG ACLr 1 .821 .026 .768 .873 
2 .780 .033 .713 .847 
control 1 .892 .026 .838 .947 










General Linear Model- Univariate ANOVAs for Post Hoc Analyses 
Between-Subjects Factors 
  Value Label N 
Group ACLr or Control .00 ACLr 17 
1.00 control 16 
 
Tests of Between-Subjects Effects 
Source Dependent Variable 
Type III Sum of 
Squares df 
Mean 







pre-fatigue injured limb knee sagittal plane rotation 1032.240a 1 1032.240 12.926 .001 12.926 .936 
post-fatigue injured limb knee sagittal plane rotation 137.335c 1 137.335 1.782 .192 1.782 .253 
pre-fatigue injured limb knee sagittal plane external 
moment 
3.344d 1 3.344 48.022 .000 48.022 1.000 
post-fatigue injured limb knee sagittal plane external 
moment 








Avg_MVIC 2.980f 1 2.980 5.120 .031 5.120 .592 
Avg_MVIC_Post .005g 1 .005 .021 .886 .021 .052 
Intercept pre-fatigue injured limb knee sagittal plane rotation 85851.573 1 85851.573 1075.079 .000 1075.079 1.000 
post-fatigue injured limb knee sagittal plane rotation 70102.626 1 70102.626 909.713 .000 909.713 1.000 
pre-fatigue injured limb knee sagittal plane external 
moment 
66.391 1 66.391 953.537 .000 953.537 1.000 
post-fatigue injured limb knee sagittal plane external 
moment 
39.700 1 39.700 365.139 .000 365.139 1.000 
Avg_MVIC 179.272 1 179.272 307.961 .000 307.961 1.000 
Avg_MVIC_Post 83.740 1 83.740 340.143 .000 340.143 1.000 
Group pre-fatigue injured limb knee sagittal plane rotation 1032.240 1 1032.240 12.926 .001 12.926 .936 
post-fatigue injured limb knee sagittal plane rotation 137.335 1 137.335 1.782 .192 1.782 .253 
pre-fatigue injured limb knee sagittal plane external 
moment 
3.344 1 3.344 48.022 .000 48.022 1.000 
post-fatigue injured limb knee sagittal plane external 
moment 








Avg_MVIC 2.980 1 2.980 5.120 .031 5.120 .592 
Avg_MVIC_Post .005 1 .005 .021 .886 .021 .052 
Error pre-fatigue injured limb knee sagittal plane rotation 2475.537 31 79.856     
post-fatigue injured limb knee sagittal plane rotation 2388.866 31 77.060     
pre-fatigue injured limb knee sagittal plane external 
moment 
2.158 31 .070 
    
post-fatigue injured limb knee sagittal plane external 
moment 
3.371 31 .109 
    
Avg_MVIC 18.046 31 .582     
Avg_MVIC_Post 7.632 31 .246     
Total pre-fatigue injured limb knee sagittal plane rotation 88868.149 33      
post-fatigue injured limb knee sagittal plane rotation 72505.163 33      
pre-fatigue injured limb knee sagittal plane external 
moment 
71.053 33 
     
post-fatigue injured limb knee sagittal plane external 
moment 
43.227 33 








Avg_MVIC 199.063 33      
Avg_MVIC_Post 91.415 33      
Corrected Total pre-fatigue injured limb knee sagittal plane rotation 3507.777 32      
post-fatigue injured limb knee sagittal plane rotation 2526.201 32      
pre-fatigue injured limb knee sagittal plane external 
moment 
5.502 32 
     
post-fatigue injured limb knee sagittal plane external 
moment 
3.714 32 
     
Avg_MVIC 21.026 32      
Avg_MVIC_Post 7.637 32      
a. R Squared = .294 (Adjusted R Squared = .272) 
b. Computed using alpha = .05 
c. R Squared = .054 (Adjusted R Squared = .024) 
d. R Squared = .608 (Adjusted R Squared = .595) 
e. R Squared = .092 (Adjusted R Squared = .063) 
f. R Squared = .142 (Adjusted R Squared = .114) 









2. Group ACLr or Control 
Univariate Tests 
Dependent Variable Sum of Squares df Mean Square F Sig. Noncent. Parameter Observed Powera 
pre-fatigue injured limb knee sagittal plane rotation Contrast 1032.240 1 1032.240 12.926 .001 12.926 .936 
Error 2475.537 31 79.856     
post-fatigue injured limb knee sagittal plane rotation Contrast 137.335 1 137.335 1.782 .192 1.782 .253 
Error 2388.866 31 77.060     
pre-fatigue injured limb knee sagittal plane external moment Contrast 3.344 1 3.344 48.022 .000 48.022 1.000 
Error 2.158 31 .070     
post-fatigue injured limb knee sagittal plane external moment Contrast .343 1 .343 3.157 .085 3.157 .406 
Error 3.371 31 .109     
Avg_MVIC Contrast 2.980 1 2.980 5.120 .031 5.120 .592 
Error 18.046 31 .582     








Error 7.632 31 .246     
The F tests the effect of Group ACLr or Control. This test is based on the linearly independent pairwise comparisons among the estimated marginal means. 
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